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INTRODUCTION 
 
In 2002, our research group started investigating children with Prader-Willi syndrome 
(PWS) and the effects and safety of growth hormone (GH) treatment. Today we know 
that long-term GH treatment during childhood counteracts the clinical course of 
increasing obesity in children with PWS and has substantially changed their 
phenotype. Combined with an early diagnosis and multidisciplinary support from a 
very young age, GH treatment has resulted in a new generation of children with 
PWS. Even though there has been a remarkable increase in the knowledge about 
PWS, answering one question generally inspires deeper and more detailed questions 
for further research. This thesis is the seventh thesis of our PWS research group and 
contains six new studies about children and young adults with PWS.  
 
This introduction describes the clinical manifestations in different stages of life, the 
genetic cause, hypothalamic dysfunction and the current knowledge on the effects of 
GH treatment in children and young adults with PWS. Furthermore, the objectives of 
the studies described in this thesis are presented.  
 
1.1 PRADER-WILLI SYNDROME  
 
Prader-Willi syndrome is a rare genetic disorder resulting from the lack of expression 
of the PWS region (locus q11-q13) on the paternally inherited chromosome 151-3. 
The incidence of PWS is estimated at 1 in every 12.000-15.000 live births and is 
considered the most common cause of genetic obesity4,5. The PWS phenotype is 
highly variable and clinical features in people with PWS change during their life, the 
most obvious being the change in appetite and satiety2,6,7. Infants with PWS show 
feeding difficulties and a lack of appetite, while children from the age of 2 years 
onwards develop an increased interest in food, gradually shifting to an unlimited 
appetite. The different stages of appetite and satiety are generally subdivided into 
nutritional phases (Table 1)7. These phases are summarized in the following 
paragraphs. 
 
 
  
Table 1. Nutritional phases
Phases Median ages Clinical characteristics
0 Prenatal to birth Decreased fetal movements and lower birth weight
1a Birth to 9 months Hypotonia with difficulty feeding and decreased appetite
1b 9 to 25 months Improved feeding and appetite, growth appropriate
2a 2.1 to 4.5 years Weight increasing without increase in appetite or calorie excess
2b 4.5 to 8 years Increased appetite and caloric intake, can feel full 
3 8 years to adulthood Hyperphagia, rarely feels full 
4 Adulthood Appetite no longer insatiable (described in some adults) 
Modified from Am J Med Gen 7
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1.1.1 Prenatal period and delivery  
 
Decreased fetal movements, breech position and assisted delivery 
 
Mothers expecting a child with PWS frequently report reduced fetal activity during 
pregnancy and the prevalence of polyhydramnios is increased7,8. Fetal growth is 
typically normal until 24 weeks of gestation, while intrauterine growth restriction and 
asymmetrical intrauterine growth are more common thereafter9,10. The fetus with 
PWS is often in breech position and assisted delivery is more common, which might 
be related to hypotonia and/or hypothalamic dysfunction of the fetus8,11. On average 
babies with PWS are born at a gestational age of 38 weeks, but both preterm and 
postterm deliveries are regularly reported7,12.  
 
1.1.2 Neonatal period 
 
Severe hypotonia and feeding difficulties 
 
Birth weight and length are generally about 15-20% lower in babies with PWS than in 
their siblings, regardless of gestational age2,13. In the newborn period, severe 
hypotonia with feeding difficulties and failure to thrive are clearly present. The 
pronounced central hypotonia causes decreased movements, lethargy with 
decreased arousal, a weak or absent cry and diminished reflexes, including the 
suckling reflex. Almost every newborn with PWS requires some type of assisted 
feeding for approximately 3-9 months to prevent failure to thrive (Figure 1).  
 
  
Figure 1. Young infants with PWS. Photos are depicted with permission from parents. 
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Despite the low-normal weight, an abnormal body composition with an increased fat 
mass percentage (FM%) and low lean body mass (LBM) is already present and 
persists throughout life14,15. Typical dysmorphic features, that may be present at birth, 
but generally become more pronounced during infancy and childhood, include a 
narrow bifrontal diameter, almond-shaped eyes, a narrow nasal bridge and a thin 
upper vermillion with down-turned corners of the mouth3,6. Finally, hypogonadism 
with genital hypoplasia and improper thermoregulation and breathing occur more 
often in PWS2,16,17.  
 
1.1.3 Infancy 
 
Improved feeding and steady growth along a growth percentile  
 
The feeding difficulties gradually improve during infancy and most infants with PWS 
grow steadily along a growth percentile with weight increasing at a normal rate7. 
There is a significant mental and motor developmental delay and developmental 
milestones are typically reached at double the normal age18-20. Physical therapy and 
speech therapy are necessary to improve muscle strength and facilitate achievement 
of developmental milestones20.  
 
1.1.4 Toddler  
 
Weight gain without a substantial change in appetite or caloric intake  
 
Usually body weight starts to increase between 18 and 36 months of age without an 
increase in calorie intake or interest in food7. Due to the abnormal body composition, 
there is an imbalance in energy intake and energy expenditure and children with 
PWS generally need 60% of the calories that healthy individuals without PWS 
need15,21. To prevent children with PWS from becoming morbidly obese, timely start 
of a well-balanced low-calorie diet and regular exercise are necessary20,22. 
 
   
Figure 2. Young children with PWS. Photos are depicted with permission from parents.  
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1.1.5 Early childhood  
 
Weight gain with an increased interest in food 
 
In early childhood the interest in food increases and the child will become overweight 
if there is no parental interference (Figure 2). Most children begin to develop food-
related behavior, which includes frequent asking and talking about food and reading 
cookbooks or watching cooking shows on television. The child is typically very 
preoccupied with the next meal and reminds others not to forget. If allowed, the child 
will eat more than he or she is supposed to and becomes obese7. In addition to the 
timely start of a well-balanced low-calorie diet and regular exercise, strict supervision 
and restriction of access to food are necessary from early childhood onwards20,22. 
 
Children with PWS grow poorly, resulting in short stature and small hands and feet. 
However, due to an early diagnosis, multidisciplinary support and GH treatment from 
a very young age, obesity and short stature are nowadays less common in children 
with PWS23. Most children with PWS have a psychomotor delay and cognitive 
impairment, resulting in a mild to moderate learning disability. Total IQ scores vary 
widely, but are around 65 points on average24-26. Other common symptoms during 
early childhood are strabismus27, scoliosis28,29, sleep-related breathing disorders30,31 
and stress-related central adrenal insufficiency32.  
 
   
Figure 3. Children with PWS. Photos are depicted with permission from parents.  
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1.1.6 Childhood and puberty  
 
Hyperphagia accompanied by food-seeking behaviour 
 
Childhood and adolescence are characterized by hyperphagia, typically 
accompanied by food seeking and a lack of satiety (Figure 3). The obsession 
towards food consumption combined with a reduced metabolic rate and physical 
activity easily leads to extreme obesity in children with PWS33. They are at risk of 
extreme overeating, which might result in acute life-threatening gastric rupture. 
Continuous parental guidance and supervision are crucial for children with PWS. 
Simultaneously with the change in eating behaviour, the majority of children with 
PWS start developing a variety of challenging behavioural and psychiatric symptoms, 
including temper tantrums, stubbornness, difficulties with changing routines and 
manipulative behaviour34-36. One third of children with PWS fulfil the criteria for 
Autism Spectrum Disorders37,38. The characteristics of PWS can be difficult to cope 
with and are likely to cause significant and long-term caregiver burden39. 
 
Puberty generally starts spontaneously, but the progression of pubertal development 
is delayed or incomplete. Both primary hypogonadism as well as hypothalamic 
dysfunction have been reported to cause the abnormal pubertal development17,40-42. 
Sex steroid replacement therapy might be needed to attain complete pubertal 
development and achieve adequate bone mineral density in adulthood43.   
 
1.1.7 Adulthood  
 
Diminishing hyperphagia  
 
Occasionally, the insatiable appetite fades and some adults with PWS are able to 
feel full. The transition from childhood to adulthood is complex and ethical issues 
regarding autonomy of persons with PWS are challenging. Pervasive food seeking 
behaviour, insistence on sameness, mood disorders and inactivity make it difficult for 
adults with PWS to live independently. Most adults require continuous assistance in 
daily life and many live in group homes. Since a few years, there are group homes 
that specialize in PWS, providing structure and clarity with regard to food, which 
significantly improves quality of life.  
 
The adult population of today was diagnosed later in life, when obesity (and its 
complications) was generally already present.	Most adults were not treated with GH 
during childhood and median adult height in untreated women is 145-150 cm and in 
men 155-160 cm. Until recently there were no reports about the phenotype of adults 
with PWS who were diagnosed in the first weeks of life and treated with GH from 
infancy onwards. It is generally believed that, if severe obesity and its complications 
can be prevented, adults with PWS may have an improved life expectancy (Figure 4).  
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Figure 4. Young adults with PWS. Photos are depicted with permission from patients and 
parents. 
 
1.2 GENETIC CAUSE  
 
1.2.1 History 
 
Prior to the availability of genetic testing, the diagnosis of PWS was based on a 
combination of clinical signs and symptoms, also known as the Holm’s criteria6. The 
first genetically diagnosed patient with PWS was described in 1976 and had a 15/15 
Robertsonian translocation44. In the 1980s deletions of the long arm of the paternally 
inherited chromosome 15 were added to the genetic causes of PWS45,46. Maternal 
uniparental disomy (mUPD) of chromosome 15 was reported to lead to PWS a few 
years later47. We now know that PWS is caused by a lack of expression of the 
paternally inherited genes of the Prader-Willi region, located on chromosome 15q11-
13, caused by either a deletion, an mUPD, an imprinting center defect (ICD) or a 
translocation3. 
 
1.2.2 Genomic imprinting  
 
Deoxyribonucleic acid (DNA) is a molecule consisting of two chains that coil around 
each other to form a double helix. The long thread of DNA consists of smaller 
threads, called chromosomes, which contain many different genes that carry the 
genetic instructions for the growth, development and functioning of all known 
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organisms (Figure 5). Humans have 46 chromosomes in the nucleus of each cell in 
their body, 23 chromosomes inherited from the father and 23 from the mother. These 
chromosomes form 23 pairs in each cell, labelled 1 to 23.  
 
Genomic imprinting is an epigenetic mechanism through which particular genes are 
imprinted or silenced during gametogenesis, causing genes to be expressed in a 
parent-of-origin-specific manner48. In healthy subjects, the PWS region on the 
paternally inherited chromosome 15 is expressed, while this region is silenced by 
imprinting on the maternally inherited chromosome 15. An abnormal or absent 
expression of paternally derived genes on the PWS region causes PWS. The PWS 
region contains numerous imprinted genes of which the exact function remains to be 
elucidated (Figure 6). 
 
 
Figure 5. Cell with nucleus, chromosomes and DNA. Reproduced with permission from 
Terese Winslow LLC, Medical and Scientific Illustration. 
 
1.2.3 Genetic subtypes  
 
Either a deletion of the paternally derived chromosome 15, or an mUPD, ICD or 
translocation of chromosome 15 may lead to PWS3 (Figure 7). The deletion subtype 
was previously described the most common cause of PWS, causing approximately 
70% of PWS cases. Nowadays, the frequency of deletions and mUPD are similar, 
most probably due to older maternal age at pregnancy and possibly an increase in 
the use of assisted reproductive technologies12. 
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70% of PWS cases. Nowadays, the frequency of deletions and mUPD are similar, 
most probably due to older maternal age at pregnancy and possibly an increase in 
the use of assisted reproductive technologies12. 
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Figure 6. PWS region on chromosome 15, locations of breakpoints BP1, BP2 and BP3 and 
position of imprinted and non-imprinted genes. Three deletion subtypes and their locations in 
the 15q11-q13 region are shown. Cen = centromere, Tel = telomere. Reproduced with 
permission from Angulo et al, Journal of Endocrinological Investigation, 2015.  
 
 
Figure 7. Schematic overview of the genetic abnormalities causing PWS. P=paternally 
inherited chromosome 15. M=maternally inherited chromosome 15. mUPD=maternal 
uniparental disomy. 
 
Deletions generally occur de novo and manifest as either a large type I deletion or a 
smaller type II deletion. The two proximal breakpoints (BP1 and BP2) and the distal 
breakpoint (BP3) seem to predispose to these typical deletions seen in PWS (Figure 
6)1,3. In mUPD, both chromosomes 15 are inherited from the mother due to gamete 
completion by the union of a nullisomic and a disomic gamete or a trisomic 
conception followed by trisomy rescue in early pregnancy and loss of the paternal 
chromosome 1549.  
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Phenotypic differences between the deletion and mUPD subtypes have been 
reported. People with the deletion subtype of PWS tend to have more typical PWS 
facial features and hypopigmentation, while people with mUPD are reported to have 
a higher verbal IQ and an increased risk of developing psychiatric problems, 
including psychosis and autism spectrum disorders1,50-52. The clinical phenotype of 
people with PWS is, however, highly variable, and there is no clear association 
between genotype and phenotype.  
 
Imprinting center defects explain less than 5% of all PWS cases53. A mutation in the 
imprinting control region of chromosome 15 results in a maternal imprint of the 
paternally derived chromosome, leading to a complete loss of the paternal 
expression of the genes of the PWS region. Less than 1% of the patients with PWS 
have an unbalanced Robertsonian translocation, where part of the paternally 
inherited chromosome 15 is transferred to another chromosome, leading to 
chromosomal deletions or additions3,54. The recurrence risk is typically very low in the 
case of a deletion or an mUPD, but if the father carries a translocation or if PWS is 
caused by an imprinting center mutation, the recurrence risk is considerably higher, 
i.e. up to 50%3.  
 
1.3 HYPOTHALAMIC DYSFUNCTION 
 
The hypothalamus is a coordinating center in the brain consisting of several small 
nuclei with a variety of functions. Its most important function is to link the nervous 
system to the endocrine system via the pituitary gland by synthesizing and secreting 
neurohormones that stimulate the pituitary, e.g. growth hormone-releasing hormone 
(GHRH), gonadotropin-releasing hormone (GnRH), corticotropin-releasing hormone 
(CRH) and thyrotropin-releasing hormone (TRH). These neurohormones are 
released into the blood stream and stimulate the anterior pituitary to secrete GH, 
gonadotropins (LH/FSH), prolactin (PRL), corticotropin (ACTH) and thyrotropin 
(TSH), respectively. Besides, the hypothalamus is involved in circadian rhythm, 
sleep, hunger, and body temperature regulation.  
 
Hypothalamic dysfunction can explain several symptoms of PWS, including 
excessive daytime sleepiness, sleep-related breathing disorders, insatiable hunger, 
temper tantrums, abnormal temperature control and hormonal dysregulation, such as 
hypogonadotropic hypogonadism, functional growth hormone deficiency and stress-
related central adrenal insufficiency11.  
 
1.4 GROWTH HORMONE TREATMENT  
 
At birth, children with PWS show a low median birth weight standard deviation score 
(SDS) of -1.4 and a low-normal median birth length of -0.50 SDS2,13. If not treated 
with GH, most children with PWS have a decreased growth velocity and a reduced 
pubertal growth spurt, resulting in a mean adult height in women of 145-150 cm and 
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155-160 cm in men13,55. These and other features, like small hands and feet, 
increased fat mass (FM) and reduced LBM, support the presence of GH deficiency56. 
However, most children do not fulfil the criteria for GH deficiency when they are 
tested for GH deficiency57. Functional GH deficiency due to hypothalamic dysfunction 
might underlie the clinical features of GH deficiency in children with PWS.  
 
The first studies investigating GH treatment in children with PWS were published in 
the 90s58-60 and GH treatment was approved for children with PWS by the Food and 
Drug Administration and by the European Medicines Agency soon thereafter. In 
2002, our research group started investigating the effects and safety of GH treatment 
in the Dutch national GH trial. After a randomized controlled trial, lasting 1 year for 
infants and 2 years for prepubertal children, all children were followed during 
continuous GH treatment in the Dutch PWS Cohort study until attainment of adult 
height (see Appendix for study designs).  
 
Today we know that long-term GH treatment is effective and safe in children with 
PWS23,61-63, improving body composition, bone mineral density, cognition, adaptive 
functioning, linear growth and adult height23,24,43,64. Combined with an early diagnosis 
and multidisciplinary support from a very young age, GH treatment counteracts the 
clinical course of increasing obesity in children with PWS and has substantially 
changed their phenotype. Currently, most Dutch infants with PWS start GH treatment 
soon after diagnosis before the age of 6 months and are followed until attainment of 
adult height in the Dutch PWS Cohort study.  
 
1.5 TOPICS OF THIS THESIS  
 
1.5.1 Psychomotor development during infancy  
 
During the first years of life, mental and motor development are delayed and children 
with PWS reach developmental milestones on average at double the normal age. 
Brain development during infancy and early childhood is very important for cognitive 
functioning on the long term65. We have shown that children with PWS have a trend 
towards smaller white matter volume, indicating reduced structural connectivity or 
aberrant myelinisation. This may reflect a delay in brain maturation and underlie 
cognitive deficits in children with PWS66.  
 
GH receptors are expressed throughout the brain and GH and IGF-I are expected to 
be involved in brain growth, development and myelinisation67,68. Short-term studies 
suggest a positive effect of GH on mental and motor development in infants and 
children with PWS19,69,70. We previously found a significant improvement in mental 
and motor development in infants with PWS after 1 year of GH treatment compared 
to randomized untreated controls19. There are currently no studies on the longer-term 
effects of GH on mental and motor development in infants with PWS. In the second 
chapter of this thesis we therefore investigated the effects of 3 years of GH on 
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psychomotor development in 63 children with PWS who started GH treatment at a 
very young age. We hypothesized that psychomotor development would not only 
improve during the first year of GH, but would continue to improve during the second 
and third year, thereby reducing the disparity compared with non-PWS peers. 
 
1.5.2 Cognitive development during childhood  
 
People with PWS typically have mild to moderate cognitive impairment with an 
average IQ between 60 and 7024,71. The physical benefits of GH treatment have been 
thoroughly investigated and include, among others, an improvement in body 
composition, linear growth and physical strength23. GH treatment is also associated 
with cognitive benefits, which are attributed to the effects of GH and insulin-like 
growth factor (IGF)-I on brain growth, development and myelinisation67,72. A recent 
review about the effects of GH treatment on cognition concluded that GH could 
stimulate GH receptors in brain areas involved in learning and memory, thereby 
improving cognitive functioning68.  
 
We previously demonstrated, during a 2-year randomized controlled trial, that 
cognitive functioning in GH-treated children with PWS developed at the same pace 
as cognitive functioning in healthy references, while in untreated controls, there was 
a significant deterioration in abstract verbal reasoning and vocabulary24. 
Furthermore, in 50 children with PWS, we found a significant improvement in abstract 
verbal reasoning and visuospatial skills during 4 years of GH treatment, indicating 
that 4 years of GH had reduced the gap between children with PWS and healthy 
controls with regard to these skills24. There are currently no studies investigating the 
effects of more than 4 years of GH in children with PWS. In the third chapter of this 
thesis we therefore investigated cognitive functioning during 8 years of GH treatment 
in 43 children with PWS. We also investigated whether starting GH treatment during 
infancy, i.e. before 2 years of age, would result in improved cognitive functioning after 
8 years of GH. We hypothesized that cognitive functioning would not deteriorate 
during long-term GH treatment and would progress at the same rate as healthy 
references. Additionally, we hypothesized that starting GH during infancy would 
benefit cognitive functioning on the long term. 
 
1.5.3 Growth hormone deficiency in adulthood  
 
Some features of people with PWS resemble those seen in growth hormone 
deficiency (GHD), such as short stature and an abnormal body composition with a 
low LBM and an increased FM. The benefits of GH treatment in children with PWS 
are well established as it improves body composition, bone mineral density (BMD), 
adaptive functioning and linear growth23,43,64. Furthermore, we and others have 
shown that GH treatment is also beneficial for adults with PWS, with a sustained 
improvement in FM and LBM when GH is continued after attainment of adult height, 
and a deterioration of body composition when GH treatment is discontinued73,74.  
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The fact that both children and adults with PWS respond very well to GH treatment, 
with a significant improvement in body composition, health profile, normalization of 
stature in children, and a significant increase in serum IGF-I and IGFBP-3 levels 
strongly supports the likelihood of GHD in these patients. However, GH treatment for 
adults with PWS is currently not reimbursed if they do not fulfil the consensus criteria 
of adult GHD. The reported prevalence of GHD in PWS is variable depending on the 
diagnostic test and the chosen cut-off points. In the fourth study of this thesis we 
investigated the prevalence of adult GHD using GHRH-Arginine tests in 60 young 
adults with PWS who had attained adult height after GH treatment during childhood, 
to have an opportunity to treat them. 
 
1.5.4 Bone mineral density in young adulthood  
 
BMD is influenced by endocrine factors such as GH, insulin-like growth factor and 
sex steroids and by body composition and body mass index (BMI)75,76. Both sex 
steroids and GH are known to play an important role in the accrual of peak bone 
mass77. Recent studies have shown that long-term GH treatment optimizes BMD in 
prepubertal children with PWS43,78, leading to a normal BMD compared to healthy 
peers43,79. During puberty, however, we found a decline in BMD in parallel to 
incomplete pubertal development and low sex hormone levels41-43. This could explain 
the reported increased prevalence of osteopenia and osteoporosis resulting in a high 
fracture risk in adults with PWS80-82.  
 
When young adults with PWS without adult GHD have attained adult height, they 
have to stop GH treatment. In GH-deficient young adults without PWS, BMD 
deteriorates after cessation of GH83-85. How BMD develops after cessation of GH 
was, however, not known in young adults with PWS. In chapter 5 of this thesis we 
therefore investigated the effects of GH versus placebo on BMD in young adults with 
PWS who had attained adult height and were treated with GH during childhood in a 
two-year, randomized, double-blind, placebo-controlled cross-over GH study. 
Secondly, we investigated the effects of no sex steroid replacement therapy (SSRT) 
versus SSRT on BMD in hypogonadal young adults with PWS. 
 
1.5.5 Sleep-related breathing disorders in young adulthood  
 
Sleep-related breathing disorders (SRBD) are common in patients with PWS, 
causing poor sleep quality and excessive daytime sleepiness86-88. There have been 
some reports on SRBD in PWS discussing the safety of GH treatment in children with 
PWS. We, however, described a non-significant decline in apnea hypopnea index 
(AHI) after 6 months of GH treatment in 35 prepubertal children with PWS and a 
recent review concluded that GH can be safely administered, provided that SRBD is 
monitored and treated appropriately30,89. 
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When young adults with PWS have attained adult height, they have to stop GH 
treatment, unless they have adult GHD. We have previously shown that young adults 
with PWS benefit from continuation of GH by maintaining the improved body 
composition obtained during childhood, without safety concerns regarding their 
metabolic health profile73,90. There were, however, no studies about the effects of GH 
on SRBD in young adults with PWS who were treated with GH during childhood. We 
therefore investigated the effects of one year of GH versus one year of placebo on 
SRBD in young adults with PWS who had attained adult height and were treated with 
GH during childhood in a two-year, randomized, double-blind, placebo-controlled 
cross-over GH study. We hypothesized that GH would not negatively influence 
SRBD. Secondly, we investigated the prevalence of obstructive sleep apnea (OSA) 
in our cohort of young adults with PWS. 
 
1.5.6 Leukocyte telomere length in young adulthood  
 
Studies in adults with PWS who were not treated with GH describe an increased risk 
of developing age-associated diseases at a relatively young adult age, e.g. diabetes 
mellitus type 2 (T2DM) and cardiovascular disease (CVD)81,91. The mortality rate of 
people with PWS was estimated to be 3% per year across all ages, rising to 7% in 
those aged over 305. As described in other syndromes, the ageing process might be 
accelerated in PWS92-95, which may partly explain the increased mortality rate and 
risk of T2DM and CVD. Ageing is characterized by a progressive time-dependent 
decline of normal tissue and organ function and recent studies have shown that 
telomere shortening is involved96,97. Telomere length shortens during proliferation 
and declines as a function of chronological age. When telomere length becomes 
critically short, the cell enters either senescence or apoptosis. The accumulation of 
senescent cells might drive the process of organismal ageing98. 
 
Chapter 7 of this thesis investigated leukocyte telomere length (LTL) in young adults 
with PWS and compared LTL to healthy young adults of similar age. As all young 
adults who participated in this study were treated with GH, we also investigated LTL 
in young adults born short for gestational age who were also treated with GH. We 
hypothesized that LTL would be shorter in young adults with PWS compared to both 
groups, independent of GH treatment, and that accelerated biological ageing could 
partly explain the increased mortality rate and risk of T2DM and CVD in adults with 
PWS.  
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1.6 AIMS AND OUTLINE OF THIS THESIS 
 
Chapter 1 gives an introduction on the topics described in this thesis.  
 
Chapter 2 describes the effects of 3 years of GH on mental and motor development 
in 63 infants and toddlers with PWS.  
 
Chapter 3 provides the results of our prospective study about cognitive functioning 
during 8 years of GH treatment in 43 children with PWS. 
 
Chapter 4 presents the prevalence of adult growth hormone deficiency in 60 young 
adults with PWS who were treated with GH during childhood.  
 
Chapter 5 describes the effects of 1 year of GH versus 1 year of placebo on bone 
mineral density in 27 young adults with PWS who were treated with GH during 
childhood. 
 
Chapter 6 describes sleep-related breathing disorders in 27 young adults with PWS 
during 1 year of GH and 1 year of placebo.  
 
Chapter 7 presents leukocyte telomere length of 47 young adults with PWS.  
 
Chapter 8 discusses the results and conclusions of this thesis taking recent literature 
and clinical implications of our findings into account.  
 
Chapter 9 contains an English and Dutch summary of the results described in this 
thesis.  
 
Chapter 10 lists an overview of publications by the PWS-team of the Dutch Growth 
Research Foundation.  
 
Chapter 11 contains a list of abbreviations, a list of publications, and a list of co-
authors affiliations. It further contains the PhD portfolio, acknowledgements, and 
curriculum vitae.  
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APPENDIX: DUTCH PRADER-WILLI SYNDROME STUDIES  
 
Dutch Growth Research Foundation 
 
Since 2002, Dutch PWS studies are performed and coordinated by the Dutch Growth 
Research Foundation (Stichting Kind en Groei). The PWS team consists of MD-
researchers, research nurses, a dietician, physical therapists and a psychologist. The 
Dutch randomized controlled GH trial (Dutch GH RCT) and follow-up study (Dutch 
PWS Cohort study) are multicenter studies investigating the effects and safety of 
long-term GH treatment in children with PWS. Every three months, MD-researchers 
and research nurses visit the 14 participating centers throughout the Netherlands and 
examine children and young adults with PWS who are treated with GH, in 
collaboration with local pediatricians and pediatric endocrinologists (Figure 8). At 
start of GH treatment, after 6 months, 12 months and yearly thereafter, various 
measurements are performed at the Erasmus University Medical Center – Sophia 
Children’s Hospital in Rotterdam.  
 
The PWS Transition study and the Young Adult PWS (YAP) study are single center 
studies investigating the effects and safety of GH in young adults with PWS. Young 
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1.6 AIMS AND OUTLINE OF THIS THESIS 
 
Chapter 1 gives an introduction on the topics described in this thesis.  
 
Chapter 2 describes the effects of 3 years of GH on mental and motor development 
in 63 infants and toddlers with PWS.  
 
Chapter 3 provides the results of our prospective study about cognitive functioning 
during 8 years of GH treatment in 43 children with PWS. 
 
Chapter 4 presents the prevalence of adult growth hormone deficiency in 60 young 
adults with PWS who were treated with GH during childhood.  
 
Chapter 5 describes the effects of 1 year of GH versus 1 year of placebo on bone 
mineral density in 27 young adults with PWS who were treated with GH during 
childhood. 
 
Chapter 6 describes sleep-related breathing disorders in 27 young adults with PWS 
during 1 year of GH and 1 year of placebo.  
 
Chapter 7 presents leukocyte telomere length of 47 young adults with PWS.  
 
Chapter 8 discusses the results and conclusions of this thesis taking recent literature 
and clinical implications of our findings into account.  
 
Chapter 9 contains an English and Dutch summary of the results described in this 
thesis.  
 
Chapter 10 lists an overview of publications by the PWS-team of the Dutch Growth 
Research Foundation.  
 
Chapter 11 contains a list of abbreviations, a list of publications, and a list of co-
authors affiliations. It further contains the PhD portfolio, acknowledgements, and 
curriculum vitae.  
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APPENDIX: DUTCH PRADER-WILLI SYNDROME STUDIES  
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PWS Reference center  
 
Since 2015, there is one Dutch Prader-Willi Reference Center accredited by the Dutch 
Ministry of Health in 2 locations:  
 
Reference Center for children and (young) adults, Rotterdam 
 
Children and young adults 
S.H. Donze, L. Damen, L. Grootjen, A. Juriaans, E.F. Mahabier, P.M.M.C. van Eekelen, E. 
Piso, G.C.B. Bindels-de Heus, A.C.S. Hokken-Koelega  
 
Previously: R.J. Kuppens, N.E. Bakker, S.T. Lo, E.P.C. Siemensma, R.F.A. Tummers-de 
Lind van Wijgaarden, D.A.M. Festen, A. Lukoshe, L. Schafthuizen, B. Kerkhof  
 
Dutch Growth Research Foundation and Erasmus University Medical Center, Sophia 
Children’s Hospital 
 
Adults 
L.C.G. de Graaff-Herder, K. Davidse  
 
Erasmus University Medical Center Rotterdam 
 
Reference Center for children, Nijmegen  
 
A.A.E.M. van der Velden, J. Geelen 
 
Radboud University Medical Center, Amalia Children’s Hospital  
 
Participating centers and pediatricians 
 
Amsterdam  J. Rotteveel, M.J.J. Finken, VU University Medical Center  
Amsterdam N. Zwaveling-Soonawala, Academic Medical Center  
Apeldoorn  L. Lunshof, Gelre Hospitals  
Den Bosch  P.E. Jira, E.G.A.H. van Mil, Jeroen Bosch Medical Center  
Den Haag  E.C.A.M. Houdijk, Haga Hospital  
Eindhoven  R.J.H. Odink, V. van Tellingen, St. Catharina Hospital  
Enschede  M.E.J. Wegdam-den Boer, Medical Center Twente  
Groningen G. Bocca, University Medical Center Groningen 
Harderwijk  M. van Leeuwen, St. Jansdal Hospital  
Leeuwarden  E. van Pinxteren-Nagler, Medical Center Leeuwarden (2002-2014)  
Leiden   D.A.J.P. Haring, Alrijne Hospital  
Leiden W. Oostdijk, C. de Bruijn, Leiden University Medical Center  
Lelystad  R. Lauwerijs, MC Zuiderzee (2002-2013)  
Nijmegen  C. Westerlaken, Canisius-Wilhelmina Hospital (2004-2011)  
Utrecht  J.J.G. Hoorweg-Nijman, H. van Wieringen, St. Antonius Hospital  
Zwolle   E.J. Schroor, Isala Hospital (2002-2014)  
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Dutch PWS Studies in children 
 
Patients 
Until July 2019, 220 Dutch children with PWS were included in the randomized 
controlled GH study and/or the PWS cohort study (Figure 9). For both studies, 
children had to meet the following criteria: 
 
Inclusion criteria 
- Genetically confirmed diagnosis of PWS; 
- Under 16 years of age;  
- Maximal bone age of less than 14 years in girls, or 16 years in boys. 
 
Exclusion criteria 
- Non-cooperative behavior; 
- Extremely low dietary intake of less than minimal required intake according to 
guidelines set by the World Health Organization; 
- Medication to reduce weight or fat; 
- In children above 3 years of age: height above 0 SDS, unless weight-for-
height is above 2 SDS; 
- Previous treatment with GH (not applicable for the Dutch PWS Cohort Study). 
 
Design 
From 2002 to 2008, 61 infants were included in the randomized controlled GH study: 
47 prepubertal children and 7 pubertal children. Infants and prepubertal children were 
randomized into either a GH-treated group or a control group for respectively 1 or 2 
years. Subsequently all were treated with GH 1 mg/m2 per day. All pubertal children 
were treated with GH, but were randomized to receive either 1 mg/m2 per day or 1.5 
mg/m2 per day until attainment of adult height. All were prospectively followed in the 
Dutch PWS cohort study in collaboration with pediatricians and pediatric 
endocrinologists throughout The Netherlands. 
 
Since 2009, infants are directly included in the PWS cohort study for follow-up during 
long term GH treatment until attainment of adult height. All children are treated with 
GH 1 mg/m2 per day and are prospectively followed in collaboration with 
pediatricians and pediatric endocrinologists throughout The Netherlands.  
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Figure 9. Design of the multicenter randomized controlled GH study (Dutch GH RCT) and 
the PWS cohort study. GH dose 1.0 mg/m2·day≈0.035 mg/kg/day, GH dose 1.5 
mg/m2·day≈0.052 mg/kg/day. 
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PWS Transition Study 
 
Patients 
Until January 2014, 28 Dutch young adults with PWS who were treated with GH 
during childhood and had attained adult height, were included in the PWS Transition 
study (Figure 10). 
 
Inclusion criteria 
- Genetically confirmed diagnosis of PWS; 
- GH treatment during childhood for at least 2 years and being on GH at time of 
inclusion; 
- Adult height attainment, defined as a height velocity less than 0.5 cm per 6 
months and complete epiphyseal fusion. 
	
Exclusion criteria 
- Non-cooperative behavior; 
- Medication to reduce weight or fat. 
 
Design 
Two-year, randomized, double-blind, placebo-controlled, cross-over study 
investigating the effects of 1 year placebo versus 1 year GH on body composition, 
metabolic health profile, cognition, bone mineral density and sleep-related breathing 
disorders. Young adults were stratified according to gender and BMI (below or above 
25 kg/m2) and then randomly and blindly assigned to receive 1 year of subcutaneous 
injections once daily at bedtime of either 0.67 mg/m2/day GH or 1 year of identical 
appearing placebo, after which they crossed-over to the alternative treatment for 
another year. Investigators were blinded for the allocation. 
 
 
Figure 10. Design of the 2-year randomized, double-blinded, placebo-controlled cross-over 
GH trial. GH dose 0.67 mg/m2·day≈0.023 mg/kg·day. 
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PWS Young Adult (YAP) Study 
 
Patients 
Until July 2019, 68 Dutch young adults with PWS who had attained adult height, were 
included in the PWS Young Adult study (Figure 11).  
 
Inclusion criteria 
- Genetically confirmed diagnosis of PWS; 
- Age < 35 years 
- Adult height attainment, defined as a height velocity less than 0.5 cm per 6 
months and complete epiphyseal fusion. 
- BMI <38 kg/m2. Patients with a BMI between 30-38 kg/m2 have to show that 
they can comply to a diet and physical exercise program during 6 months 
resulting in weight loss.  
 
Exclusion criteria 
- Non-cooperative behavior; 
- Medication to reduce weight or fat; 
- Severe sleep related breathing disorders;  
- BMI >38 kg/m2. 
 
Design 
Prospective study in young adults with PWS investigating the efficacy and safety of 
GH treatment after attainment of adult height. Patients who received GH treatment 
during childhood will restart GH in a dose of 0.33 mg/m2 per day. Patients who were 
not treated with GH during childhood will start GH in a dose of 0.15 mg/m2 per day 
and after 4 weeks the dose will be increased to 0.33 mg/m2 per day. Prior to (re)start 
of GH several medical tests will be performed.   
 
Figure 11. Design of the prospective study in young adults with PWS. GH dose 0.33 
mg/m2·day≈0.012 mg/kg·day. 
 
Please note that the current thesis does not include results about the efficacy and 
safety of GH treatment in young adults participating in the YAP study. However, all 
young adults with PWS participating in the YAP study were subjected to a GHRH-
Arginine test after attainment of adult height to evaluate adult growth hormone 
deficiency (results in chapter 4) and 47 of 68 young adults participated in the study 
investigating leukocyte telomere length (results in chapter 7).   
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ABSTRACT 
 
Context Infants and toddlers with Prader-Willi Syndrome (PWS) have mental and 
motor developmental delay. Short-term data suggest a positive effect of growth 
hormone (GH) on mental and motor development in infants and children with PWS. 
There are, however, no longer-term results about the effects of GH treatment on 
mental and motor development. 
  
Objective To investigate the longer-term effects of GH on psychomotor development 
in infants and toddlers with PWS and the effect of age at start of GH treatment on 
psychomotor development. 
 
Design Prospective cohort study during 3 years of GH treatment  
 
Intervention All children were treated with growth hormone 1 mg/m2/day (≈0.035 
mg/kg/day).  
 
Main outcome measures Mental and motor developmental age assessed with 
Bayleys Scales of Infant Development II (BSID-II) and expressed as % of the 
expected development (100%). 
 
Results During 3 years of GH, mean (SEM) mental development increased from 
58.1% (2.8) at baseline to 79.6% (3.7), and motor development from 41.9% (2.9) to 
78.2% (3.9; both p<0.01). A lower baseline psychomotor development and a younger 
age at start of GH treatment were associated with a higher increase in mental and 
motor development (p<0.01). 
 
Conclusions Mental and motor development increased significantly during 3 years 
of GH treatment, reducing the gap between infants with PWS and healthy peers. The 
younger at start of GH treatment, the greater the improvement in psychomotor 
development.   
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INTRODUCTION 
 
Prader-Willi syndrome (PWS) is a neurodevelopmental disorder resulting from the 
absence of locus q11-q13 (PWS region) on the paternally derived chromosome 15, 
caused by a paternal deletion, maternal uniparental disomy (mUPD), imprinting 
center defect or paternal chromosomal translocation. Early features of the syndrome 
include muscular hypotonia, feeding difficulties with poor weight gain and mental and 
motor developmental delay. When children get older, they develop short stature, 
hyperphagia with an increased risk of obesity, neurobehavioral problems and a mild 
to moderate cognitive impairment with an average IQ between 60 and 701-4. 
 
Long-term continuous growth hormone (GH) treatment in children with PWS 
improves body composition, linear growth, physical strength and adaptive 
functioning5,6. Short-term data suggested a positive effect of GH on mental and motor 
development in infants and children with PWS7-10. In 29 infants with PWS, aged 6 
months to 3 years, we found a significant improvement in mental and motor 
development after 1 year of GH treatment compared to randomized controls. Both 
mental and motor development declined in infants that were not treated with GH7. To 
our knowledge, there are currently no reports on the longer-term effects of GH on 
mental and motor development in infants with PWS. In this prospective cohort study, 
we therefore investigated the effects of 3 years of GH treatment on psychomotor 
development in a large group of infants with PWS who started GH treatment at a very 
young age. We hypothesized that psychomotor development would not only improve 
during the first year of GH treatment but would continue to improve during the second 
and third year, thereby reducing the disparity between children with PWS and non-
PWS peers. As there could be an age dependent effect of GH on psychomotor 
development, we also investigated if starting GH at a younger age would correlate 
with greater mental and motor development during 3 years of GH. We hypothesized 
that starting GH treatment at a younger age would result in a greater improvement in 
psychomotor development.  
 
METHODS 
 
Patients 
The study group consisted of 63 infants and toddlers with PWS. All fulfilled the 
following inclusion criteria; 1) genetically confirmed diagnosis of PWS, 2) naïve to GH 
treatment at time of enrolment, 3) uncomplicated pregnancy and delivery, 4) 
maximum age of 3 years at first evaluation, 5) at least 2 Bayley Scales of Infant 
Development II (BSID-II) tests during 3 years of GH treatment. Six of 63 infants 
participated in our previous study investigating psychomotor development in PWS 
infants and toddlers during 1 year of GH treatment compared to randomized 
controls7. The study protocol was approved by the Medical Ethics Committee of the 
Erasmus Medical Center (Rotterdam, The Netherlands) and by the collaborating 
centers. Written informed consent was obtained from the parents. 
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42  | Chapter 2   
 
 
Design  
All participants were followed at the Dutch PWS Reference Center. To investigate the 
effect of GH on mental and motor development, BSID-II scores were analysed from 
the start of GH treatment. Children were treated with Genotropin (Pfizer Inc., New 
York, NY) administered subcutaneously once daily at bedtime in a dose of 1 
mg/m2/day (≈0.035 mg/kg/day) for at least 3 consecutive years. The GH dose was 
regularly adjusted based on calculated body surface area and serum insulin-like 
growth factor (IGF)-I levels. IGF-I levels were expressed as SDS, adjusting for age 
and gender11. GH dose was lowered if serum IGF-I was > 3 SDS.  
 
Anthropometry 
All children were examined every 3 months. Standing height was measured using a 
Harpenden Stadiometer and supine height with a Harpenden Infantometer (Holtain 
Ltd., Crosswell, UK). Weight was measured on a calibrated electric scale (Servo 
Balance KA-20-150S; Servo Berkel Prior, Katwijk, The Netherlands) and head 
circumference with a measuring tape. Height, weight, body mass index (BMI) and 
head circumference were expressed as standard deviation scores (SDS) using 
Growth Analyser 4.0 (available at www.growthanalyser.org), adjusting for gender and 
age according to Dutch reference values12,13.   
 
Psychomotor development 
Mental and motor development were measured annually using BSID-II. BSID-II is an 
individually administered and standardized instrument for developmental diagnostics 
that can be used to evaluate the cognitive and motor development of young children 
with a ‘developmental age’ between 0 and 3.5 years. BSID-II yields two scores: 
mental developmental age (in months) and motor developmental age (in months). 
The mental scale consists of items in relation to visual and auditory information 
processing, language development, memory, eye–hand coordination, imitation and 
problem solving. The motor scale assesses fine and gross motor skills. All tests were 
performed by one experienced psychologist (E.M.) in our PWS Reference Center 
(Erasmus University Medical Center, Rotterdam, the Netherlands), and the results 
were compared with reference data derived from healthy infants and toddlers of 
comparable age14,15. Mental and motor development were expressed as percentage 
of the expected mental and motor development for their age (%ed) and calculated as 
follows: (developmental age / chronological age) * 100. 
 
Body composition 
Body composition was annually assessed, using dual-energy x-ray absorptiometry 
(DXA, Lunar Prodigy, GE Healthcare, Chalfont St giles, UK). Total fat mass (FM; kg) 
and lean body mass (LBM; kg) were measured. LBM was calculated as fat-free mass 
(FFM) minus bone-mineral content. All scans were made on the same machine, and 
quality assurance was performed daily. The intra-assay coefficient of variation (CV) 
for fat tissue was 0.41% to 0.88%; for LBM 1.57% to 4.49%16. As reference values 
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for DXA in this age group are not yet available, FM and LBM were expressed as 
percentage of total body weight (FM% and LBM%). 
 
Statistical analysis 
Statistical analyses were performed with SPSS 24.0 (SPSS Inc., Chicago, IL). Data 
were expressed as mean (standard deviation, SD). In case of a non-Gaussian 
distribution data were expressed as median (interquartile range, IQR). Test results of 
psychomotor development were expressed as developmental age divided by 
chronological age and multiplied by 100, reflecting the percentage of the expected 
development (%ed) for that age. To compare psychomotor development with normal 
development (100%ed), a one-sided t-test was used. Gender and genotypic 
differences in baseline psychomotor development were calculated by independent 
samples T-tests. Correlations between baseline psychomotor development and age, 
head circumference and LBM% were calculated by Pearson’s correlation analysis in 
case of a Gaussian distribution and by Spearman’s correlation analysis in case of a 
non-Gaussian distribution.  
 
Mental and motor development during 3 years of GH were analysed using linear 
mixed model analysis with years of GH-use (0 = baseline, 1 = 1 year of GH 
treatment, 2 = 2 years of GH treatment and 3 = 3 years of GH treatment) as a 
categorical independent variable and a first-order autoregressive (AR(1)) covariance 
matrix. The effects of genotype, age at start of GH and the change in head 
circumference and body composition on psychomotor development during GH 
treatment was determined by using these variables as factors (in case of nominal or 
ordinal variables) or covariates (in case of scale variables) in the model. Results 
were adjusted for age and baseline psychomotor development. The effect of age at 
start of GH on psychomotor development was only corrected for baseline 
psychomotor development. P-values less than 0.05 were considered statistically 
significant. 
 
RESULTS  
 
Baseline characteristics 
Sixty-three infants and toddlers with PWS (35 boys, 28 girls) participated in the 
current evaluation of psychomotor development during 3 years of GH treatment. 
Baseline clinical characteristics are shown in Table 1. Thirty-one children had a 
deletion (49.2%), 31 children a maternal uniparental disomy (mUPD; 49.2%) and 1 a 
paternal translocation (1.6%). Birth weight SDS, height SDS, weight for age and 
weight for height SDS and head circumference for age SDS were all significantly 
below 0 SDS. GH treatment was started at a median (IQR) age of 1.0 year (0.7-1.6).  
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Baseline percentage of expected mental and motor development (%) are shown in 
Figure 1. Mean (SEM) baseline mental and motor development were 58.1% (16.1) 
and 41.9% (13.9), respectively, both being significantly lower than in healthy 
references (p<0.001).  
 
 
Figure 1. Mental and motor development before start of GH in infants and toddlers with 
PWS. Black dots represent mental development, grey squares represent motor development. 
  
Table 1. Baseline characteristics in 63 infants and toddlers with PWS
Boys / girls (n) 35 / 28
Genetic subtype: Deletion / mUPD / translocation 31 / 31 / 1
Gestational age (weeks) 39.8 (38.0 to 41.2)
Birth weight (SDS) -1.1* (-1.8 to -0.6)
Age at start GH treatment (yrs) 1.0 (0.7 ; 1.6)
Height for age (SDS) -1.7* (-2.6 to -1.0)
Weight for age (SDS) -1.8* (-2.5 to -0.7)
Weight for height (SDS) -0.6* (-1.4 ; 0.5)
FM% 28.6 (26.2 to 34.6)
Head circumference for age (SDS) -1.3* (-1.7 to -0.5)
Data expressed as median with (IQR). *P < 0.01, compared to 0 SDS. 
GH: growth hormone. FM%: fat mass percentage.
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There was a large variation in psychomotor development with mental development 
ranging from 24 to 91% of healthy peers and motor development from 15 to 78%. 
Baseline motor development was significantly lower than mental development 
(p<0.001). Mental and motor development were positively correlated (r = 0.69, 
p<0.001), meaning that infants with a higher baseline motor developmental score 
had a higher baseline mental developmental score and vice versa. 
 
Baseline psychomotor development was not different between boys and girls or 
between infants with a deletion or an mUPD (all p>0.07). We also found no 
significant association between head circumference and baseline mental and motor 
development (p=0.40 and p=0.08, resp.). A younger age was significantly associated 
with lower baseline mental development, but not motor development (p=0.01 and 
p=0.29, resp.). Baseline height SDS was weakly associated with baseline motor 
development (r=0.26, p=0.047), but baseline LBM% was not significantly associated 
with baseline motor development (p=0.47).  
 
Psychomotor development during 3 years of GH treatment 
During the first year of GH, mean (SEM) mental development increased from 58.1% 
(2.8) to 65.7% (1.6) and motor development from 41.9% (2.9) to 54.8% (1.7) (both 
p<0.01). After the first year of GH, mean (SEM) mental and motor development 
increased further to respectively 79.6 (3.7) and 78.2% (3.9) after 3 years of GH (both 
p<0.01; Figure 2), thus further reducing the disparity between infants with PWS and 
healthy peers of the same age. In spite of this improvement, the average mental and 
motor development after 3 years of GH were still significantly lower compared to 
healthy references (both p<0.001). The change in mental developmental during 3 
years of GH was significantly associated with the change in motor development 
(r=0.71, p<0.001). 
 
 
Figure 2. Mental and motor development during 3 years of GH in infants and toddlers with 
PWS presented as means with 95% CI. Significant changes compared to baseline are 
indicated with an asterisk. The dashed lines represent the maximum score of 100%.   
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Figure 1. Mean (SEM) baseline mental and motor development were 58.1% (16.1) 
and 41.9% (13.9), respectively, both being significantly lower than in healthy 
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Figure 1. Mental and motor development before start of GH in infants and toddlers with 
PWS. Black dots represent mental development, grey squares represent motor development. 
  
Table 1. Baseline characteristics in 63 infants and toddlers with PWS
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Genetic subtype: Deletion / mUPD / translocation 31 / 31 / 1
Gestational age (weeks) 39.8 (38.0 to 41.2)
Birth weight (SDS) -1.1* (-1.8 to -0.6)
Age at start GH treatment (yrs) 1.0 (0.7 ; 1.6)
Height for age (SDS) -1.7* (-2.6 to -1.0)
Weight for age (SDS) -1.8* (-2.5 to -0.7)
Weight for height (SDS) -0.6* (-1.4 ; 0.5)
FM% 28.6 (26.2 to 34.6)
Head circumference for age (SDS) -1.3* (-1.7 to -0.5)
Data expressed as median with (IQR). *P < 0.01, compared to 0 SDS. 
GH: growth hormone. FM%: fat mass percentage.
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There was a large variation in psychomotor development with mental development 
ranging from 24 to 91% of healthy peers and motor development from 15 to 78%. 
Baseline motor development was significantly lower than mental development 
(p<0.001). Mental and motor development were positively correlated (r = 0.69, 
p<0.001), meaning that infants with a higher baseline motor developmental score 
had a higher baseline mental developmental score and vice versa. 
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between infants with a deletion or an mUPD (all p>0.07). We also found no 
significant association between head circumference and baseline mental and motor 
development (p=0.40 and p=0.08, resp.). A younger age was significantly associated 
with lower baseline mental development, but not motor development (p=0.01 and 
p=0.29, resp.). Baseline height SDS was weakly associated with baseline motor 
development (r=0.26, p=0.047), but baseline LBM% was not significantly associated 
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The course of mental and motor development during 3 years of GH was not 
significantly different between boys and girls and between infants with a deletion or 
an mUPD (all p>0.17). A younger age at start of GH treatment was significantly 
associated with a better improvement in mental development (=-5.5, SE=1.9, 
p<0.01) and motor development (=-7.8, SE=2.1, p<0.001). Head circumference 
increased significantly from -1.0 SDS at baseline to 0.1 SDS after 3 years (p<0.01), 
but this change in head circumference was not significantly associated with the 
course of mental and motor development (p=0.77 and p=0.88, resp.). Neither the 
change in height SDS nor the change in LBM% significantly influenced motor 
development during 3 years of GH (p=0.33 and p=0.99, resp.).  
 
DISCUSSION 
 
In this study, we assessed psychomotor development during 3 years of GH in a large 
group of 63 infants and toddlers with PWS with a median age of 1 year at start of GH 
treatment. PWS infants and toddlers demonstrated delayed mental and motor 
development compared to healthy references, but, as psychomotor development in 
children with PWS significantly increased during 3 years of GH treatment, the 
disparity between children with PWS and healthy references decreased. 
Furthermore, the younger the age at start of GH treatment, the greater the increase 
in psychomotor development.  
 
Mental and motor development did not merely increase during the first year, but also 
in the second and third year of GH treatment. Hence, psychomotor development kept 
on improving, raising the mental and motor potential of infants with PWS. We 
previously found a significant improvement in mental and motor development after 1 
year of GH treatment compared to randomized, untreated controls in 29 infants with 
PWS with a median (IQR) age of 2.0 (1.3 – 3.0) years7. In a subsequent study in 20 
infants, the combination of GH and physical training resulted in a clinically relevant 
improvement in motor development10. Myers et al. reported a trend towards improved 
mobility and stability in infants and toddlers with PWS after 1 year of GH (n=14) 
compared to randomized controls (n=11), and more progression in language and 
cognitive development (n=7 vs. n=5). The authors noted that it was difficult to 
quantify differences between groups, because of small groups and large within group 
variance8. 
 
Our data show a significant improvement in mental and motor development during 3 
years of GH in very young children with PWS. However, we cannot exclude that part 
of this increase may be explained by spontaneous improvement of hypotonia with 
age and early start of physical therapy, as has been suggested based on a study 
comparing the effect of 1 year of GH or Co-enzyme Q10 (CoQ10) in 26 infants and 
toddlers with PWS17. Because all children with PWS in the Netherlands are treated 
with GH from a young age, we could not compare psychomotor development of GH-
treated infants to that of infants without GH treatment.   
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We acknowledge that an RCT would be the first-choice design to investigate the 
longer-term effects of GH on mental and motor development in infants with PWS, but 
it would be unethical to withhold GH for 3 years, knowing the positive effects of GH 
on numerous outcomes in children with PWS. We do not expect that parents and/or 
clinicians, anticipating positive results, influenced the results of this study, as the 
results are based on BSID-II tests carried out by an independent psychologist. 
Additionally, this study was performed in very young children with PWS and the 
likelihood of them deliberately influencing the results of the BSID-II is negligible.  
 
We have previously shown that mental and motor development decreased in infants 
who were not treated with GH, while psychomotor development significantly 
increased in those who were treated with GH. Thus, it is likely that psychomotor 
development would have remained similar or would have decreased if children were 
not treated with GH7. This shows that GH treatment plays an important role in 
psychomotor development in infants with PWS, aside from the spontaneous 
improvement with age. Six patients also participated in our previous study, but 
compared to the 63 patients included in this study, this low number did not unduly 
influence the results presented in this paper. Moreover, the present data of a larger 
group confirm the preliminary findings of the first study in 29 infants with PWS7. 
 
Baseline psychomotor development varied widely among infants and toddlers with 
PWS with developmental scores ranging from 15 to 91% of healthy references. This 
variability was especially large in infants younger than 1 year of age. Infants with a 
higher motor developmental score had a higher mental developmental score, which 
could be related to the fact that some mental developmental milestones cannot be 
reached without reaching certain motor developmental milestones first. For example, 
infants with poor head stability will not be able to visually follow (the voice of) their 
parent(s) and/or caregiver(s). It could be that once infants and toddlers have reached 
certain motor milestones (e.g. sitting or walking independently), they are capable to 
better explore their environment, which enhances their mental development. This is 
supported by the significant correlation between the change in motor and mental 
development during 3 years of GH. Infants with an improvement in motor 
development would thus be more likely to improve their mental abilities7,17.  
 
Brain development during infancy and early childhood is very important for cognitive 
functioning on the long term18. We previously found that children with PWS had a 
trend towards smaller white matter volume, indicating reduced structural connectivity 
or aberrant myelinisation in children with PWS, which may reflect a delay in brain 
maturation and underlie cognitive deficits in these children19. GH receptors are 
expressed throughout the brain and GH and IGF-I are expected to be involved in 
brain growth, development and myelinisation. As serum IGF-I levels are low in 
children with PWS prior to starting GH treatment, GH might improve brain 
development by increasing IGF-I levels20,21. 
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We found that the younger the age at start of GH treatment, the greater the 
improvement in psychomotor development, suggesting that starting GH treatment 
early, in a critical period of neurodevelopment, could enhance psychomotor and 
cognitive development on the longer term21,22. One of our previous studies also 
reported a significant effect of age at start of GH on cognitive development in 50 pre-
pubertal children2. Furthermore, another study in 42 children with PWS stated that if 
GH was started during infancy, GH had a larger effect on adaptive functioning6. More 
studies are required to confirm these findings in subjects with PWS. 
  
In contrast to our expectations, but in line with previous data7, we did not find a 
significant association between psychomotor development and head circumference, 
neither at baseline, nor during 3 years of GH treatment. Head circumference 
increased from low-normal to normal during GH, but the change in head 
circumference relative to the change in height was below one, which means that 
height SDS increased more than head circumference SDS (data not shown). Thus, it 
seems that the neuroregulatory role of GH and IGF-I in the central nervous system is 
more important for psychomotor development than the increase in head 
circumference20,23. 
  
Our study is the first to investigate the effects of 3 years of GH treatment on 
psychomotor development. BSID-II is suitable for children with a developmental age 
between 0 and 3.5 years and can be compared to references using mental and motor 
index scores. As infants and toddlers with PWS have delayed psychomotor 
development, their BSID-II results may only be described in terms of developmental 
age. Expressing this developmental age as a percentage of the expected mental and 
motor development for their age allowed us to evaluate psychomotor development 
during 3 years of GH, despite their delay in psychomotor development14. It is not 
possible to perform a study about the effects of more than 3 years of GH on mental 
and motor development with the BSID-II, as most children will exceed the maximum 
developmental age during the first 3 years of GH treatment. 
 
In conclusion, our study shows that, in a large group of infants and toddlers with 
PWS, mental and motor development increased significantly during 3 years of GH 
treatment, reducing the gap between infants with PWS and healthy peers. Infants 
with lower baseline psychomotor development advanced more than infants with 
higher baseline psychomotor development. Currently, the increased awareness of 
PWS and the improved genetic tests have made it possible to diagnose PWS during 
early infancy. As starting GH treatment at a younger age seems to result in better 
psychomotor development, we nowadays start GH treatment in very young infants 
with PWS.  
 49                                                Psychomotor development in young children with PWS |  
ACKNOWLEDGMENTS 
 
We express our gratitude to all children and parents for their enthusiastic 
participation in this study and thank Mariëlle van Eekelen for all her work. We thank 
all collaborating pediatric-endocrinologists, pediatricians and other health care 
providers.  
  
48  | Chapter 2   
 
We found that the younger the age at start of GH treatment, the greater the 
improvement in psychomotor development, suggesting that starting GH treatment 
early, in a critical period of neurodevelopment, could enhance psychomotor and 
cognitive development on the longer term21,22. One of our previous studies also 
reported a significant effect of age at start of GH on cognitive development in 50 pre-
pubertal children2. Furthermore, another study in 42 children with PWS stated that if 
GH was started during infancy, GH had a larger effect on adaptive functioning6. More 
studies are required to confirm these findings in subjects with PWS. 
  
In contrast to our expectations, but in line with previous data7, we did not find a 
significant association between psychomotor development and head circumference, 
neither at baseline, nor during 3 years of GH treatment. Head circumference 
increased from low-normal to normal during GH, but the change in head 
circumference relative to the change in height was below one, which means that 
height SDS increased more than head circumference SDS (data not shown). Thus, it 
seems that the neuroregulatory role of GH and IGF-I in the central nervous system is 
more important for psychomotor development than the increase in head 
circumference20,23. 
  
Our study is the first to investigate the effects of 3 years of GH treatment on 
psychomotor development. BSID-II is suitable for children with a developmental age 
between 0 and 3.5 years and can be compared to references using mental and motor 
index scores. As infants and toddlers with PWS have delayed psychomotor 
development, their BSID-II results may only be described in terms of developmental 
age. Expressing this developmental age as a percentage of the expected mental and 
motor development for their age allowed us to evaluate psychomotor development 
during 3 years of GH, despite their delay in psychomotor development14. It is not 
possible to perform a study about the effects of more than 3 years of GH on mental 
and motor development with the BSID-II, as most children will exceed the maximum 
developmental age during the first 3 years of GH treatment. 
 
In conclusion, our study shows that, in a large group of infants and toddlers with 
PWS, mental and motor development increased significantly during 3 years of GH 
treatment, reducing the gap between infants with PWS and healthy peers. Infants 
with lower baseline psychomotor development advanced more than infants with 
higher baseline psychomotor development. Currently, the increased awareness of 
PWS and the improved genetic tests have made it possible to diagnose PWS during 
early infancy. As starting GH treatment at a younger age seems to result in better 
psychomotor development, we nowadays start GH treatment in very young infants 
with PWS.  
 49                                                Psychomotor development in young children with PWS |  
ACKNOWLEDGMENTS 
 
We express our gratitude to all children and parents for their enthusiastic 
participation in this study and thank Mariëlle van Eekelen for all her work. We thank 
all collaborating pediatric-endocrinologists, pediatricians and other health care 
providers.  
  
50  | Chapter 2   
 
REFERENCES 
1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genetics in 
medicine : official journal of the American College of Medical Genetics. 2011. 
2. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial 
effects of growth hormone treatment on cognition in children with Prader-Willi 
syndrome: a randomized controlled trial and longitudinal study. The Journal of clinical 
endocrinology and metabolism. 2012;97(7):2307-2314. 
3. Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H. Cognitive abilities and 
genotype in a population-based sample of people with Prader-Willi syndrome. Journal 
of intellectual disability research : JIDR. 2004;48(Pt 2):172-187. 
4. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, 
genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249-1263. 
5. Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone 
treatment in children with Prader-Willi syndrome: maintaining the positive effects. The 
Journal of clinical endocrinology and metabolism. 2013;98(10):4013-4022. 
6. Lo ST, Festen DA, Tummers-de Lind van Wijngaarden RF, Collin PJ, Hokken-
Koelega AC. Beneficial Effects of Long-Term Growth Hormone Treatment on 
Adaptive Functioning in Infants With Prader-Willi Syndrome. American journal on 
intellectual and developmental disabilities. 2015;120(4):315-327. 
7. Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and 
during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. 
Clinical endocrinology. 2008;68(6):919-925. 
8. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of 
growth hormone therapy in young children with Prader-Willi syndrome: physical and 
neurodevelopmental benefits. American journal of medical genetics Part A. 
2007;143A(5):443-448. 
9. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth 
hormone improves mobility and body composition in infants and toddlers with Prader-
Willi syndrome. The Journal of pediatrics. 2004;145(6):744-749. 
10. Reus L, Pelzer BJ, Otten BJ, et al. Growth hormone combined with child-specific 
motor training improves motor development in infants with Prader-Willi syndrome: a 
randomized controlled trial. Research in developmental disabilities. 
2013;34(10):3092-3103. 
11. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma 
levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the 
evaluation of childhood growth hormone deficiency. Horm Res. 1998;50(3):166-176. 
12. Fredriks AM, van Buuren S, Burgmeijer RJ, et al. Continuing positive secular growth 
change in The Netherlands 1955-1997. Pediatric research. 2000;47(3):316-323. 
13. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index 
measurements in 1996-7 compared with 1980. Archives of disease in childhood. 
2000;82(2):107-112. 
14. Bayley N. Bayley Scales of Infant Development (2nd edition). The Psychological 
Corporation, San Antonio, TX.1993. 
15. van der Meulen BF, Ruiter, S.A.J., Lutje Spelberg, H.C. & Smrkovsky. Bayley Scales 
of Infant Development-II [Dutch version]. Swets & Zeitlinger BV, Lisse, The 
Netherlands2002. 
16. Guo Y, Franks PW, Brookshire T, Antonio Tataranni P. The intra- and inter-
instrument reliability of DXA based on ex vivo soft tissue measurements. Obesity 
research. 2004;12(12):1925-1929. 
17. Eiholzer U, Meinhardt U, Rousson V, Petrovic N, Schlumpf M, l'Allemand D. 
Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects 
of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet A. 
2008;146A(7):873-880. 
 51                                                Psychomotor development in young children with PWS |  
18. Gale CR, O'Callaghan FJ, Godfrey KM, Law CM, Martyn CN. Critical periods of brain 
growth and cognitive function in children. Brain. 2004;127(Pt 2):321-329. 
19. Lukoshe A, Hokken-Koelega AC, van der Lugt A, White T. Reduced cortical 
complexity in children with Prader-Willi Syndrome and its association with cognitive 
impairment and developmental delay. PLoS One. 2014;9(9):e107320. 
20. Aberg D. Role of the growth hormone/insulin-like growth factor 1 axis in 
neurogenesis. Endocrine development. 2010;17:63-76. 
21. Nyberg F, Hallberg M. Growth hormone and cognitive function. Nat Rev Endocrinol. 
2013;9(6):357-365. 
22. Dykens EM, Roof E, Hunt-Hawkins H. Cognitive and adaptive advantages of growth 
hormone treatment in children with Prader-Willi syndrome. Journal of child 
psychology and psychiatry, and allied disciplines. 2017;58(1):64-74. 
23. Lai Z, Roos P, Zhai O, et al. Age-related reduction of human growth hormone-binding 
sites in the human brain. Brain research. 1993;621(2):260-266. 
 
 
50  | Chapter 2   
 
REFERENCES 
1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genetics in 
medicine : official journal of the American College of Medical Genetics. 2011. 
2. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial 
effects of growth hormone treatment on cognition in children with Prader-Willi 
syndrome: a randomized controlled trial and longitudinal study. The Journal of clinical 
endocrinology and metabolism. 2012;97(7):2307-2314. 
3. Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H. Cognitive abilities and 
genotype in a population-based sample of people with Prader-Willi syndrome. Journal 
of intellectual disability research : JIDR. 2004;48(Pt 2):172-187. 
4. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, 
genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249-1263. 
5. Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone 
treatment in children with Prader-Willi syndrome: maintaining the positive effects. The 
Journal of clinical endocrinology and metabolism. 2013;98(10):4013-4022. 
6. Lo ST, Festen DA, Tummers-de Lind van Wijngaarden RF, Collin PJ, Hokken-
Koelega AC. Beneficial Effects of Long-Term Growth Hormone Treatment on 
Adaptive Functioning in Infants With Prader-Willi Syndrome. American journal on 
intellectual and developmental disabilities. 2015;120(4):315-327. 
7. Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and 
during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. 
Clinical endocrinology. 2008;68(6):919-925. 
8. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of 
growth hormone therapy in young children with Prader-Willi syndrome: physical and 
neurodevelopmental benefits. American journal of medical genetics Part A. 
2007;143A(5):443-448. 
9. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth 
hormone improves mobility and body composition in infants and toddlers with Prader-
Willi syndrome. The Journal of pediatrics. 2004;145(6):744-749. 
10. Reus L, Pelzer BJ, Otten BJ, et al. Growth hormone combined with child-specific 
motor training improves motor development in infants with Prader-Willi syndrome: a 
randomized controlled trial. Research in developmental disabilities. 
2013;34(10):3092-3103. 
11. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma 
levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the 
evaluation of childhood growth hormone deficiency. Horm Res. 1998;50(3):166-176. 
12. Fredriks AM, van Buuren S, Burgmeijer RJ, et al. Continuing positive secular growth 
change in The Netherlands 1955-1997. Pediatric research. 2000;47(3):316-323. 
13. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index 
measurements in 1996-7 compared with 1980. Archives of disease in childhood. 
2000;82(2):107-112. 
14. Bayley N. Bayley Scales of Infant Development (2nd edition). The Psychological 
Corporation, San Antonio, TX.1993. 
15. van der Meulen BF, Ruiter, S.A.J., Lutje Spelberg, H.C. & Smrkovsky. Bayley Scales 
of Infant Development-II [Dutch version]. Swets & Zeitlinger BV, Lisse, The 
Netherlands2002. 
16. Guo Y, Franks PW, Brookshire T, Antonio Tataranni P. The intra- and inter-
instrument reliability of DXA based on ex vivo soft tissue measurements. Obesity 
research. 2004;12(12):1925-1929. 
17. Eiholzer U, Meinhardt U, Rousson V, Petrovic N, Schlumpf M, l'Allemand D. 
Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects 
of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet A. 
2008;146A(7):873-880. 
 51                                                Psychomotor development in young children with PWS |  
18. Gale CR, O'Callaghan FJ, Godfrey KM, Law CM, Martyn CN. Critical periods of brain 
growth and cognitive function in children. Brain. 2004;127(Pt 2):321-329. 
19. Lukoshe A, Hokken-Koelega AC, van der Lugt A, White T. Reduced cortical 
complexity in children with Prader-Willi Syndrome and its association with cognitive 
impairment and developmental delay. PLoS One. 2014;9(9):e107320. 
20. Aberg D. Role of the growth hormone/insulin-like growth factor 1 axis in 
neurogenesis. Endocrine development. 2010;17:63-76. 
21. Nyberg F, Hallberg M. Growth hormone and cognitive function. Nat Rev Endocrinol. 
2013;9(6):357-365. 
22. Dykens EM, Roof E, Hunt-Hawkins H. Cognitive and adaptive advantages of growth 
hormone treatment in children with Prader-Willi syndrome. Journal of child 
psychology and psychiatry, and allied disciplines. 2017;58(1):64-74. 
23. Lai Z, Roos P, Zhai O, et al. Age-related reduction of human growth hormone-binding 
sites in the human brain. Brain research. 1993;621(2):260-266. 
 
 
 Chapter 3 
 
Cognitive functioning in children with Prader-Willi 
syndrome during 8 years of growth hormone 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stephany H. Donze 
Layla Damen 
Eva F. Mahabier  
Anita C.S. Hokken-Koelega 
 
European Journal of Endocrinology 2019; in press
  
 
  
Chapter 1 
 
General introduction 
 
 Chapter 3 
 
Cognitive functioning in children with Prader-Willi 
syndrome during 8 years of growth hormone 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stephany H. Donze 
Layla Damen 
Eva F. Mahabier  
Anita C.S. Hokken-Koelega 
 
European Journal of Endocrinology 2019; in press
  
 
  
Chapter 1 
 
General introduction 
 
54  | Chapter 3   
 
ABSTRACT 
 
Objective: Children with Prader-Willi syndrome (PWS) have mild to moderate 
cognitive impairment. Short-term studies showed positive effects of growth hormone 
(GH) on cognitive development. This study investigated the effects of 8 years of GH 
on cognitive development in children with PWS. We also investigated whether 
starting GH during infancy results in higher cognitive functioning after 8 years of GH. 
 
Design: Longitudinal study in 43 children with PWS during 8 years of GH (median 
age at GH start 8.1 years). Cognitive functioning after 8 years was compared to 
another group of 22 children with PWS (median age at GH start 1.4 years). 
 
Methods: Cognitive functioning measured by Wechsler Intelligence Scale for 
Children. Vocabulary, Similarities and Block Design subtests were expressed as 
standard deviation scores (SDS) and total IQ (TIQ) calculated.  
 
Results: Estimated mean (95%CI) Block Design SDS changed from -2.2 (-2.6;-1.8) 
at GH start to -1.8 (-2.2;-1.4) after 8 years of GH (p=0.18), Similarities SDS from -1.5 
(-2.1;-0.9) to -1.3 (-1.9;-0.7, p=0.66), TIQ from 66 (60;72) to 69 (63;75, p=0.57). 
Vocabulary SDS remained similar, being -1.9 (-2.3;-1.4) at GH start and -1.9 (-2.4;-
1.5) after 8 years (p=0.85). After 8 years of GH Vocabulary SDS and TIQ were higher 
in the children who started GH during infancy, compared to those who started GH 
later in childhood (p<0.01, p=0.04, resp.).  
 
Conclusions: Cognitive functioning in children with PWS remains similar during 
long-term GH and develops at the same pace as healthy peers.   
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INTRODUCTION 
 
Prader-Willi syndrome (PWS) is a rare genetic disorder resulting from the loss of 
expression of locus q11-q13 (PWS region) on the paternally derived chromosome 15. 
This loss of expression is mostly due to a paternal deletion or maternal uniparental 
disomy (mUPD) and leads to a characteristic phenotype including muscular 
hypotonia, short stature, hyperphagia with an increased risk of obesity, psychomotor 
delay, neurobehavioral problems and cognitive impairment1. Patients with PWS 
typically have mild to moderate cognitive impairment with an average IQ between 60 
and 702,3. 
 
Growth hormone (GH) is a registered treatment for children with PWS since 2000. 
The physical benefits have been thoroughly investigated and include an improvement 
in body composition, linear growth and physical strength4-7. GH treatment is also 
associated with cognitive benefits, which are attributed to the effects of GH and 
insulin-like growth factor (IGF)-I on brain growth, development and myelinisation8,9. A 
recent review about the effects of GH treatment on cognition concluded that GH 
could stimulate GH receptors in brain areas involved in learning and memory, 
thereby improving cognitive functioning10. 
 
In PWS, few studies have investigated the effects of GH on cognitive functioning. 
Findings were not unequivocal, with some studies reporting an improvement in 
psychomotor development and cognition2,6,11-13, while others described no cognitive 
benefits of GH14,15. We previously demonstrated in a 2-year randomized controlled 
trial that cognitive functioning in GH-treated children with PWS developed at the 
same pace as cognitive functioning in healthy references, while abstract verbal 
reasoning and vocabulary significantly deteriorated in untreated controls6. 
Furthermore, in 50 children with PWS who started GH at a mean age of 7.8 years, 
we found a significant improvement in abstract verbal reasoning and visuospatial 
skills during 4 years of GH treatment2. Most of these studies evaluated short-term 
effects of GH in children with PWS and there are currently no studies investigating 
the effects of more than 4 years of GH in children with PWS.  
  
In this prospective study, we therefore investigated the longitudinal effects of 8 years 
of GH treatment on cognitive functioning in children with PWS from our Dutch PWS 
cohort. We also investigated whether starting GH treatment during infancy, i.e. before 
the age of 2 years, would result in higher cognitive functioning after 8 years of GH 
compared to starting GH later in childhood. We hypothesized that cognitive 
functioning would not deteriorate during long-term GH treatment and would progress 
at the same pace as healthy references. Additionally, we hypothesized that starting 
GH during infancy could benefit cognitive functioning more than starting GH later in 
childhood.  
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METHODS 
 
Patients 
A longitudinal, prospective cohort study was performed in 43 children with PWS to 
investigate the effects of 8 years of GH on cognitive functioning. All children were 
selected from our Dutch PWS Cohort based on the following criteria; 1) genetically 
confirmed diagnosis of PWS, 2) naïve to GH treatment at time of enrolment, 3) at 
least 3 Wechsler Intelligence Scale for Children (WISC) tests performed during 8 
years of GH. Thirty-five of 43 children participated in our previous study investigating 
cognitive development in children with PWS during 4 years of GH treatment2.  
 
In addition, a cross-sectional study was performed to investigate whether starting GH 
treatment during infancy, i.e. before the age of 2 years, would result in improved 
cognitive functioning after 8 years of GH. We compared WISC results after 8 years of 
GH of a separate group of 22 children with PWS from our Dutch PWS Cohort who 
started GH treatment during infancy to the 43 longitudinally studied children who 
started GH later in childhood. We could not evaluate the longitudinal effects of 8 
years of GH on cognitive functioning in the first group, because WISC is not suitable 
for children younger than 6 years of age. After 8 years of continuous GH treatment, 
all 22 children who started GH during infancy were older than 6 years and cognitive 
functioning could be tested by WISC.  
 
The study protocol was approved by the Medical Ethics Committee of the Erasmus 
Medical Center (Rotterdam, The Netherlands) and the collaborating centers. Written 
informed consent was obtained from parents and from children older than 12 years; 
assent was obtained from children younger than 12 years. 
 
Design 
In this prospective cohort study all participants were followed at the Dutch PWS 
Reference Center in collaboration with paediatric endocrinologists and paediatricians 
in other hospitals in the Netherlands. Children were treated with Genotropin (Pfizer, 
New York), administered subcutaneously once daily at bedtime in a dose of 1 
mg/m2/day (≈0.035 mg/kg/day) for 8 consecutive years. All children were GH naïve 
at start of the study. The GH dose was regularly adjusted based on calculated body 
surface area and serum IGF-I levels. During the study, all children were seen every 
three months for anthropometric measurements by the PWS team of the Dutch PWS 
Reference Center. Cognitive functioning was measured biennially during 8 years of 
GH treatment by a psychologist experienced in testing children with PWS, in our 
PWS Reference Center (Erasmus University Medical Center/Sophia Children’s 
Hospital, Rotterdam, The Netherlands). 
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Anthropometry 
Height was measured using a Harpenden stadiometer (Holtain Limited, Crosswell, 
United Kingdom); weight was measured on a calibrated electronic digital scale 
(Servo Balance KA-20-150S; Servo Berkel Prior, Katwijk, The Netherlands) and head 
circumference with a measuring tape. Height, weight, body mass index (BMI) and 
head circumference were expressed as standard deviation scores (SDS) adjusting 
for gender and age according to Dutch reference values16,17 using Growth Analyser 
4.0 (available at www.growthanalyser.org). 
 
Cognition 
Cognitive functioning was assessed by a shortened version of the Wechsler 
Intelligence Scale for Children (WISC), which is suitable for children between the age 
of 6 and 16 years18. The WISC is a well-recognized measure of cognitive ability and 
demonstrates strong reliability for diagnosis of mild to moderate intellectual 
disability19. The subtests Block Design, Vocabulary and Similarities were used. Block 
design was used to assess performance IQ, Vocabulary and Similarities were used 
to assess verbal IQ20. Short versions of the total tests were performed because of the 
limited attention span of children with PWS. Results of the short version of the WISC 
are correlated with the full-scale IQ test21-23.  
 
All scores were expressed as SDS based on a Dutch population with the same age. 
Normalized scores ranged from 1 (-3 SDS) to 19 (+3 SDS), with a mean of 10 (0 
SDS). A subtest score between -2 and +2 SDS was considered within the normal 
range. Calculation of total IQ was performed using: Total IQ (TIQ) = 45.3 + 2.91 x 
Vocabulary SDS + 2.5 x Block design SDS). This formula has been used in other 
studies and is based on a Dutch reference population24,25.    
 
Statistical analysis 
Statistical analyses were performed with the Statistical Package for the Social 
Sciences 24.0 (SPSS, Chicago, Illinois). Baseline data were expressed as median 
(interquartile range, IQR). Gender and genotypic differences in baseline cognitive 
functioning and cognitive functioning after 8 years of GH were calculated by Mann-
Whitney U tests. Correlations between cognitive functioning and age, head 
circumference and serum IGF-I levels were calculated by Spearman’s correlation 
analysis. 
 
Changes in cognitive functioning during 8 years were analysed using repeated 
measurements analysis, with years of GH use (0 = baseline, 24 = 2 years of GH 
treatment, 48 = 4 years of GH treatment, 72 = 6 years of GH treatment, 96 = 8 years 
of GH treatment) as a categorical independent variable and a compound symmetry 
covariance matrix. The results of the repeated measurement analyses were 
expressed as estimated mean (95% confidence interval, CI). The effects of age, 
gender, genotype, head circumference and serum IGF-I levels on cognitive 
functioning during GH-treatment were investigated by using these variables as 
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factors (in case of nominal or ordinal variables) or covariates (in case of scale 
variables) in the model. All subtest scores and TIQ scores were corrected for age, 
gender and genotype. 
 
Cognitive functioning after 8 years of GH of the children with PWS who started GH 
during infancy (before the age of 2 years) were compared to the longitudinally 
studied children with PWS who started GH later in childhood by using unpaired t-
tests. P-values less than 0.05 were considered statistically significant. 
 
RESULTS 
 
Baseline clinical characteristics and cognitive functioning 
Forty-three children with PWS (29 girls) who started GH at a median (IQR) age of 8.1 
(6.6; 11.5) years were studied during 8 years of continuous GH. Baseline clinical 
characteristics and cognitive functioning are shown in Table 1. Estimated mean 
baseline Block Design score was below the lower limit of the reference range of a 
healthy Dutch population without PWS; while Vocabulary and Similarities subtest 
scores were within the reference ranges, i.e. between -2 and +2 SDS. Estimated 
mean (95% CI) baseline TIQ was 66 (60; 72), consistent with a mild mental 
impairment. 
 
 
 
Baseline cognitive functioning was neither different between boys and girls, nor 
between children with a deletion and a mUPD / imprinting center defect (ICD) / 
translocation (p>0.12). Older age tended to be associated with a lower score on the 
Table 1. Clinical characteristics at start of GH in longitudinally studied children with PWS
Number (girls) 43 (29)
Genetic subtype: Deletion / mUPD / ICD / translocation / # 18 / 17 / 4 / 1 / 3
Age at start GH treatment (yrs) 8.1 (6.6; 11.5) 
Height (SDS) -2.4 (-3.5; -1.6)
Weight for height (SDS) 1.9 (1.2; 2.6) 
BMI for age (SDS) 1.4 (0.7; 1.9)
Head circumference (SDS) -0.6 (-0.9; -0.2)
IGF-I (SDS) -1.8 (-2.2; -1.4)
Block Design (SDS) -2.2 (-2.6; -1.8) 
Vocabulary (SDS) -1.9 (-2.3; -1.4) 
Similarities (SDS) -1.5 (-2.1; -0.9) 
Total IQ 66 (60; 72)
Data expressed as median (IQR).  
mUPD = maternal uniparental disomy. ICD = imprinting center defect. # = genotype unknown.
GH = growth hormone. BMI = body mass index. IGF-I = insulin-like growth factor 1.
Cognitive functioning, head circumference and IGF-I are expressed as estimated mean (95% CI).
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Similarities subtest (r=-0.4, p=0.05). The other subtests and estimated TIQ were not 
associated with age (p>0.16). Baseline head circumference was positively 
associated with Block Design SDS (r=0.41, p=0.04) and estimated TIQ (r=0.41, 
p=0.04), but not with Vocabulary and Similarities SDS (r=0.29, p=0.16 and r=0.05, 
p=0.82, resp.). Baseline IGF-I tended to be associated with Block Design SDS 
(r=0.42, p=0.05), but not with the other subtests (p>0.17). 
 
Cognitive functioning during 8 years of GH treatment 
Estimated mean (95% CI) Block Design SDS changed from -2.2 (-2.6; -1.8) at start of 
GH to -1.8 (-2.2; -1.4) after 8 years of GH (p=0.18) and Similarities SDS from -1.5 (-
2.1; -0.9) to -1.3 (-1.9; -0.7, p=0.66). Vocabulary SDS remained similar, being -1.9 (-
2.3; -1.4) at baseline and -1.9 (-2.4; -1.5) after 8 years (p=0.85). These results 
demonstrate that visuospatial skills, abstract verbal reasoning and vocabulary skills 
develop at the same pace as healthy references (Figure 1). Mean estimated (95% 
CI) TIQ changed from 66 (60; 72) to 69 (63; 75, p=0.57). After 8 years of GH, 
estimated TIQ ranged from 51 to 94 and 30% of the children had an estimated TIQ 
above 70, the cut-off for mental disability. Overall, cognitive functioning remained 
similar during 8 years of GH and did not deteriorate.  
 
 
Figure 1. Cognitive functioning during 8 years of GH treatment in children with PWS who 
started GH during childhood. The grey rectangles define the normal range of cognitive 
functioning.  
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estimated TIQ ranged from 51 to 94 and 30% of the children had an estimated TIQ 
above 70, the cut-off for mental disability. Overall, cognitive functioning remained 
similar during 8 years of GH and did not deteriorate.  
 
 
Figure 1. Cognitive functioning during 8 years of GH treatment in children with PWS who 
started GH during childhood. The grey rectangles define the normal range of cognitive 
functioning.  
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Influence of clinical and genetic characteristics on cognitive development 
The course of cognitive functioning during 8 years of GH was similar in boys and girls 
(p>0.26). Genotype significantly influenced the course of Block Design SDS during 8 
years of GH (p<0.01): in children with a deletion, estimated mean (95% CI) Block 
Design SDS changed from -1.8 (-2.3; -1.3) at baseline to -1.5 (-2.0; -1.0) after 8 
years (p=0.13), while it remained similar in children with a mUPD / ICD / 
translocation, being -2.4 SDS (-2.7; -2.1) at baseline and -2.5 (-2.8; -2.2) after 8 
years (p=0.76). After 8 years, median Block Design SDS was significantly higher in 
the children with a deletion (p=0.02). We found no effect of genotype on the course 
of the other subtests (p>0.30). Estimated mean (95% CI) head circumference SDS 
increased from -0.6 (-0.9; -0.2) at baseline to -0.1 (-0.5; 0.2) after 8 years (p<0.01) 
and IGF-I SDS from -1.8 (-2.2; -1.4) to 1.7 (1.3; 2.2, p<0.01), but neither the change 
in head circumference nor the change in IGF-I SDS was associated with the change 
in cognitive functioning during 8 years of GH (p>0.25). A higher IGF-I SDS after 8 
years of GH was still associated with a higher Block Design SDS after 8 years of GH 
(r=0.43, p=0.04). The association between IGF-I and the other subtests after 8 years 
was not statistically significant (p>0.14). 
 
Effect of age at start of GH on cognitive functioning after 8 years of GH  
To investigate whether starting GH during infancy, i.e. before the age of 2 years, 
would result in better cognitive functioning compared to starting GH later in 
childhood, we compared WISC results after 8 years of GH of a (separate) group of 
22 children from our Dutch PWS cohort who started GH at a median (IQR) age of 1.4 
(1.0; 1.8) years to those of the 43 longitudinally investigated children who started GH 
later in childhood (Table 2 and Figure 2). We could not evaluate the longitudinal 
effects of 8 years of GH on cognitive functioning in the first group, because WISC is 
not suitable for children younger than 6 years of age. After 8 years of GH, the 22 
children who started GH during infancy were significantly younger and taller than the 
43 children who started GH later in childhood (p<0.02). Children who started GH 
during infancy had a significantly higher Vocabulary SDS (p<0.01) and estimated TIQ 
score (p=0.04; Figure 2) after 8 years of GH. Scores on the Block Design and 
Similarities subtests were similar (p=0.48 and p=0.16, resp.) between the two groups.  
  
 
Table 2. Clinical characteristics after 8 years of GH
Number (girls) 43 (29) 22 (9)
Genetic subtype
 Deletion / mUPD / ICD / translocation / # 18 / 17 / 4 / 1 / 3 12 / 9 / 0 / 0 / 1
Age at start GH treatment (yrs) 8.11 (6.6; 11.5) 1.4 (1.0; 1.8) 
Age after 8 years of GH (yrs) 16.01 (14.5; 19.4) 9.5 (9.0; 9.8) 
Height (SDS) -0.91 (-1.5; 0.2) 0.2 (-1.0; 1.3) 
Weight for height (SDS) 1.5 (0.3; 2.0) 1.3 (0.2; 1.8) 
Head circumference (SDS) 0.3 (-1.1; 1.1) 0.2 (0.1; 0.5)
Data expressed as median (IQR). 1p<0.02 compared to 22 children who started GH before 2 years of age. 
mUPD = maternal uniparental disomy. ICD = imprinting center defect. # = genotype unknown. GH = growth hormone.
Start of GH during childhood Start of GH during infancy
 61                                                                    Cognitive functioning in children with PWS |  
 
Figure 2. Cognitive functioning after 8 years of GH of the 22 children who started GH 
treatment during infancy, before the age of 2 years, compared to 43 longitudinally studied 
children who started GH later in childhood. Data are presented as mean (SEM). The grey 
rectangles define the normal range of cognitive functioning, the black dots represent the 
children who started GH treatment during infancy and the white triangles represent the 
children who started GH later in childhood. 
 
DISCUSSION 
 
This is the first long-term study investigating cognitive functioning during 8 years of 
continuous GH treatment in children with PWS. Our results demonstrate that the SD 
scores for visuospatial skills, verbal reasoning skills and vocabulary, as well as 
estimated TIQ remain similar during 8 years of GH treatment. This shows that 
cognitive development in GH-treated children with PWS progresses at the same 
pace as healthy references and does not deteriorate.   
 
We previously demonstrated in a 2-year randomized controlled trial that cognitive 
functioning in GH-treated children with PWS developed at the same pace as 
cognitive functioning in healthy references, while there was a significant deterioration 
in abstract verbal reasoning and vocabulary in untreated controls2. In 50 children with 
PWS who were treated with GH for 4 years, visuospatial skills and abstract verbal 
reasoning improved significantly2. In the current study during 8 years of GH 
treatment, the improvement in visuospatial skills did not reach statistical significance. 
Yet, our results are reassuring and they show that GH treatment is able to maintain a 
similar level of cognitive development compared to healthy references.  
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treatment, the improvement in visuospatial skills did not reach statistical significance. 
Yet, our results are reassuring and they show that GH treatment is able to maintain a 
similar level of cognitive development compared to healthy references.  
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We should bear in mind that, although GH seems to benefit cognitive functioning, it 
does so in the context of a developmental disorder with a lower total IQ than the 
general population. Longer duration of GH treatment, therefore, does not 
automatically lead to a continuous increase in IQ scores12. 
 
Because all children with PWS in the Netherlands are treated with GH from a young 
age, we could not compare cognitive development of GH-treated children with PWS 
to children with PWS who were not treated with GH. We acknowledge that an RCT 
would be the first-choice design to investigate the effects of long-term GH on 
cognitive functioning in children with PWS, but it would be unethical to withhold GH 
treatment for 8 years, knowing its positive effects on various outcomes in children 
with PWS. As our short-term RCT showed a deterioration of cognitive abilities in 
children with PWS who were not treated with GH during 2 years2, it is possible that 
cognitive functioning would have deteriorated if the children in the current study were 
not treated with GH. The fact that cognitive functioning did not deteriorate and the 
progress of cognitive development in children with PWS during 8 years of GH 
treatment was similar to healthy references could therefore be interpreted as a 
positive result. 
 
How the genetic aberrations underlying PWS lead to cognitive impairment is largely 
unknown. Studies have shown that it may be related to lower brain volumes and 
lower cortical complexity, due to alterations in gene networks that are important for 
early brain development26,27. Another question that still needs to be elucidated is the 
mechanism through which GH could affect cognitive functioning. A recent review 
about the effects of GH on cognition concluded that GH might stimulate GH receptors 
in brain areas involved in learning and memory, thereby improving cognitive 
functioning10. It is known that GH receptors are located throughout the brain and that 
GH and IGF-I affect the genesis of neurons, thereby stimulating brain growth, 
development and myelinisation8,9.  
 
A study in untreated adults with PWS reported a correlation between lower IGF-I 
levels and poorer intellectual skills28. We also found a non-significant correlation 
between lower visuospatial skills and lower serum IGF-I levels (r=0.42, p=0.05). This 
shows that GH treatment might improve cognitive functioning by increasing IGF-I 
levels in patients with PWS. However, it has also been shown that GH has effects on 
the central nervous system that are independent of IGF-I levels29. Baseline head 
circumference and visuospatial skills at start of GH were significantly associated. 
However, the increase in head circumference during GH was not associated with the 
change in cognitive functioning, demonstrating that, even though head circumference 
has previously been associated with cognitive functioning, other determinants might 
be more important for cognitive development and head growth25,30,31. 
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After 8 years of GH, children with a deletion had significantly better visuospatial skills 
compared to those with a mUPD / ICD / translocation. Some studies have also 
described genotypic differences in performance IQ1-3. It is however difficult to draw 
definite conclusions, due to the large variability in cognitive functioning and the small 
sample-size. After 8 years of GH, estimated TIQ in our study ranged from 51 to 94 
and 30% of children had an estimated IQ above 70 points, the cut-off for mental 
disability. This broad variety in cognitive functioning has been reported in other 
studies and underlines the importance of individual assessment of cognitive and 
social functioning in children with PWS, regardless of the genetic defect. By doing so, 
we can help identify the difficulties that individual children with PWS face and 
develop strategies to best deal with these difficulties27. 
 
Some studies show a correlation between age at start of GH and the effect of GH on 
cognitive functioning. The younger children are at the start of GH treatment, the more 
they might benefit with regard to psychomotor and cognitive development11-13. GH 
treatment in children with PWS is started in a critical period of neurodevelopment, 
which might ameliorate cognitive functioning on the long-term. We found a 
significantly higher vocabulary and estimated TIQ score after 8 years of GH 
treatment in the 22 children who started GH treatment during infancy compared to 
the 43 children who started GH later in childhood. Because WISC is not suitable for 
children younger than 6 years of age, we could not evaluate cognitive functioning at 
start of GH treatment and the longitudinal effects of 8 years of GH in the first group. 
Nevertheless, our results suggest that an early start of GH during infancy might be 
beneficial for cognitive development, as reported in previous studies11-13. 
 
Combined with an early diagnosis and multidisciplinary support from a very young 
age, long-term GH treatment during childhood counteracts the clinical course of 
increasing obesity in PWS and has substantially changed the phenotype of children 
with PWS. Our study shows that cognitive development during 8 years of GH in 
children with PWS progresses at the same pace as healthy peers and does not 
deteriorate. It also shows that vocabulary and estimated TIQ scores after 8 years of 
GH are higher in children who started GH during infancy, a critical period of 
neurodevelopment. Further studies are necessary to confirm our findings. 
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ABSTRACT 
 
Objective Some features of subjects with Prader-Willi syndrome (PWS) resemble 
those seen in growth hormone deficiency (GHD). Children with PWS are treated with 
growth hormone (GH), which has substantially changed their phenotype. Currently, 
young adults with PWS must discontinue GH after attainment of adult height when 
they do not fulfil the criteria of adult GHD. Limited information is available about the 
prevalence of GHD in adults with PWS. This study aimed to investigate the GH/IGF-I 
axis and the prevalence of GHD in previously GH-treated young adults with PWS. 
 
Design Cross-sectional study in 60 young adults with PWS. 
 
Measurements Serum IGF-I and IGFBP-3 levels, GH-peak during combined GHRH-
Arginine stimulation test. 
 
Results Serum IGF-I was <-2 SDS in 2 (3%) patients and IGFBP-3 was within the 
normal range in all but one patient. Median (IQR) GH peak was 17.8 µg/l (12.2; 29.7) 
[≈53.4 mU/l] and below 9 µg/l in 9 (15%) patients. Not one patient fulfilled the criteria 
for adult GHD (GH-peak <9 µg/l and IGF-I<-2 SDS), also when BMI-dependent 
criteria were used. A higher BMI and a higher fat mass percentage were significantly 
associated with a lower GH peak. There was no significant difference in GH peak 
between patients with a deletion or a maternal uniparental disomy (mUPD). 
 
Conclusions In a large group of previously GH-treated young adults with PWS, 
approximately 1 in 7 exhibited a GH peak <9 µg/l during a GHRH-Arginine test. 
However, none of the patients fulfilled the consensus criteria for adult GHD.    
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INTRODUCTION 
 
Prader-Willi syndrome (PWS) is a rare disorder resulting from the lack of expression 
of the PWS region (q11-q13) on the paternally derived chromosome 15. This is 
mostly caused by a paternal deletion or maternal uniparental disomy (mUPD) and in 
some cases by an imprinting center defect or paternal chromosomal translocation1,2. 
Clinical findings change with age, with infancy being characterized by muscular 
hypotonia and failure to thrive, while short stature, psychomotor delay, hyperphagia 
and obesity are more prominent during childhood and adulthood1,3. 
 
Some features of people with PWS resemble those seen in growth hormone 
deficiency (GHD), such as short stature and an abnormal body composition with a 
low lean body mass (LBM) and an increased fat mass (FM). Long-term continuous 
growth hormone (GH) treatment in children with PWS improves body composition, 
linear growth, physical strength, cognition and adaptive functioning, substantially 
changing the phenotype of children with PWS4-9. Currently, young adults with PWS 
have to stop GH treatment after attainment of adult height, when they do not fulfil the 
criteria of adult GHD. Studies have shown that GH treatment is beneficial for adults 
with PWS, with a sustained improvement in FM and LBM when GH is continued after 
attainment of adult height, and a deterioration of body composition when GH 
treatment is discontinued10,11. 
 
Reduced serum insulin-like growth factor (IGF)-I levels and a reduced GH response 
to provocative stimuli were found in a varying percentage of children and adults with 
PWS3,12-18. Most studies in adults with PWS have investigated GHD in adults who 
were not treated with GH during childhood and the prevalence of GHD varied 
dependent on the diagnostic test and the chosen cut-off points, which were or were 
not corrected for BMI. This study aimed to assess the GH response to a GHRH-
Arginine stimulation test in a large sample of young adults with PWS who had 
attained adult height and were previously treated with GH during childhood.  
 
METHODS 
 
Patients 
Inclusion criteria for the present study were (1) genetically confirmed diagnosis of 
PWS by a positive methylation test, (2) growth hormone (GH) treatment during 
childhood for at least two years, and (3) having attained adult height, defined as a 
height velocity less than 0.5 cm per six months and epiphyseal closure as 
demonstrated by a radiograph of the left hand and wrist. Exclusion criteria were (1) 
medication to reduce weight (fat) or (2) non-cooperative behaviour. Sixty subjects 
were included, who were all on a diet and exercise program. Written informed 
consent was obtained from patients and their parents or legal representatives. The 
study protocol was approved by the Medical Ethics Committee of the Erasmus 
University Medical Center, Rotterdam.  
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Design 
All participants were followed at the Dutch PWS Reference Center. They were 
treated with biosynthetic GH (Pfizer Inc., New York, NY) during childhood, 
administered subcutaneously once daily at bedtime in a dose of 1.0 mg/m2/day 
(≈0.035 mg/kg/day). The GH dose was regularly adjusted based on calculated body 
surface area and serum IGF-I levels. At attainment of adult height, GH treatment was 
discontinued for at least six weeks prior to performing a standard GH-stimulation test 
with Growth Hormone Releasing Hormone (GHRH) and Arginine19. 
 
Anthropometry 
Standing height was measured using a Harpenden Stadiometer and weight was 
measured on a calibrated electric scale (Servo Balance KA-20-150S; Servo Berkel 
Prior, Katwijk, The Netherlands). Height, weight and body mass index (BMI) were 
expressed as standard deviation scores (SDS) using Growth Analyser 4.0 (available 
at www.growthanalyser.org), adjusting for age (18 years) and sex according to Dutch 
reference values20,21.   
 
Body composition 
Body composition was assessed by dual-energy x-ray absorptiometry (DXA, Lunar 
Prodigy, GE Healthcare, Chalfont St Giles, UK), within four months of the GHRH-
Arginine stimulation test in 41 participants. Total fat mass (FM; kg) and lean body 
mass (LBM; kg) were assessed. All scans were made on the same machine, with 
daily quality assurance. The intra-assay coefficient of variation (CV) for fat tissue was 
0.41 to 0.88% and for LBM 1.57 to 4.49%22. FM was also expressed as percentage 
of total body weight (FM%). LBM was calculated as fat-free mass minus bone 
mineral content. FM% SDS and LBM SDS were calculated according to age- and 
sex-matched Dutch reference values23. 
 
GHRH/Arginine test 
Growth hormone stimulation tests started at 8.30 am after overnight fasting, with the 
patients recumbent. After an indwelling catheter had been placed, each participant 
received GHRH (1 µg /kg as intravenous bolus at 0 minutes, with a maximum dose of 
100 µg) and Arginine (0.5 g/kg during 30 minutes, with a maximum dose of 50 g). 
Blood samples for GH determination were drawn at 0, 15, 30, 45, 60 and 90 minutes 
after the intravenous bolus of GHRH. Levels of GH, IGF-I and IGFBP-3 were 
measured using the IDS-iSYS immunoassay system, which is based on 
chemiluminescence. The intra-assay variations were <6.4%, <7.5% and <5.1%, 
respectively. Levels of IGF-I and IGFBP-3 were expressed as SDS, adjusting for age 
and gender24,25.  
 
Statistical analysis 
Statistical analyses were performed with SPSS 24.0 (SPSS Inc., Chicago, IL). Data 
were expressed as median (IQR). The GH response to GHRH and Arginine was 
assessed by the evaluation of the highest GH plasma concentration, i.e. the GH 
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peak. GHD in adults was defined as a GH peak level after GHRH-Arginine test < 9 
µg/l in combination with a serum IGF-I SDS level < –2 adjusted for age and 
gender3,19. We also applied the BMI-dependent cut-off points for the GHRH-Arginine 
test: a GH peak of < 11.5 µg/l if BMI is < 25 kg/m2, a GH peak of < 8.0 µg /l if BMI is 
25-30 kg/m2, and a GH peak of < 4.2 µg/l if BMI > 30 kg/m2 26.  
 
Pearson’s correlation coefficients were used to assess relationships between IGF-I 
and GH peak and anthropometric measurements and body composition variables. 
Student’s t-tests were used to calculate differences between groups. P values less 
than 0.05 were considered statistically significant.  
 
RESULTS 
 
Baseline characteristics 
Sixty young adults with PWS (27 males, 33 females) with a median (IQR) age of 17.9 
(16.3; 19.6) years were included in the current evaluation of GH response to a 
GHRH-Arginine stimulation test (Table 1). GH treatment during childhood was started 
at a median (IQR) age of 6.6 (4.0; 8.8) years. Twenty-nine young adults had a 
deletion (48.3%), 25 a maternal uniparental disomy (mUPD; 41.7%) and five a 
paternal translocation (8.3%). One patient refused further investigation of the genetic 
subtype.  
 
 
 
Twenty-nine patients were receiving sex steroid replacement therapy (SSRT) and 
seven had spontaneous estrogen or testosterone levels within the normal range. The 
remaining 24 subjects were considered hypogonadal, but were not receiving SSRT at 
time of evaluation.  
Table 1. Clinical characteristics at adult height and during childhood 
Age (yrs) 17.9 (16.3; 19.6) 6.6 (4.0; 8.8)
Male / Female (n) 27 / 33 27 / 33
Genetic subtype 
 Deletion / mUPD / translocation / a 29 / 25 / 5 / 1 29 / 25 / 5 / 1
Height for age (SDS) -1.0 (-1.7; -0.3) -2.2 (-3.0; -1.8)
BMI 24.2 (21.1; 27.9) 17.9 (16.3; 19.4)
BMI for age (SDS) 1.1 (-0.2; 1.9) -0.6 (-1.1; 0.1)
FM% 40.5 (35.7; 47.5) 34.2 (28.9; 38.3)
FM% SDS 2.3 (1.8; 2.6) 2.3 (2.1; 2.6)
LBM SDS -2.3 (-3.1; -1.2) -2.5 (-2.8; -2.0)
Data expressed as median (IQR). agenetic subtype unknown. 
BMI: body mass index. FM%: fat mass percentage. LBM: lean body mass.
FM and LBM at adult height was assessed in 41 individuals and in 38 individuals during childhood. 
Adult height During	childhood	
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GH response to GHRH-Arginine test 
Table 2 and Figure 1 show the results of the GHRH-Arginine tests and serum IGF-I 
and IGFBP-3 levels. Median (IQR) GH peak was 17.8 µg/l (12.2; 29,7) [≈53.4 mU/l]. 
Median (IQR) serum IGF-I was -0.4 (-1.1; 0.4) SDS and IGFBP-3 1.6 (1.0; 2.2) SDS.  
Serum IGF-I was < -2 SDS in two (3%) patients and IGFBP-3 was within the normal 
range in all but one participant. Nine participants had a peak GH level < 9 µg/l (15%) 
during the GHRH-Arginine test. None of these patients also had an IGF-I level < -2 
SDS.  
 
 
 
 
Figure 1. GH Peak and IGF-I SDS according to age in 60 young adults with PWS. The 
dashed line shows the cut-off value for GHD (9 µg/l). The open circles represent patients 
with an IGF-I SDS < -2 SDS, the black circles > -2 SDS.   
Table 2. GH response to GHRH-Arginine stimulation test
IGF-I (nmol/l) 32.4 (21.3; 39.6) 7.5 (5.2; 12.7)
IGF-I SDS -0.4 (-1.1; 0.4) -1.7 (-2.2; -0.9)
IGFBP-3 (mg/l) 4.7 (4.0; 5.7) 1.2 (0.9; 1.5)
IGFBP-3 SDS 1.6 (1.0; 2.2) -2.0 (-3.1; -1.4)
GH peak (µg/l) 17.8 (12.2; 29.7) -
Time to GH peak (min) 45.0 (30.0; 60.0) -
Data expressed as median (IQR). *GH naïve before start of GH treatment.
IGF-I: Insulin-like Growth Factor. IGFBP-3: Insulin-like Growth Factor-Binding Protein 3. 
GH: growth hormone.
Adult height During childhood*
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When BMI-dependent criteria were used, nine participants (15%) had a GH peak 
below the cut-off. Again, none of these patients also had an IGF-I < -2 SDS. Thus, 
not one of our patients fulfilled the criteria of adult GHD. 
 
GH peak was not significantly different between participants with a deletion and 
those with a mUPD (p=0.99) or between males and females (p=0.41). There was 
also no significant difference in GH peak between hypogonadal patients who were 
not receiving SSRT and patients who were receiving SSRT or had spontaneous 
estrogen and testosterone levels within the normal range at the time of the GHRH-
Arginine stimulation test (p=0.67). 
 
Correlation analyses  
A higher BMI SDS and a higher FM% SDS were significantly associated with a lower 
GH peak (r= -0.46, p<0.01 and r= -0.43, p<0.01, resp.). The GH peak, however, did 
neither correlate with age or waist-hip ratio (both p>0.13), nor with IGF-I SDS 
(r=0.01, p=0.93). There was no significant correlation between IGF-I SDS and BMI 
SDS or FM% SDS (r= -0.14, p=0.94 and r= 0.008, p=0.96, resp.). 
 
IGF-I at start of GH treatment during childhood 
Clinical characteristics and median serum IGF-I and IGFBP-3 levels of the young 
adults at start of GH treatment during childhood are shown in Tables 1 and 2, 
respectively. Before starting GH treatment at a median age of 6.6 years, 18 children 
(30%) had an IGF-I < -2 SDS. Serum IGF-I was unknown in eight children (13.3%). 
 
Of the 18 children with an IGF-I < -2 SDS at start of GH, only two had an IGF-I < -2 
SDS after cessation of GH. None of them had a GH peak < 9 µg/l during the GHRH-
Arginine test. So, none of the young adults with an IGF-I < -2 SDS at start of GH 
during childhood fulfilled the criteria of adult GHD after cessation of GH treatment at 
attainment of adult height, also when BMI-dependent cut-off values were used. 
Before start of GH treatment, there was no significant difference in height, BMI, FM% 
and LBM SDS between children with an IGF-I < -2 SDS and > -2 SDS (all p>0.34).  
 
DISCUSSION 
 
This study investigated the GH/IGF-I axis and the prevalence of growth hormone 
deficiency (GHD) in a large group of 60 young adults with PWS, who were treated 
with GH for more than 10 years during childhood until attainment of adult height. 
Against expectations, our data show that none of the patients had adult GHD 
according to the consensus criteria, also when BMI was taken into account. Results 
were variable, with some patients having a low serum IGF-I and normal GH peak, 
and others a normal serum IGF-I and low GH peak. In most countries, adults with 
PWS cannot be treated with GH after attainment of adult height, if they do not fulfil 
the consensus criteria for adult GHD. 
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GH response to GHRH-Arginine test 
Table 2 and Figure 1 show the results of the GHRH-Arginine tests and serum IGF-I 
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range in all but one participant. Nine participants had a peak GH level < 9 µg/l (15%) 
during the GHRH-Arginine test. None of these patients also had an IGF-I level < -2 
SDS.  
 
 
 
 
Figure 1. GH Peak and IGF-I SDS according to age in 60 young adults with PWS. The 
dashed line shows the cut-off value for GHD (9 µg/l). The open circles represent patients 
with an IGF-I SDS < -2 SDS, the black circles > -2 SDS.   
Table 2. GH response to GHRH-Arginine stimulation test
IGF-I (nmol/l) 32.4 (21.3; 39.6) 7.5 (5.2; 12.7)
IGF-I SDS -0.4 (-1.1; 0.4) -1.7 (-2.2; -0.9)
IGFBP-3 (mg/l) 4.7 (4.0; 5.7) 1.2 (0.9; 1.5)
IGFBP-3 SDS 1.6 (1.0; 2.2) -2.0 (-3.1; -1.4)
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Time to GH peak (min) 45.0 (30.0; 60.0) -
Data expressed as median (IQR). *GH naïve before start of GH treatment.
IGF-I: Insulin-like Growth Factor. IGFBP-3: Insulin-like Growth Factor-Binding Protein 3. 
GH: growth hormone.
Adult height During childhood*
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When BMI-dependent criteria were used, nine participants (15%) had a GH peak 
below the cut-off. Again, none of these patients also had an IGF-I < -2 SDS. Thus, 
not one of our patients fulfilled the criteria of adult GHD. 
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Arginine stimulation test (p=0.67). 
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SDS or FM% SDS (r= -0.14, p=0.94 and r= 0.008, p=0.96, resp.). 
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the consensus criteria for adult GHD. 
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Patients with PWS have several clinical features that resemble those seen in GHD, 
including short stature and an abnormal body composition with an increased fat mass 
and decreased muscle mass1. Both children and adults with PWS respond 
favourably to GH treatment, with a complete normalization of stature in children, an 
increase in serum IGF-I and IGFBP-3 levels and a significant improvement in body 
composition, without safety concerns4,10,11. It was generally believed that young 
adults with PWS would have GHD and could continue GH treatment after attainment 
of adult height. However, completely unexpected, none of the 60 young adults 
fulfilled the current consensus criteria for the diagnosis of adult GHD. Only two of our 
patients (3%) had an IGF-I level < -2 SDS and none of them had a GH peak < 9 µg/l. 
Thus, a decreased IGF-I level was not accompanied by a low GH peak during 
provocative testing. On the other hand, nine (15%) patients had a low GH peak, but 
completely normal serum IGF-I levels. 
 
The reported prevalence of GHD in children and adults with PWS varies. According 
to a review by Burman et al. 40-100% of children with PWS fulfilled the criteria for GH 
deficiency, depending on the stimulation test used12. Three recent studies 
investigated the prevalence of GHD in mostly GH-naïve adult PWS patients, aged 16 
– 43 years, by performing GHRH-Arginine tests3,16,27. Two of these studies, in 15 and 
41 adult patients, also reported a low prevalence of GHD, with only one (8%) and six 
(15%) of the participants fulfilling the diagnostic criteria for GHD according to BMI-
dependent cut-off points, respectively3,27. In contrast, Grugni et al. described severe 
GHD in 16 out of 37 adults with PWS (43.5%)16. However, mean BMI of their study 
group was 45.2 kg/m2, which is much higher than the median BMI of 24.2 kg/m2 in 
our study and the reported median BMI of approximately 27 kg/m2 in the other two 
studies3,27. Even though BMI-dependent cut-off points were used, a mean BMI of 
45.2 kg/m2 is so far above the upper limit of 30 kg/m2 that there is an increased 
likelihood of a blunted GH response to a GHRH-Arginine test. Conceivably, the 
current BMI-dependent cut-off points may not be suitable for patients with very 
severe obesity28. Also, in contrast to the adults investigated in the aforementioned 
studies, all young adults participating in our study were treated with GH from a 
median age of 6.6 years until attainment of adult height.  
 
The GHRH-Arginine test is reported as reliable as the insulin tolerance test (ITT) for 
(re)testing patients treated with GH during childhood19,29. Given the increased risk of 
severe side effects during an ITT and the higher burden of this test, we chose to 
perform GHRH-Arginine instead of insulin tolerance tests. There is discussion about 
the appropriate cut-off values for GH peak during GHRH-Arginine tests. A cut-off 
value of 15.9 µg/l for severe adult GHD has been proposed for retesting late 
adolescents with childhood-onset GHD. However, due to the small number of 
overweight patients, a separate cut-off for adolescents with a high BMI was not 
obtained30. One third of our patients had a BMI > 25 kg/m2 and the cut-off values as 
proposed by Dreismann et al., are therefore not applicable to our patients with PWS. 
We decided to use the BMI-adjusted adult cut-off values instead26.  
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Two studies in young children with PWS described a low GH peak after Clonidine or 
Arginine in 68 - 85%17,31. One of these studies in 27 children with PWS also 
performed a combined test (GHRH-Arginine or GHRH-pyridostigmine test), which 
showed a much lower prevalence of GHD (15%) than the Clonidine and Arginine 
tests31. As studies in adults with PWS have described a higher prevalence of GHD 
after combined stimulation tests, the authors of both studies suggested that GHD in 
PWS might be due to an evolving process, with pituitary GH reserve decreasing with 
age17,31. Although we did not perform GH stimulation tests during childhood before 
starting GH treatment, our data show that, of the 18 children with an IGF-I < -2 SDS 
at start of GH treatment, all but two patients had normal serum IGF-I levels (>-2 SDS) 
after cessation of GH at adult height attainment. This finding contradicts the 
hypothesis that GHD might become more prevalent with age.  
 
Our data are in line with those of most non-PWS patients with idiopathic childhood-
onset GHD, who have a normal GH response when retested as adults32-34. The 
reasons why are unknown, but may include a variable GH response to stimulation, 
GHD being a transient condition or GHD being partial, preventing normal growth 
during childhood, but not causing symptoms in adulthood. We can, however, not 
exclude that GH treatment stimulates GH secretory cells in the pituitary, and that this 
GH effect persists, even after GH treatment is discontinued. This hypothesis is 
supported by a recent RCT, which showed that one year of placebo in previously 
GH-treated young adults with PWS did not deteriorate cognitive functioning and 
might suggest that the neurotropic effects of long-term GH during childhood last into 
adulthood35.  
 
During the transition period, the body undergoes physical and psychological changes 
that conclude the shift from childhood to adulthood. GH seems to play an important 
role in this transition, as it favourably influences body composition, lipid profile and 
peak bone density in adolescents with GHD36. In PWS, studies have shown a 
deterioration of body composition after cessation of GH treatment, while continuing 
GH after attainment of adult height maintained the improved FM and LBM obtained 
during childhood, supporting the presence of clinical GHD10,11. However, as most 
adults with PWS do not fulfil the consensus criteria for adult GHD, they currently 
cannot be treated with GH after attainment of adult height.  
 
In conclusion, in a large group of previously GH-treated patients with PWS, GH peak 
levels during a GHRH-Arginine test were low in 15% of patients, but not one patient 
fulfilled the criteria for adult GHD. These results are against expectations, as several 
studies have shown that GH treatment has positive effects on body composition and 
health profile in adults with PWS.   
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INTRODUCTION 
 
Prader-Willi syndrome (PWS) results from the lack of expression of the PWS region 
on the paternally inherited chromosome 15, caused by a deletion, maternal 
uniparental disomy (mUPD), imprinting center defect (ICD) or translocation1. 
Hypothalamic dysfunction is an underlying cause for most symptoms of PWS2. 
Treatment with growth hormone (GH) during childhood improves the abnormal body 
composition and enhances mental and motor development, cognition, adaptive 
functioning, linear growth, and bone mineral density (BMD)3-8. 
  
BMD is influenced by endocrine factors such as GH, insulin-like growth factor (IGF)-I 
and sex steroids, but also by body composition and body mass index (BMI)9,10. Both 
sex steroids and GH are known to play an important role in the accrual of peak bone 
mass, which is attained between the age of 18 to 20 years in girls, and 20 to 22 years 
in boys11,12. Recent studies have shown that GH treatment optimizes BMD in 
prepubertal children with PWS4,13, leading to a normal BMD compared to peers4,14. 
During puberty, however, we found a decline in BMD in parallel to incomplete 
pubertal development and low sex hormone levels4,15,16. This could explain the 
reported increased prevalence of osteopenia and osteoporosis resulting in a high 
fracture risk in adults with PWS17-19. The adults in the latter studies were, however, 
not treated with GH or sex steroid replacement therapy (SSRT). 
 
When young adults with PWS without adult GH deficiency have attained adult height 
(AH), they have to stop GH treatment. Recently, we found that young adults with 
PWS who were treated with GH during childhood and have attained AH benefit from 
continuation of GH, by maintaining the improved body composition obtained during 
childhood20. GH treatment is, however, currently not approved for adults with PWS, 
unless they are GH-deficient. In GH-deficient young adults without PWS, BMD 
deteriorates after cessation of GH21-23. Given the beneficial effects of GH on BMD 
during childhood, we hypothesized that BMD would deteriorate during placebo in 
young adults with PWS, while it would be maintained by GH treatment. We, 
therefore, investigated the effects of GH versus placebo on BMD, measured by dual-
energy x-ray absorptiometry (DXA), in young adults with PWS who had attained adult 
height (AH) and were treated with GH during childhood, in a two-year, randomized, 
double-blind, placebo-controlled cross-over GH study. Secondarily, we investigated 
the effects of no SSRT versus SSRT on BMD in hypogonadal young adults with 
PWS.  
 
METHODS 
 
Patients 
Inclusion criteria of the present study were (1) genetically confirmed diagnosis of 
PWS; (2) GH treatment during childhood for at least two years and being on GH at 
time of inclusion (AH); and (3) AH attainment, defined as a height velocity less than 
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ABSTRACT 
 
Context The prevalence of osteoporosis is increased in adults with Prader-Willi 
syndrome (PWS). In children with PWS, growth hormone (GH) treatment has 
beneficial effects on bone mineral density (BMD). BMD might deteriorate after 
cessation of GH at adult height (AH), while continuing GH might maintain BMD. 
 
Objective To investigate the effects of GH versus placebo, and furthermore the 
effects of sex steroid replacement therapy (SSRT), on BMD in GH-treated young 
adults with PWS who had attained AH. 
 
Design Two-year, randomized, double-blind, placebo-controlled, cross-over GH 
study. 
 
Patients 27 young adults with PWS, stratified for gender and BMI. All patients were 
randomly and blindly assigned to receive GH (0.67 mg/m2/day) and placebo, both 
during one year.  
 
Measurements Bone mineral density of the total body (BMDTB) and lumbar spine 
(BMDLS) SDS, measured by dual-energy x-ray absorptiometry. 
 
Results At AH, BMDTBSDS was significantly lower compared to healthy peers 
(p<0.01), while BMADLSSDS was similar. Both BMDTBSDS and BMADLSSDS were 
similar during one year of GH versus one year of placebo. In hypogonadal young 
adults without SSRT, BMDTBSDS and BMADLSSDS decreased during the two-year 
study (p=0.11 and p=0.01), regardless of GH or placebo, while BMDTBSDS increased 
in those with SSRT (p<0.01). 
  
Conclusions: Compared to GH treatment, one year of placebo after attainment of 
AH does not deteriorate BMD SDS in young adults with PWS. In addition, our data 
suggest that GH is not able to prevent the decline in BMD SDS in hypogonadal 
young adults with PWS, unless it is combined with SSRT.   
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0.5 cm per six months and complete epiphyseal fusion. Exclusion criteria were (1) 
medication to reduce weight or fat or (2) non-cooperative behavior. From June 2008 
to January 2014, 33 young adults with PWS fulfilled the inclusion criteria. Two did not 
want to continue daily injections and three refused participation due to too large 
burden of hospital visits. Of the 28 included patients, one 16.7-year old participant 
(BMI 25.0 kg/m2) died of gastric rupture and necrosis, three months after inclusion 
while receiving placebo. Her data were excluded from the present study. 
 
During childhood, patients were treated with the standard GH dose of 1.0 mg/m2/day. 
GH dose was lowered in eight children, due to high serum IGF-I levels. In the present 
study, GH dose was lowered to 0.67 mg/m2/day (≈0.023 mg/kg/day) in all patients. 
Eight patients were using thyroid hormone supplementation (29.6%), two modafinil 
(7.4%), and one patient was using risperidone and citalopram. During the two-year 
study, 8 out of 16 hypogonadal girls, and 3 out of 7 hypogonadal boys received an 
adult dose of sex steroid replacement therapy. All patients were on a diet and 
exercise program.  
 
Design 
Two-year, randomized, double-blind, placebo-controlled, cross-over study 
investigating the effects of one year GH treatment versus one year placebo on bone 
mineral density. Young adults were stratified according to gender and BMI 
(below/above 25 kg/m2) and then randomly and blindly assigned to receive one year 
of subcutaneous injections once daily at bedtime of either 0.67 mg/m2/day GH 
(Genotropin®, 5 mg/ml, Pfizer) or one year of identical appearing placebo (Pfizer), 
after which they crossed-over to the alternative treatment for another year. An 
independent statistician generated the random allocation sequence. Investigators, 
patients and parents were blinded for the allocation. An independent physician 
monitored the safety during the study. Unblinding was not necessary. 
 
Measurements 
Patients were examined every three months by the PWS-team of the Dutch Growth 
Research Foundation in collaboration with pediatric endocrinologists and 
pediatricians in the Netherlands. At each visit, the injection dose was adjusted to the 
calculated body surface area. In addition, patients visited the Erasmus University 
Medical Center at baseline, 6, 12, 18 and 24 months, to obtain bone mineral density 
(BMD), body composition, height and weight.   
  
Bone mineral content (BMC; in grams), BMD (in grams per square centimeter) of the 
total body and lumbar spine (BMDTB and BMDLS), fat mass (FM) and lean body mass 
(LBM) were measured by DXA (Lunar Prodigy; GE Healthcare). All scans were made 
on the same machine, with daily quality assurance. The intra-assay coefficients of 
variation were 1.04% for BMDLS, 0.64% for BMDTB and BMC, 0.41-0.88% for fat 
tissue and 1.57-4.49% for LBM. In case of short stature, BMDLS is underestimated by 
the areal presentation and should therefore be corrected for bone size by calculating 
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the BMADLS. The model: BMADLS = BMDLS * [4/(*width)] was used, with width as 
the mean width of the second to fourth lumbar vertebral body24. BMDTBSDS, 
BMDLSSDS and BMADLSSDS were calculated to age- and sex-matched reference 
values from the Dutch population25,26. Low BMD was defined as a BMDTBSDS or 
BMADLSSDS score of less than -2.027. FM was expressed as percentage of total 
body weight (FM%). FM% SDS and LBM SDS were calculated according to age- and 
sex-matched Dutch reference values26. 
 
Standing height was measured with a calibrated Harpenden stadiometer, weight was 
determined on a calibrated scale (ServoBalance KA-20-150S) and BMI was 
calculated. Height, weight and BMI were expressed as SDS28,29. SDS values were 
calculated with GrowthAnalyser 4.0 (available at www.growthanalyser.org). 
 
Assays 
Blood samples were collected after an overnight fast and IGF-I, testosterone and 
estradiol levels measured in one laboratory. IGF-I was measured using an 
immunometric technique on Immulite 1000 (LKGF1, Siemens Medical Solutions 
Diagnostics) with an interassay variation <7.3%. IGF-I levels were expressed as 
SDS, adjusting for age and gender30. Total early morning serum testosterone and 
estradiol levels were determined by coated tube RIA (Immulite, DPC, Siemens). The 
intra- and interassays CVs of testosterone were below 6 and 9% and for estradiol 
below 5 and 7%, respectively. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 24.0. A power calculation was 
performed, indicating that 24 patients were required to detect a treatment difference if 
the true difference between treatments was 0.6, with a power of 80%. This was 
based on the assumption that the standard deviation of the difference in the 
response variables was 1. To account for attrition, 4 more patients were added. As 
data were normally distributed, parametric tests were used and data expressed as 
mean (standard deviation (SD)). Effects of GH versus placebo were calculated using 
linear mixed model analysis with BMDTBSDS and BMADLSSDS as dependent 
variables and a first-order autoregressive (AR(1)) covariance matrix. Possible carry-
over effects were analyzed by adding the interaction between period and treatment, 
but not found.  
 
The effect of no SSRT versus SSRT was evaluated in hypogonadal young adults 
with PWS using mixed model analysis. In girls, hypogonadism was defined as serum 
estradiol levels <100 pmol/l and/or Tanner stage 3 or less from the age of 14 years, 
and/or no menarche from the age of 16 years. In boys, hypogonadism was defined 
as serum testosterone levels <5 nmol/l and/or Tanner stage 3 or less from the age of 
16 years, and/or serum testosterone levels <10 nmol/l from the age of 18 years. P-
values less than 0.05 were considered statistically significant.  
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Study approval 
Written informed consent was obtained from patients and parents. The study protocol 
was approved by the Medical Ethics Committee of Erasmus University Medical 
Center, Rotterdam, and registered at the Dutch Trial Register (www.trialregister.nl 
NTR1038).  
 
RESULTS 
 
Baseline characteristics  
Table 1 shows the baseline characteristics of 27 young adults with PWS (19 girls, 8 
boys). All participants completed all visits. At baseline, mean (SD) age and BMI SDS 
were 17.2 (1.8) years and 0.9 (1.3), respectively. During childhood, GH treatment 
was started at a mean (SD) age of 8.5 (3.5) years and patients received GH 
treatment for 8.7 (3.2) years until attainment of AH. There were significantly more 
patients with an mUPD, ICD or translocation in the group that received GH in the 
second phase of the RCT, compared to those who received GH in the first phase 
(p=0.04). Baseline BMDTBSDS, BMADLSSDS and other baseline characteristics were 
not significantly different between the treatment groups. 
 
 
 
Bone mineral density at adult height  
At AH, mean (SD) BMDTBSDS and BMADLSSDS were -0.7 (1.1) and -0.1 (1.1), 
respectively (Table 1). Compared to healthy peers, mean BMDTBSDS was 
significantly lower (p<0.01), while BMADLSSDS was similar (p=0.75). Four out of 27 
patients had a BMDTB lower than -2.0 SDS (14.8%), while none of the patients had a 
BMADLSSDS below -2.0 SDS.  
Table 1. Baseline characteristics of total group and per treatment schedule
Boys / girls (n)
Genetic subtype 
 Deletion / mUPD / ICD / translocation
Age (yrs) 17.2 (1.8) 17.2 (2.2) 17.3 (1.2)
Height for age (SDS) -1.3 (0.9) -1.3 (0.9) -1.2 (0.9)
BMI for age (SDS) 0.9 (1.3) 1.0 (1.2) 0.7 (1.3)
Age at start GH treatment (yrs) 8.5 (3.5) 8.2 (3.8) 8.9 (3.2)
Duration of GH treatment (yrs) 8.7 (3.2) 8.9 (3.8) 8.4 (2.5)
IGF-I (SDS) 2.2 (1.0) 1.8 (1.2) 2.5 (0.8)
SSRT (n) 11 5 6
Tanner stage (M or G; 2 / 3 / 4 / 5)
FM% 38.0 (10.9) 39.4 (10.9) 36.4 (11.0)
FM (kg) 25.2 (10.0) 26.3 (10.3) 24.0 (9.9)
Lean mass (kg) 37.5 (7.8) 37.1 (8.3) 37.9 (7.6)
BMDTB (SDS) -0.7 (1.1) -0.5 (0.9) -1.0 (1.3)
BMDLS (SDS) -0.5 (1.1) -0.2 (1.0) -0.7 (1.2)
BMADLS (SDS) -0.1 (1.1) 0.2 (0.9) -0.4 (1.2)
BMC (SDS) -1.0 (1.0) -0.8 (0.8) -1.3 (1.1)
Data expressed as mean with (SD). BMI: body mass index. GH: growth hormone. IGF-I: insulin-like growth factor.  
SSRT: sex steroid replacement therapy. FM%: fat mass percentage. FM: fat mass. BMD: bone mineral density. 
TB: total body. LS: lower spine. BMAD: bone mineral apparent density. BMC: bone mineral content.
9 / 15 / 2 / 1 2 / 10 / 1 / 1 7 / 5 / 1 / 0
5 / 3 / 10 / 9 2 / 3 / 4 / 5 3 / 0 / 6 / 4
PWS (n=27) Placebo / GH (n=14) GH / Placebo (n=13)
8 / 19 4 / 10 4 / 9
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Bone mineral density during GH versus placebo 
Figure 1 shows BMD during one year GH and one year placebo. Compared to GH 
treatment, placebo did not significantly deteriorate BMDTBSDS and BMADLSSDS 
(p=0.51 and p=0.37, resp.). During the two years, BMDTBSDS did not significantly 
change (p=0.20), but BMADLSSDS declined significantly, independent of GH or 
placebo (p<0.01). Similarly, there was no significant difference in the change in 
BMDTB and BMADLS in g/cm3 between GH and placebo, also after correcting for age 
and sex (data not shown). There were no bone fractures, neither during one year of 
GH nor during one year of placebo. 
 
 
Figure 1. BMDTBSDS and BMADLSSDS during 1 year of GH and 1 year of placebo, 
presented as means with 95% CI. The dotted lines represent the period with placebo. 
Significant changes in the total group compared to baseline are indicated with an asterisk. 
 
Bone mineral density and the effect of SSRT in hypogonadal young adults 
We evaluated the effect of no SSRT versus SSRT in hypogonadal young adults with 
PWS during the two-year study. Sixteen out of 19 girls (84.2%) and 7 out of 8 boys 
(87.5%) were hypogonadal of which 8 girls (50%) and 3 boys (42.9%) received 
SSRT. At AH, BMDTBSDS and BMADLSSDS were similar in hypogonadal young 
adults with and without SSRT (p=0.49 and p=0.39, resp.), but the course of 
BMDTBSDS and BMADLSSDS during the two-year study was significantly different 
between the two groups (Figure 2). In hypogonadal patients without SSRT, 
BMDTBSDS slightly decreased from -0.8 to -0.9 SDS (p=0.11), while BMADLSSDS 
decreased from -0.2 at AH to -0.6 SDS during the two-year study (p=0.01), 
independent of GH or placebo. In hypogonadal patients receiving SSRT, BMDTBSDS 
increased significantly from -1.1 at AH to -0.7 SDS during the two-year study 
(p<0.01), while BMADLSSDS remained similar (-0.5 SDS at AH and after two years, 
p=0.79). We also evaluated the effect of no SSRT versus SSRT only in hypogonadal 
women with PWS, but the results were similar to the results in the total group (data 
not shown). Results remained similar after adjusting for age, gender, genotype and 
body composition.   
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Figure 2. BMDTBSDS and BMADLSSDS during 1 year of GH and 1 year of placebo, 
presented as means with 95% CI, in hypogonadal young adults with SSRT (figures on the 
left; black symbols) and hypogonadal young adults with PWS without SSRT (figures on the 
right; white symbols). The dotted lines represent the period with placebo. Significant changes 
in the total group compared to baseline are indicated with an asterisk. 
 
DISCUSSION 
 
This is the first, randomized, double-blind, placebo-controlled cross-over GH study in 
young adults with PWS who were treated with GH during childhood until attainment 
of AH, investigating the effects of cessation versus continuation of GH on BMD. Our 
study demonstrates that, BMDTBSDS and BMADLSSDS were similar during one year 
of GH versus one year of placebo. Independent of GH or placebo, sex steroids had a 
significant role in the course of BMDTBSDS and BMADLSSDS during the two years, 
as both BMDTBSDS and BMADLSSDS decreased in hypogonadal young adults 
without SSRT, while BMDTBSDS improved in hypogonadal young adults who did 
receive SSRT. 
 
Our study shows that, compared to GH treatment, one year of placebo does not 
cause a significant decrease in BMDTBSDS and BMADLSSDS in young adults with 
PWS, who were treated with GH during childhood. This is in line with a study in GH-
naïve adults with PWS (average age 29 years) who were randomized to GH or 
placebo for one year, followed by GH for two additional years. Despite an increase in 
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markers of bone formation, BMDTBSDS did not significantly change, while 
BMADLSSDS significantly decreased during one year of GH compared to placebo. 
There were no changes in BMDTBSDS or BMADLSSDS during the two-year open-
label GH period31. In patients with adult-onset GH deficiency, GH replacement results 
in an initial increase in bone resorption, with a temporary decrease in BMD, and only 
after one year of GH treatment, a gradual increase in BMD32. It might be that one 
year is too short to show an effect of GH versus placebo on BMD. Another 
explanation could be that GH does not predominantly regulate BMD in young adults 
with PWS.  
 
Our data show that, independent of GH or placebo, both BMDTBSDS and 
BMADLSSDS decreased in hypogonadal young adults without SSRT, while 
BMDTBSDS improved in hypogonadal young adults who did receive SSRT. This is in 
line with Jørgensen et al., who found a higher BMDTBSDS in women with PWS on 
SSRT or with normal cyclic estrogen levels compared to hypogonadal women with 
PWS31. There is an important relation between estradiol and testosterone and 
BMD33. In women, adequate levels of estradiol prevent excessive bone resorption34, 
while androgen stimulates the proliferation of preosteoblasts and differentiation of 
osteoblasts33. Previously, we observed a decrease in both BMDTBSDS and 
BMADLSSDS in 64 pubertal children in parallel to a lack of pubertal progression and 
low sex hormone levels4. This occurred opposite to the required increase in BMD 
towards the peak bone mass, which is normally achieved in the early twenties. In this 
study, almost 15% of adolescents with PWS had a baseline BMDTB lower than -2.0 
SDS, which was partially caused by untreated hypogonadism. Not reaching an 
adequate peak bone mass, will lead to an increased fracture risk in later life19,35.  
 
Both a decreased BMD and an increased fracture risk have been described in non-
GH treated adults with PWS18,36. Our data show that BMD SDS decreases in 
hypogonadal young adults with PWS, increasing the gap between hypogonadal 
young adults with PWS and healthy references. It seems that GH is not able to 
prevent this decline in BMD SDS unless it is combined with SSRT, indicating that sex 
steroids play a major role in the development and conservation of BMD in 
adolescents and (young) adults with PWS. Although the administration of SSRT was 
not randomized and our study might have had a selection bias, this suggests that 
SSRT should be considered in non-eugonadal adolescents with PWS to improve 
their bone health in adulthood. There is no consensus on when to start SSRT in 
adolescents with PWS and at which dose. Parents and physicians are reluctant to 
start SSRT, especially in male patients, because of worries about possible side 
effects (e.g. increase in behavioral problems). Very preliminary data show that side 
effects are rare if the dose of SSRT is increased slowly. Further studies are needed 
to confirm our results and to evaluate the optimal dose and starting age of SSRT and 
the long-term effects of combining GH with SSRT on BMD in people with PWS. 
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the long-term effects of combining GH with SSRT on BMD in people with PWS. 
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In conclusion, our study shows that, compared to GH, one year of placebo after 
attainment of AH does not deteriorate BMDTBSDS and BMADLSSDS in young adults 
with PWS. As BMD SDS in hypogonadal young adults with PWS without SSRT 
decreased compared to those who did receive SSRT, our results suggest that GH is 
not able to prevent the decline in BMD SDS in hypogonadal young adults with PWS, 
unless it is combined with SSRT. Close monitoring of BMD in adolescents and young 
adults with PWS is recommended and SSRT should be considered in case of 
hypogonadism and a declining BMD SDS. 
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ABSTRACT 
 
Context Sleep-related breathing disorders (SRBD) are common in people with 
Prader-Willi syndrome (PWS). Young adults with PWS benefit from GH continuation 
after adult height by maintaining the improved body composition obtained during 
childhood. There are, however, no studies about the effects of GH on SRBD in young 
adults with PWS who were treated with GH during childhood. 
 
Objective To investigate the effects of GH versus placebo on SRBD in young adults 
with PWS who were treated with GH during childhood and had attained adult height.  
 
Design 2-year, randomized, double-blind, placebo-controlled, cross-over GH-study  
in 27 young adults with PWS, stratified for gender and BMI. 
 
Intervention Cross-over intervention with GH (0.67 mg/m2/day) and placebo, both 
during one year. 
  
Main outcome measures Apnea hypopnea index (AHI), obstructive apnea index 
(OAI), central apnea index (CAI), measured by polysomnography.  
 
Results Compared to placebo, GH treatment did not increase AHI, CAI or OAI 
(p>0.35). The effect of GH versus placebo was neither different between men and 
women, nor between patients with a deletion or mUPD/ICD. After 2 years, there was 
no difference in AHI, CAI or OAI compared to baseline (p>0.18). Two patients (7%) 
fulfilled the criteria of obstructive sleep apnea (OSA), regardless of GH or placebo.  
 
Conclusions GH compared to placebo does not cause a significant increase in AHI, 
CAI or OAI in adults with PWS who were treated with GH during childhood and have 
attained adult height. Our findings are reassuring and prove that GH can be safely 
administered. 
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INTRODUCTION 
 
Prader-Willi syndrome (PWS) is a genetic disorder, which results from the lack of 
expression of the PWS region on the paternally inherited chromosome 15, caused by 
a deletion, maternal uniparental disomy (mUPD), imprinting center defect (ICD) or 
translocation1,2. Hypothalamic dysfunction is an underlying cause for many 
symptoms related to PWS, which include muscular hypotonia and failure to thrive 
during infancy, and short stature, hyperphagia and obesity during childhood and 
adulthood. Both children and adults with PWS have an abnormal body composition 
with an increased fat mass (FM) and low lean body mass (LBM), even if there is no 
obesity1,3.  
 
Sleep-related breathing disorders (SRBD) are common in patients with Prader-Willi 
syndrome, causing poor sleep quality and excessive daytime sleepiness4-6. PWS 
children have a high Apnea Hypopnea Index (AHI), which is mainly due to central 
apneas and hypopneas7. Obstructive apneas occur more in children and adults with 
a higher BMI7,8. There are several other factors that are thought to influence SRBD in 
PWS, such as facial dysmorphia, lack of response to hypoxia and hypercapnia, and 
airway collapse caused by pharyngeal wall hypotonia and adenoid/tonsil 
hypertrophy4,9. We have also demonstrated that there might be an alteration in 
central ventilatory regulation during stress10.  
 
Currently, children with PWS are treated with long-term growth hormone (GH) 
improving the abnormal body composition, mental and motor development, cognition, 
adaptive functioning and linear growth11-16. There have been some reports on SRBD 
in PWS discussing the safety of GH treatment in children with PWS. We have 
described a non-significant decline in AHI after 6 months of GH treatment in 35 
prepubertal children with PWS and a recent review has concluded that GH can be 
safely administered, provided that SRBD is monitored and treated appropriately7,17.  
 
When young adults with PWS have attained adult height, they have to stop GH 
treatment, unless they are GH deficient. Recently, we found that young adults with 
PWS benefit from continuation of GH compared to placebo by maintaining the 
improved body composition obtained during childhood18. To our knowledge, there are 
no studies about the effects of GH versus placebo on SRBD in young adults with 
PWS who were treated with GH during childhood. We, therefore, investigated the 
effects of one year of GH versus one year of placebo on SRBD, measured by 
polysomnography (PSG), in young adults with PWS who had attained adult height 
and were treated with GH during childhood, in a two-year, randomized, double-blind, 
placebo-controlled cross-over study. We hypothesized that GH would not negatively 
influence SRBD. Secondly, we investigated the prevalence of obstructive sleep 
apnea (OSA) in our cohort of young adults with PWS.   
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METHODS 
 
Patients 
Inclusion criteria were (1) genetically confirmed diagnosis of PWS; (2) GH treatment 
during childhood for at least two years until adult height and on GH at time of 
inclusion; and (3) adult height attainment, defined as complete epiphyseal fusion and 
a height velocity less than 0.5 cm per six months. Exclusion criteria were (1) 
medication to reduce weight or fat or (2) non-cooperative behavior. From June 2008 
to January 2014, 33 young adults with PWS fulfilled the inclusion criteria. Three 
refused participation due to too large burden of hospital visits and two did not want to 
continue daily injections. Of the 28 included patients, one 16.7-year old participant 
(BMI 25.0 kg/m2) died of gastric rupture and necrosis three months after inclusion 
while receiving placebo. Her data were excluded from the present analyses. 
 
During childhood, patients were treated with the standard GH dose of 1.0 mg/m2/day. 
High serum insulin-like growth factor (IGF)-I levels caused lowering of the GH dose in 
eight children. Eleven patients received an adult dose of sex steroid replacement 
therapy (40.7%), 8 patients were using thyroid hormone supplementation (29.6%), 
two modafinil (7.4%), and one patient was using risperidone and citalopram.  
 
Design 
Two-year, randomized, double-blind, placebo-controlled, cross-over study 
investigating the effects of one year of GH treatment versus one year of placebo on 
sleep-related breathing disorders (SRBD). Young adults were stratified according to 
gender and BMI (below/above 25 kg/m2) and then randomly and blindly assigned to 
receive one year of subcutaneous injections once daily at bedtime of either 0.67 
mg/m2/day GH (Genotropin®, 5 mg/ml, Pfizer) or one year of identical appearing 
placebo (Pfizer), after which they crossed-over to the alternative treatment for 
another year. An independent statistician generated the random allocation sequence. 
Investigators, patients and parents were blinded for the allocation. An independent 
physician monitored the safety during the study. Unblinding was not necessary. 
 
Measurements 
Patients were examined every three months by the PWS-team of the Dutch Growth 
Research Foundation, in collaboration with pediatric endocrinologists and 
pediatricians in the Netherlands. At each visit, the injection dose was adjusted to the 
calculated body surface area. In addition, patients visited the Erasmus Medical 
Center at baseline, 6, 12, 18 and 24 months, to obtain body composition, height and 
weight. FM and LBM were measured by DXA (Lunar Prodigy; GE Healthcare). All 
scans were made on the same machine, with daily quality assurance. FM was 
expressed as percentage of total body weight (FM%). FM% SDS and LBM SDS were 
calculated according to age- and sex-matched Dutch reference values19. Standing 
height was measured with a calibrated Harpenden stadiometer (Holtain Ltd., 
Crosswell, UK), weight was determined on a calibrated scale (ServoBalance KA-20-
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150S) and BMI was calculated. Height, weight and BMI were expressed as SDS20,21. 
SDS values were calculated with GrowthAnalyser 4.0 (available at 
www.growthanalyser.org).  
   
At start of the study, after one year and after 2 years, a polysomnography (PSG) was 
performed at the Sleep-Wake Center SEIN, Zwolle, The Netherlands. Young adults 
were admitted to the sleep center at 17.00h, accompanied by one parent. We 
inquired for typical symptoms of OSA at each visit. Recordings included 
electroencephalogram, electro-oculogram, one channel derivation of 
electrocardiogram, and surface electromyography of the submental muscle and both 
anterior tibial muscles. Nasal-oral airflow was monitored by nasal pressure prongs 
fixed in the nose, respiratory effort by thoraco-abdominal gauges and oxygen 
saturation (SaO2) by pulse oximetry. All polysomnographic records were evaluated 
independently by 2 persons, both certified in PSG analysis, and scored according to 
the adult rules of the American Academy of Sleep Medicine (AASM) Manual22. 
Seventeen patients also had a PSG during childhood GH treatment.  
 
An obstructive apnea was defined as a reduction of airflow of 90% or more for at 
least 10 seconds with continuous breathing effort during the apnea. An apnea was 
considered central if the respiratory event was associated with absent breathing 
effort for 10 seconds or more with an arousal or a decrease in SaO2 of at least 3%. 
Hypopneas were defined as a reduction of airflow of at least 30% for 10 seconds or 
more, with a decrease in SaO2 of at least 3% or an arousal22. The number of 
obstructive, central and mixed apneas and hypopneas were counted during the total 
sleep time and an Apnea-Hypopnea Index (AHI) was calculated per hour of sleep. 
The Obstructive Apnea Index (OAI) was defined as the number of obstructive apneas 
per hour of sleep and the Central Apnea Index (CAI) as the number of central apneas 
per hour of sleep. OSA was defined as an AHI  5 events/h associated with typical 
symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, 
awakening with gasping or choking sensation, snoring, witnessed apneas) or an AHI 
 15 events/h, regardless of symptoms23.  
 
Assays 
Blood samples were collected after an overnight fast and serum IGF-I levels 
measured in one laboratory. IGF-I was measured using an immunometric technique 
on Immulite 1000 (LKGF1, Siemens Medical Solutions Diagnostics) with an 
interassay variation <7.3%. IGF-I levels were expressed as SDS, adjusting for age 
and gender24.  
 
Statistical analysis 
Statistical analyses were performed with SPSS 24.0. Data were expressed as mean 
(SD) in case of a Gaussian distribution and as median (interquartile range (IQR)) in 
case of a non-Gaussian distribution. Gender and genotypic differences in AHI, CAI 
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calculated body surface area. In addition, patients visited the Erasmus Medical 
Center at baseline, 6, 12, 18 and 24 months, to obtain body composition, height and 
weight. FM and LBM were measured by DXA (Lunar Prodigy; GE Healthcare). All 
scans were made on the same machine, with daily quality assurance. FM was 
expressed as percentage of total body weight (FM%). FM% SDS and LBM SDS were 
calculated according to age- and sex-matched Dutch reference values19. Standing 
height was measured with a calibrated Harpenden stadiometer (Holtain Ltd., 
Crosswell, UK), weight was determined on a calibrated scale (ServoBalance KA-20-
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150S) and BMI was calculated. Height, weight and BMI were expressed as SDS20,21. 
SDS values were calculated with GrowthAnalyser 4.0 (available at 
www.growthanalyser.org).  
   
At start of the study, after one year and after 2 years, a polysomnography (PSG) was 
performed at the Sleep-Wake Center SEIN, Zwolle, The Netherlands. Young adults 
were admitted to the sleep center at 17.00h, accompanied by one parent. We 
inquired for typical symptoms of OSA at each visit. Recordings included 
electroencephalogram, electro-oculogram, one channel derivation of 
electrocardiogram, and surface electromyography of the submental muscle and both 
anterior tibial muscles. Nasal-oral airflow was monitored by nasal pressure prongs 
fixed in the nose, respiratory effort by thoraco-abdominal gauges and oxygen 
saturation (SaO2) by pulse oximetry. All polysomnographic records were evaluated 
independently by 2 persons, both certified in PSG analysis, and scored according to 
the adult rules of the American Academy of Sleep Medicine (AASM) Manual22. 
Seventeen patients also had a PSG during childhood GH treatment.  
 
An obstructive apnea was defined as a reduction of airflow of 90% or more for at 
least 10 seconds with continuous breathing effort during the apnea. An apnea was 
considered central if the respiratory event was associated with absent breathing 
effort for 10 seconds or more with an arousal or a decrease in SaO2 of at least 3%. 
Hypopneas were defined as a reduction of airflow of at least 30% for 10 seconds or 
more, with a decrease in SaO2 of at least 3% or an arousal22. The number of 
obstructive, central and mixed apneas and hypopneas were counted during the total 
sleep time and an Apnea-Hypopnea Index (AHI) was calculated per hour of sleep. 
The Obstructive Apnea Index (OAI) was defined as the number of obstructive apneas 
per hour of sleep and the Central Apnea Index (CAI) as the number of central apneas 
per hour of sleep. OSA was defined as an AHI  5 events/h associated with typical 
symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, 
awakening with gasping or choking sensation, snoring, witnessed apneas) or an AHI 
 15 events/h, regardless of symptoms23.  
 
Assays 
Blood samples were collected after an overnight fast and serum IGF-I levels 
measured in one laboratory. IGF-I was measured using an immunometric technique 
on Immulite 1000 (LKGF1, Siemens Medical Solutions Diagnostics) with an 
interassay variation <7.3%. IGF-I levels were expressed as SDS, adjusting for age 
and gender24.  
 
Statistical analysis 
Statistical analyses were performed with SPSS 24.0. Data were expressed as mean 
(SD) in case of a Gaussian distribution and as median (interquartile range (IQR)) in 
case of a non-Gaussian distribution. Gender and genotypic differences in AHI, CAI 
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and OAI were calculated by independent samples T-tests or Mann-Whitney U tests 
depending on the distribution. 
 
Effects of GH versus placebo were calculated using the following formulas for 1) AHI: 
(AHI during GH - AHI during Placebo) / 2; 2) (CAI during GH - CAI during 
Placebo) / 2 and 3) (OAI during GH - OAI during Placebo) / 2. The mean outcome 
of these calculations was compared to 0 using a one-sample t-test. We did not find 
carry-over or period effects, which were analyzed by comparing the change in AHI, 
CAI and OAI during GH and placebo between the two treatment sequences (GH 
followed by placebo and placebo followed by GH) and during the first and second 
year of the study, respectively. AHI, CAI and OAI at start and after 2 years in the 
current study were compared to AHI, CAI and OAI during the childhood PSG using 
Wilcoxon Signed Ranks tests. Correlations between AHI, CAI or OAI and height 
SDS, BMI SDS, FM% SDS or IGF-I SDS were calculated by Spearman’s correlation 
analysis. P-values less than 0.05 were considered statistically significant.  
 
Study approval 
Written informed consent was obtained from patients and parent(s) / caregiver(s). 
The study protocol was approved by the Medical Ethics Committee of Erasmus 
University Medical Center, Rotterdam, and registered at the Dutch Trial Register 
(www.trialregister.nl NTR1038).  
 
RESULTS 
 
Baseline characteristics at adult height 
 
Clinical characteristics 
Baseline clinical characteristics of the 27 young adults with PWS who participated in 
this study after attainment of adult height are shown in Table 1. Mean (SD) age and 
BMI were 17.2 (1.8) years and 0.9 (1.3) SD-score (SDS), respectively. The group 
that received GH in the second year of the study consisted of more patients with an 
mUPD or ICD (p=0.046). There were no other significant differences between the 
treatment groups (all p>0.24). 
 
Sleep-related breathing 
Baseline median (IQR) total sleep time was 8.1 (7.0; 8.7) hours and AHI 3.6 (1.4; 4.7) 
events/hour (Table 2). Total sleep time was longer in the patients who received GH in 
the second phase of the RCT (p=0.02). The other polysomnographic characteristics 
were similar in both treatment arms (all p>0.06). Four participants had an abnormal 
AHI of  5 events/hour at baseline (14.8%), but none of them had typical symptoms 
of OSA and therefore did not fulfil the current criteria of OSA in adults 23. 
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Male PWS patients had a higher median AHI and CAI than female PWS patients (4.7 
vs. 2.1 and 1.9 vs. 0.8, resp., both p=0.01). Median OAI was 0 in both male and 
female patients (p=0.67). There was no difference in AHI and CAI between young 
adults with a deletion and an mUPD or ICD (all p>0.24). OAI was slightly higher in 
patients with an mUPD or ICD than in patients with a deletion (0.2 vs. 0.0, p=0.04). 
Neither height SDS nor BMI SDS, FM% SDS or IGF-I SDS at adult height were 
associated with AHI, CAI or OAI at adult height.  
 
Sleep-related breathing during GH versus placebo 
Compared to placebo, one year of GH did not increase AHI, CAI or OAI (p>0.35) 
(Figure 1). The effect of GH versus placebo on AHI, CAI or OAI was neither different 
between boys and girls (p>0.23), nor between young adults with a deletion or an 
mUPD or ICD (p>0.14). After 2 years, there was no significant difference in AHI, CAI 
or OAI compared to baseline, regardless of GH or placebo (p>0.18). 
 
Table 3 shows the 11 patients with an AHI of  5 events/hour during at least one of 
the PSG’s performed during the 2-year study. At start of the study, 4 patients had an 
AHI of  5 events/hour. Seven patients developed an AHI of  5 events/hour during 
the study, 5 during placebo and 2 during GH. Two of them fulfilled the current criteria 
of OSA (7% of the total group), because they also developed mild complaints of 
Table 1. Baseline characteristics of the total group and per treatment schedule
Boys / girls (n)
Genetic subtype 
 Deletion / mUPD / ICD / translocation
Age (yrs) 17.2 (1.8) 17.2 (2.2) 17.3 (1.2)
Duration of childhood GH treatment (yrs) 8.7 (3.2) 8.9 (3.8) 8.4 (2.5)
Adult height (SDS) -1.3 (0.9) -1.3 (0.9) -1.2 (0.9)
BMI (kg/m2) 24.1 (4.0) 24.6 (4.1) 23.6 (4.1)
BMI (SDS) 0.9 (1.3) 1.0 (1.2) 0.7 (1.3)
IGF-I (SDS) 2.2 (1.0) 1.8 (1.2) 2.5 (0.8)
FM% 38.0 (10.9) 39.4 (10.9) 36.4 (11.0)
FM% (SDS) 1.7 (0.7) 1.8 (0.7) 1.6 (0.7)
Lean mass (kg) 37.5 (7.8) 37.1 (8.3) 37.9 (7.6)
Lean mass (SDS) -1.6 (1.0) -1.6 (1.0) -1.6 (0.9)
Data expressed as mean with (SD). GH: growth hormone.  FM%: fat mass percentage. 
*The group that received GH in the second year of the study consisted of more patients with an mUPD or ICD (p=0.046). 
9 / 15 / 2 / 1 2 / 10 / 1 / 1* 7 / 5 / 1 / 0
PWS (n=27) Placebo / GH (n=14) GH / Placebo (n=13)
8/19 4/10 4/9
Table 2. Baseline sleep-related breathing in the total group and per treatment schedule
Total Sleep Time (hours) 8.1 (7.0; 8.7) 8.4 (7.7; 8.9)* 7.4 (6.5; 8.1)
Apnea hypopnea index 3.6 (1.4; 4.7) 3.4 (1.0; 4.7) 3.8 (1.7; 4.8)
Central apnea index 1.1 (0.6; 2.0) 1.0 (0.5; 2.3) 1.1 (0.6; 1.9)
Obstructive apnea index 0.0 (0.0; 0.3) 0.0 (0.0; 0.2) 0.0 (0.0; 0.6)
Duration longest apnea (seconds) 22.2 (18.6; 27.9) 23.3 (20.1; 28.1) 20.4 (18.1; 25.1)
Median sleep SaO2 (%) 96.0 (95.5; 96.7) 96.1 (94.6; 96.7) 96.0 (95.6; 96.8)
Minimum SaO2 (%) 90.0 (86.0; 92.0) 89.0 (83.0; 92.0) 91.0 (88.5; 92.5)
Data expressed as median (IQR). SaO2: oxygen saturation.
*Total Sleep Time was significantly longer in the patients who received GH in the second phase of the RCT (p=0.02).
PWS (n=27) Placebo / GH (n=14) GH / Placebo (n=13)
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and OAI were calculated by independent samples T-tests or Mann-Whitney U tests 
depending on the distribution. 
 
Effects of GH versus placebo were calculated using the following formulas for 1) AHI: 
(AHI during GH - AHI during Placebo) / 2; 2) (CAI during GH - CAI during 
Placebo) / 2 and 3) (OAI during GH - OAI during Placebo) / 2. The mean outcome 
of these calculations was compared to 0 using a one-sample t-test. We did not find 
carry-over or period effects, which were analyzed by comparing the change in AHI, 
CAI and OAI during GH and placebo between the two treatment sequences (GH 
followed by placebo and placebo followed by GH) and during the first and second 
year of the study, respectively. AHI, CAI and OAI at start and after 2 years in the 
current study were compared to AHI, CAI and OAI during the childhood PSG using 
Wilcoxon Signed Ranks tests. Correlations between AHI, CAI or OAI and height 
SDS, BMI SDS, FM% SDS or IGF-I SDS were calculated by Spearman’s correlation 
analysis. P-values less than 0.05 were considered statistically significant.  
 
Study approval 
Written informed consent was obtained from patients and parent(s) / caregiver(s). 
The study protocol was approved by the Medical Ethics Committee of Erasmus 
University Medical Center, Rotterdam, and registered at the Dutch Trial Register 
(www.trialregister.nl NTR1038).  
 
RESULTS 
 
Baseline characteristics at adult height 
 
Clinical characteristics 
Baseline clinical characteristics of the 27 young adults with PWS who participated in 
this study after attainment of adult height are shown in Table 1. Mean (SD) age and 
BMI were 17.2 (1.8) years and 0.9 (1.3) SD-score (SDS), respectively. The group 
that received GH in the second year of the study consisted of more patients with an 
mUPD or ICD (p=0.046). There were no other significant differences between the 
treatment groups (all p>0.24). 
 
Sleep-related breathing 
Baseline median (IQR) total sleep time was 8.1 (7.0; 8.7) hours and AHI 3.6 (1.4; 4.7) 
events/hour (Table 2). Total sleep time was longer in the patients who received GH in 
the second phase of the RCT (p=0.02). The other polysomnographic characteristics 
were similar in both treatment arms (all p>0.06). Four participants had an abnormal 
AHI of  5 events/hour at baseline (14.8%), but none of them had typical symptoms 
of OSA and therefore did not fulfil the current criteria of OSA in adults 23. 
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Male PWS patients had a higher median AHI and CAI than female PWS patients (4.7 
vs. 2.1 and 1.9 vs. 0.8, resp., both p=0.01). Median OAI was 0 in both male and 
female patients (p=0.67). There was no difference in AHI and CAI between young 
adults with a deletion and an mUPD or ICD (all p>0.24). OAI was slightly higher in 
patients with an mUPD or ICD than in patients with a deletion (0.2 vs. 0.0, p=0.04). 
Neither height SDS nor BMI SDS, FM% SDS or IGF-I SDS at adult height were 
associated with AHI, CAI or OAI at adult height.  
 
Sleep-related breathing during GH versus placebo 
Compared to placebo, one year of GH did not increase AHI, CAI or OAI (p>0.35) 
(Figure 1). The effect of GH versus placebo on AHI, CAI or OAI was neither different 
between boys and girls (p>0.23), nor between young adults with a deletion or an 
mUPD or ICD (p>0.14). After 2 years, there was no significant difference in AHI, CAI 
or OAI compared to baseline, regardless of GH or placebo (p>0.18). 
 
Table 3 shows the 11 patients with an AHI of  5 events/hour during at least one of 
the PSG’s performed during the 2-year study. At start of the study, 4 patients had an 
AHI of  5 events/hour. Seven patients developed an AHI of  5 events/hour during 
the study, 5 during placebo and 2 during GH. Two of them fulfilled the current criteria 
of OSA (7% of the total group), because they also developed mild complaints of 
Table 1. Baseline characteristics of the total group and per treatment schedule
Boys / girls (n)
Genetic subtype 
 Deletion / mUPD / ICD / translocation
Age (yrs) 17.2 (1.8) 17.2 (2.2) 17.3 (1.2)
Duration of childhood GH treatment (yrs) 8.7 (3.2) 8.9 (3.8) 8.4 (2.5)
Adult height (SDS) -1.3 (0.9) -1.3 (0.9) -1.2 (0.9)
BMI (kg/m2) 24.1 (4.0) 24.6 (4.1) 23.6 (4.1)
BMI (SDS) 0.9 (1.3) 1.0 (1.2) 0.7 (1.3)
IGF-I (SDS) 2.2 (1.0) 1.8 (1.2) 2.5 (0.8)
FM% 38.0 (10.9) 39.4 (10.9) 36.4 (11.0)
FM% (SDS) 1.7 (0.7) 1.8 (0.7) 1.6 (0.7)
Lean mass (kg) 37.5 (7.8) 37.1 (8.3) 37.9 (7.6)
Lean mass (SDS) -1.6 (1.0) -1.6 (1.0) -1.6 (0.9)
Data expressed as mean with (SD). GH: growth hormone.  FM%: fat mass percentage. 
*The group that received GH in the second year of the study consisted of more patients with an mUPD or ICD (p=0.046). 
9 / 15 / 2 / 1 2 / 10 / 1 / 1* 7 / 5 / 1 / 0
PWS (n=27) Placebo / GH (n=14) GH / Placebo (n=13)
8/19 4/10 4/9
Table 2. Baseline sleep-related breathing in the total group and per treatment schedule
Total Sleep Time (hours) 8.1 (7.0; 8.7) 8.4 (7.7; 8.9)* 7.4 (6.5; 8.1)
Apnea hypopnea index 3.6 (1.4; 4.7) 3.4 (1.0; 4.7) 3.8 (1.7; 4.8)
Central apnea index 1.1 (0.6; 2.0) 1.0 (0.5; 2.3) 1.1 (0.6; 1.9)
Obstructive apnea index 0.0 (0.0; 0.3) 0.0 (0.0; 0.2) 0.0 (0.0; 0.6)
Duration longest apnea (seconds) 22.2 (18.6; 27.9) 23.3 (20.1; 28.1) 20.4 (18.1; 25.1)
Median sleep SaO2 (%) 96.0 (95.5; 96.7) 96.1 (94.6; 96.7) 96.0 (95.6; 96.8)
Minimum SaO2 (%) 90.0 (86.0; 92.0) 89.0 (83.0; 92.0) 91.0 (88.5; 92.5)
Data expressed as median (IQR). SaO2: oxygen saturation.
*Total Sleep Time was significantly longer in the patients who received GH in the second phase of the RCT (p=0.02).
PWS (n=27) Placebo / GH (n=14) GH / Placebo (n=13)
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snoring and daytime sleepiness, one during GH, the other during placebo 23. AHI in 
these 2 patients consisted mainly of hypopneas, OAI being 0 and 1.2 events/hour. 
Both were obese and had tonsillar hypertrophy, for which they were referred to an 
otolaryngologist. One patient with an AHI  5 events/hour and moderate complaints 
of daytime sleepiness did not fulfil the criteria of OSA, because he was also 
diagnosed with narcolepsy and on modafinil during the study. 
 
 
Figure 1. Apnea Hypopnea Index (AHI), Central Apnea Index (CAI) and Obstructive AI (OAI) 
during one year of GH and one year of placebo, presented as median. The dotted lines 
represent the period with placebo. There were no significant changes during GH versus 
placebo. 
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snoring and daytime sleepiness, one during GH, the other during placebo 23. AHI in 
these 2 patients consisted mainly of hypopneas, OAI being 0 and 1.2 events/hour. 
Both were obese and had tonsillar hypertrophy, for which they were referred to an 
otolaryngologist. One patient with an AHI  5 events/hour and moderate complaints 
of daytime sleepiness did not fulfil the criteria of OSA, because he was also 
diagnosed with narcolepsy and on modafinil during the study. 
 
 
Figure 1. Apnea Hypopnea Index (AHI), Central Apnea Index (CAI) and Obstructive AI (OAI) 
during one year of GH and one year of placebo, presented as median. The dotted lines 
represent the period with placebo. There were no significant changes during GH versus 
placebo. 
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Sleep-related breathing during childhood and adulthood 
Seventeen participants (62.9%) had a PSG during childhood GH treatment (Table 4). 
AHI ranged from 1.0 to 14.7 events/hour and 6 children had an AHI of  5 
events/hour (35%). Only two of these children were reported to have obstructive 
apneas, OAI being 1.9 and 2.0 events/hour. 
 
 
 
Compared to the childhood PSG, AHI, CAI and OAI were neither significantly higher 
at adult height nor after 2 years in the study (all p>0.21). The change in AHI, CAI or 
OAI from childhood to adulthood was neither different between boys and girls 
(p>0.09), nor between patients with a deletion or an mUPD or ICD (p>0.13). 
 
DISCUSSION 
 
This randomized, double-blind, placebo-controlled cross-over GH study in young 
adults with PWS who were treated with GH during childhood until attainment of adult 
height, investigated the effects of GH versus placebo on sleep-related breathing. We 
have previously shown that young adults with PWS benefit from continuation of GH 
by maintaining the improved body composition obtained during childhood, without 
safety concerns regarding their metabolic health profile18,25. Our study demonstrates 
that, compared to placebo, GH does not cause an increase in AHI, CAI or OAI in 
young adults with PWS. These findings are reassuring and prove that GH can be 
safely administered with regard to SRBD. 
 
Only one other study examined SRBD during GH treatment in 10 adults with PWS26. 
The authors performed a PSG at baseline and 6 weeks after the initiation of GH 
treatment. Nine of 10 adults showed an improvement in AHI. One adult with 
worsening of the AHI had a concurrent respiratory infection and tonsillar 
hypertrophy26. In children with PWS, several studies investigated the effects of GH 
on SRBD7,27-29. We previously found a non-significant decline in AHI after 6 months 
of GH treatment in 35 prepubertal children with PWS with a median age of 6.0 years 
at start of GH7. Al-Saleh et al. reported no significant change in obstructive apnea 
hypopnea index (OAHI) and CAI during 2 years of GH treatment in 15 children with 
PWS with a median age of 3.7 years at start of GH27. The same research group 
Table 4. Sleep-related breathing during childhood, at adult height and after 2 years
After 2 years (n=14)
Age (years) 10.0 (8.0; 11.5) 17.4 (15.2; 18.3)* 19.3 (16.7; 20.4)*
Total Sleep Time (hours) 8.4 (7.7; 8.7) 8.2 (7.2; 8.9) 7.9 (7.4; 9.0)
Apnea hypopnea index 4.1 (2.6; 6.2) 3.8 (1.4; 4.8) 3.0 (1.2; 5.5)
Central apnea index 1.2 (0.6; 2.8) 1.0 (0.5; 2.1) 1.0 (0.3; 1.5)
Obstructive apnea index 0.0 (0.0; 0.4) 0.0 (0.0; 0.9) 0.0 (0.0; 0.5)
Duration longest apnea (seconds) 18.0 (16.0; 24.5) 22.3 (19.3; 27.2) 21.9 (17.8; 33.8)
Median sleep SaO2 (%) 92.0 (87.0; 98.0) 96.0 (95.5; 96.5)
* 96.1 (95.0; 97.0)*
Number of awakenings 13 (7; 18) 14 (11; 21) 16 (11; 26)*
Data expressed as median (IQR). SaO2: oxygen saturation.
Wilcoxon Signed Rank Tests were performed. * = p<0.05 compared to childhood PSG. 
Childhood (n=17) Adult height (n=17)
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investigated OAHI and CAI in 28 young children with PWS and found a significant 
improvement of the CAI and no significant difference in OAHI between the baseline 
and follow-up PSG, regardless of GH treatment28. Overall, studies about the effects 
of GH on SRBD in children and adults with PWS conclude that GH treatment does 
not negatively influence AHI. However, medical professionals should be aware that 
(mild) upper respiratory tract infections and/or adenotonsillar hypertrophy can cause 
increased obstructive apneas7,29.  
 
The reported prevalence of OSA in people with PWS is variable, due to wide age 
ranges, different diagnostic criteria and a potential referral bias5,6,30. Recent 
guidelines define OSA in adults as an AHI of  5 events/hour combined with typical 
complaints for OSA (e.g. daytime sleepiness, snoring, or witnessed apneas), or an 
AHI of  15 events/hour regardless of complaints23. According to these guidelines, 
two participants in our study (7%) fulfilled the diagnostic criteria of OSA, regardless of 
GH or placebo. However, only one of them had obstructive apneas during sleep with 
an OAI of merely 1.2 events/hour. Based on these patients we would suggest, 
besides evaluating AHI, to specifically assess the number of obstructive apneas. OAI 
might be a more accurate parameter than AHI for diagnosing OSA.   
  
We could compare a PSG performed during childhood GH treatment with a PSG 
performed at adult height and after 2 years in the current study in 17 and 14 
participants, respectively. There was no significant difference in AHI, OAI or CAI 
between the childhood PSG and the PSG at adult height or the PSG after 2 years in 
the study, regardless of GH treatment or placebo. During the childhood PSG, 35% of 
children had an AHI of  5 events/hour. At start and finish of the current study, 
respectively 15% and 22% of young adults, had an AHI of  5 events/hour. These 
data demonstrate that long-term GH treatment during childhood has no negative 
consequences with regard to the prevalence of SRBD in young adults with PWS.  
 
We have previously shown that long-term GH treatment in combination with a healthy 
lifestyle can counteract the clinical course of PWS during childhood and reduce the 
prevalence of morbid obesity12. Median baseline BMI of the participants in the current 
study was 24.1, which is much lower than (young) adults with PWS who were never 
treated with GH. Also, unlike previous reports, we did not find a correlation between 
AHI and BMI or FM% SDS. It is likely that, due to the reduced prevalence of obesity 
in our cohort of young adults with PWS, SRBD occurs less common.  
 
The current consensus guideline for GH treatment in PWS recommends performing a 
PSG before and 3-6 months after starting GH treatment in children with PWS31. 
Based on our data in adults with PWS, we would not recommend a standard PSG at 
attainment of adult height in non-obese patients with PWS who were treated with GH 
during childhood and will continue GH treatment in adulthood. However, clinical signs 
of SRBD need to be monitored and, when indicated, a PSG should be performed.  
 
104 | Chapter 6   
 
Sleep-related breathing during childhood and adulthood 
Seventeen participants (62.9%) had a PSG during childhood GH treatment (Table 4). 
AHI ranged from 1.0 to 14.7 events/hour and 6 children had an AHI of  5 
events/hour (35%). Only two of these children were reported to have obstructive 
apneas, OAI being 1.9 and 2.0 events/hour. 
 
 
 
Compared to the childhood PSG, AHI, CAI and OAI were neither significantly higher 
at adult height nor after 2 years in the study (all p>0.21). The change in AHI, CAI or 
OAI from childhood to adulthood was neither different between boys and girls 
(p>0.09), nor between patients with a deletion or an mUPD or ICD (p>0.13). 
 
DISCUSSION 
 
This randomized, double-blind, placebo-controlled cross-over GH study in young 
adults with PWS who were treated with GH during childhood until attainment of adult 
height, investigated the effects of GH versus placebo on sleep-related breathing. We 
have previously shown that young adults with PWS benefit from continuation of GH 
by maintaining the improved body composition obtained during childhood, without 
safety concerns regarding their metabolic health profile18,25. Our study demonstrates 
that, compared to placebo, GH does not cause an increase in AHI, CAI or OAI in 
young adults with PWS. These findings are reassuring and prove that GH can be 
safely administered with regard to SRBD. 
 
Only one other study examined SRBD during GH treatment in 10 adults with PWS26. 
The authors performed a PSG at baseline and 6 weeks after the initiation of GH 
treatment. Nine of 10 adults showed an improvement in AHI. One adult with 
worsening of the AHI had a concurrent respiratory infection and tonsillar 
hypertrophy26. In children with PWS, several studies investigated the effects of GH 
on SRBD7,27-29. We previously found a non-significant decline in AHI after 6 months 
of GH treatment in 35 prepubertal children with PWS with a median age of 6.0 years 
at start of GH7. Al-Saleh et al. reported no significant change in obstructive apnea 
hypopnea index (OAHI) and CAI during 2 years of GH treatment in 15 children with 
PWS with a median age of 3.7 years at start of GH27. The same research group 
Table 4. Sleep-related breathing during childhood, at adult height and after 2 years
After 2 years (n=14)
Age (years) 10.0 (8.0; 11.5) 17.4 (15.2; 18.3)* 19.3 (16.7; 20.4)*
Total Sleep Time (hours) 8.4 (7.7; 8.7) 8.2 (7.2; 8.9) 7.9 (7.4; 9.0)
Apnea hypopnea index 4.1 (2.6; 6.2) 3.8 (1.4; 4.8) 3.0 (1.2; 5.5)
Central apnea index 1.2 (0.6; 2.8) 1.0 (0.5; 2.1) 1.0 (0.3; 1.5)
Obstructive apnea index 0.0 (0.0; 0.4) 0.0 (0.0; 0.9) 0.0 (0.0; 0.5)
Duration longest apnea (seconds) 18.0 (16.0; 24.5) 22.3 (19.3; 27.2) 21.9 (17.8; 33.8)
Median sleep SaO2 (%) 92.0 (87.0; 98.0) 96.0 (95.5; 96.5)
* 96.1 (95.0; 97.0)*
Number of awakenings 13 (7; 18) 14 (11; 21) 16 (11; 26)*
Data expressed as median (IQR). SaO2: oxygen saturation.
Wilcoxon Signed Rank Tests were performed. * = p<0.05 compared to childhood PSG. 
Childhood (n=17) Adult height (n=17)
 105                                       Sleep related breathing disorders in young adults with PWS |  
investigated OAHI and CAI in 28 young children with PWS and found a significant 
improvement of the CAI and no significant difference in OAHI between the baseline 
and follow-up PSG, regardless of GH treatment28. Overall, studies about the effects 
of GH on SRBD in children and adults with PWS conclude that GH treatment does 
not negatively influence AHI. However, medical professionals should be aware that 
(mild) upper respiratory tract infections and/or adenotonsillar hypertrophy can cause 
increased obstructive apneas7,29.  
 
The reported prevalence of OSA in people with PWS is variable, due to wide age 
ranges, different diagnostic criteria and a potential referral bias5,6,30. Recent 
guidelines define OSA in adults as an AHI of  5 events/hour combined with typical 
complaints for OSA (e.g. daytime sleepiness, snoring, or witnessed apneas), or an 
AHI of  15 events/hour regardless of complaints23. According to these guidelines, 
two participants in our study (7%) fulfilled the diagnostic criteria of OSA, regardless of 
GH or placebo. However, only one of them had obstructive apneas during sleep with 
an OAI of merely 1.2 events/hour. Based on these patients we would suggest, 
besides evaluating AHI, to specifically assess the number of obstructive apneas. OAI 
might be a more accurate parameter than AHI for diagnosing OSA.   
  
We could compare a PSG performed during childhood GH treatment with a PSG 
performed at adult height and after 2 years in the current study in 17 and 14 
participants, respectively. There was no significant difference in AHI, OAI or CAI 
between the childhood PSG and the PSG at adult height or the PSG after 2 years in 
the study, regardless of GH treatment or placebo. During the childhood PSG, 35% of 
children had an AHI of  5 events/hour. At start and finish of the current study, 
respectively 15% and 22% of young adults, had an AHI of  5 events/hour. These 
data demonstrate that long-term GH treatment during childhood has no negative 
consequences with regard to the prevalence of SRBD in young adults with PWS.  
 
We have previously shown that long-term GH treatment in combination with a healthy 
lifestyle can counteract the clinical course of PWS during childhood and reduce the 
prevalence of morbid obesity12. Median baseline BMI of the participants in the current 
study was 24.1, which is much lower than (young) adults with PWS who were never 
treated with GH. Also, unlike previous reports, we did not find a correlation between 
AHI and BMI or FM% SDS. It is likely that, due to the reduced prevalence of obesity 
in our cohort of young adults with PWS, SRBD occurs less common.  
 
The current consensus guideline for GH treatment in PWS recommends performing a 
PSG before and 3-6 months after starting GH treatment in children with PWS31. 
Based on our data in adults with PWS, we would not recommend a standard PSG at 
attainment of adult height in non-obese patients with PWS who were treated with GH 
during childhood and will continue GH treatment in adulthood. However, clinical signs 
of SRBD need to be monitored and, when indicated, a PSG should be performed.  
 
106 | Chapter 6   
 
In conclusion, our study shows that, compared to placebo, AHI does not significantly 
increase during GH treatment in young adults with PWS who were previously treated 
with GH during childhood. GH treatment has positive effects on body composition 
and health profile in adults with PWS. The results of the current study are reassuring 
and prove that GH can be safely administered. However, clinical signs of SRBD need 
to be monitored in children and adults with PWS, as obstructive apneas occur in 
patients with adenotonsillar hypertrophy and/or (mild) upper respiratory tract 
infections. 
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ABSTRACT 
 
Objective Adults with Prader-Willi syndrome (PWS) are at increased risk of 
developing age-associated diseases early in life and, like in premature ageing 
syndromes, ageing might be accelerated. We investigated leukocyte telomere length 
(LTL), a marker of biological age, in young adults with PWS and compared LTL to 
healthy young adults of similar age. As all young adults with PWS were treated with 
growth hormone (GH), we also compared LTL in PWS subjects to GH-treated young 
adults born short for gestational age (SGA).  
 
Design Cross-sectional study in age-matched young adults; 47 with PWS, 135 
healthy and 75 born SGA. 
 
Measurements LTL measured by quantitative PCR, expressed as T/S ratio.  
 
Results Median (IQR) LTL was 2.6 (2.4; 2.8) at a median (IQR) age of 19.2 (17.7; 
21.3) years in PWS, 3.1 (2.9; 3.5) in healthy young adults and 3.1 (2.8; 3.4) in the 
SGA group. Median LTL in PWS was significantly lower compared to both control 
groups (p<0.01). In PWS, a lower LTL tended to be associated with a lower total IQ 
(r=0.35, p=0.08). There was no association between LTL and duration of GH 
treatment, cumulative GH dose or several risk factors for cardiovascular disease or 
type 2 diabetes mellitus.  
 
Conclusions Young adults with PWS have significantly shorter median LTL 
compared to age-matched healthy young adults and GH-treated young adults born 
SGA. The shorter telomeres might play a role in the premature ageing in PWS, 
independent of GH. Longitudinal research is needed to determine the influence of 
LTL on ageing in PWS.  
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INTRODUCTION 
 
Prader-Willi syndrome (PWS) is a rare disorder resulting in a variable phenotype with 
muscular hypotonia and failure to thrive during infancy, and short stature, mental 
retardation, hyperphagia and obesity in childhood and adulthood1,2. PWS is caused 
by a lack of expression of the PWS region (q11-q13) on the paternally derived 
chromosome 15, mostly caused by a paternal deletion or maternal uniparental 
disomy (mUPD) and in some cases by an imprinting center defect (ICD) or paternal 
chromosomal translocation1,3. Growth hormone (GH) is an approved treatment for 
children with PWS improving body composition, linear growth, physical strength, 
cognition and adaptive functioning4-9. Studies have shown that GH treatment also 
benefits adults with PWS, with a sustained improvement in body composition when 
GH is continued after attainment of adult height10,11. However, up to now GH 
treatment is not registered for adults with PWS. Studies in adults with PWS who were 
not treated with GH describe an increased risk of age-associated diseases early in 
life, e.g. diabetes mellitus type 2 (T2DM), cardiovascular disease (CVD), and 
cognitive decline12,13. The mortality rate of people with PWS was estimated to be 3% 
per year across all ages, rising to 7% in those aged over 3014. One explanation for 
the increased mortality rate and risk of age-associated diseases could be that, like in 
premature ageing syndromes, the ageing process is accelerated in PWS15-18.  
 
Ageing is characterized by a progressive time-dependent decline of normal tissue 
and organ function and recent studies have shown that telomere shortening is 
involved in this process19-22. Telomeres are highly conserved TTAGGG tandem 
repeat DNA sequences at the end of each chromosome arm. Their main function is 
to protect the end of the chromosomes from inappropriate DNA repair mechanisms, 
preventing the loss of crucial DNA. Telomeres shorten during proliferation and 
telomere length declines as a function of chronological age. When telomere length 
becomes critically short, the cell enters either senescence (i.e. irreversible cessation 
of division) or apoptosis (i.e. programmed cell death). The accumulation of senescent 
cells might be driving the process of tissue and organismal ageing21-23.   
 
We hypothesized that accelerated biological ageing could partly explain the 
increased mortality rate and increased risk of developing age-associated diseases 
early in life in adults with PWS. Since telomeres are suggested to play a role in 
biological ageing and telomere length had not yet been studied in people with PWS, 
we investigated leukocyte telomere length (LTL) in young adults with PWS and 
compared LTL to healthy young adults of similar age. As all young adults who 
participated in this study were treated with GH, we also investigated LTL in young 
adults born short for gestational age (SGA) who were also treated with GH. We 
hypothesized that LTL would be shorter in young adults with PWS compared to both 
groups, independent of GH treatment. Finally, we assessed whether cognitive 
functioning and putative risk factors for T2DM and CVD correlated with LTL.  
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METHODS 
 
Patients 
We included 47 young adults participating in the Dutch Young Adult PWS (YAP) 
study, whose primary objective was to evaluate the effects and safety of GH 
treatment in young adults with PWS who were treated with GH during childhood. 
Inclusion criteria were 1) genetically confirmed diagnosis of PWS by a positive 
methylation test, 2) at least two years of GH treatment during childhood, and (3) 
having attained adult height, defined as a height velocity less than 0.5 cm per six 
months and epiphyseal closure as demonstrated by a radiograph of the left hand and 
wrist. Exclusion criteria were (1) medication to reduce weight (fat) or (2) non-
cooperative behaviour.  
 
We compared LTL in GH-treated young adults with PWS to healthy participants from 
the PROGRAM cohort24 and to young adults born SGA of similar age treated with  7 
years of GH (1 mg/m2/day) because of their short stature25. The healthy participants 
from the PROGRAM cohort were all 1) 17 - 24 years, 2) born singleton, 3) Caucasian 
and 4) had an uncomplicated neonatal period without severe asphyxia, sepsis, or 
long-term complications of respiratory ventilation and/or oxygen supply. The Medical 
Ethics Committee of the Erasmus University Medical Center approved the study 
protocols. Written informed consent was obtained from patients and/or their parents 
or legal representatives. 
 
Anthropometric measurements 
All patients with PWS were followed at the Dutch PWS Reference Center and treated 
with biosynthetic GH (Pfizer Inc., New York, NY) during childhood in a dose of 1.0 
mg/m2/day (≈0.035 mg/kg/day) and, at the time of LTL measurement, in a dose of 
0.33 mg/m2/day (≈0.012 mg/kg/day). The GH dose was regularly adjusted based on 
calculated body surface area and serum insulin-like growth factor (IGF)-I levels. 
Standing height was measured using a Harpenden Stadiometer and weight on a 
calibrated electric scale (ServoBalance KA-20-150S). Height, weight and body mass 
index (BMI) were expressed as standard deviation score (SDS) using 
GrowthAnalyser 4.0 (available at www.growthanalyser.org), adjusting for age and sex 
according to Dutch reference values26,27. Systolic and diastolic blood pressure was 
measured using an appropriately sized cuff while sitting and expressed as SDS, 
adjusting for height and sex28.  
 
Body composition and cognitive functioning 
Body composition was assessed by dual-energy x-ray absorptiometry (DXA, Lunar 
Prodigy, GE Healthcare, Chalfont St Giles, UK). Total fat mass (FM; kg) and lean 
body mass (LBM; kg) were assessed. All scans were made on the same machine, 
with daily quality assurance. The intra-assay coefficient of variation (CV) for fat tissue 
was 0.41 to 0.88% and for LBM 1.57 to 4.49%29. FM was also expressed as 
percentage of total body weight (FM%). LBM was calculated as fat-free mass minus 
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bone mineral content. FM% SDS was calculated according to age- and sex-matched 
Dutch reference values and LBM SDS according to height- and sex-matched Dutch 
reference values30. The Wechsler Adult Intelligence Scale (WAIS) was used to 
assess total IQ (TIQ) in patients over 16 years of age31 and the Wechsler Intelligence 
Scale (WISC) in patients below 16 years of age32.  
 
Laboratory measurements 
Blood samples were collected after overnight fasting. Genomic DNA was isolated 
from peripheral leukocytes using standard procedures. DNA samples were kept 
frozen at -20°C until assayed. All LTL measurements were performed in the same 
laboratory at the University of Leicester, UK. LTL was measured by the quantitative 
PCR-based technique as previously described33-35. Telomere sequence copy number 
(T) and single copy gene (36B4,S) were measured in separate reactions and 
calculated relative to a calibrator sample (genomic DNA from K562 cell line) included 
on each run. Leukocyte telomere length was subsequently expressed as T/S ratio. 
For quality control, all samples were checked for concordance between duplicate 
values and samples with >0.2 cycle difference in take-off value were excluded and 
re-run. Samples which amplified outside of the linear range of the assay were also 
excluded and re-run. Reproducibility of the assay was tested by re-running 47 
samples of the age-matched healthy participants and the SGA group together with 
the PWS samples36. The correlation between the original and new LTL results was 
0.87 and the mean CV 6.4%. 
 
Blood levels of glucose, insulin, total cholesterol (TC), low-density lipoprotein 
cholesterol (LDLc) and high-density lipoprotein cholesterol (HDLc), triglyceride (TG) 
were determined in the Biochemical and Endocrine laboratories of the Erasmus 
Medical Center, Rotterdam.  
 
Statistical analysis 
Statistical analyses were performed with SPSS 24.0 (SPSS Inc., Chicago, IL). LTL 
was expressed as T/S ratio and data as median (interquartile range, IQR). 
Continuous variables of young adults with PWS, healthy young adults and young 
adults born SGA were compared using Kruskal-Wallis and Mann-Whitney U tests 
and categorical variables were compared using Chi-Square tests. ANCOVA was 
used to correct for age, gender, gestational age, birth length and birth weight SDS.  
In young adults with PWS, gender and genotypic differences in clinical characteristics 
were calculated by independent samples T-tests in case of a Gaussian distribution 
and by Mann-Whitney U tests in case of a non-Gaussian distribution. Correlations 
between LTL and anthropometric measurements, body composition, cognitive 
functioning and metabolic health parameters were calculated by Pearson correlation 
analysis in case of a normal distribution and by Spearman correlation analysis in 
case of a non-Gaussian distribution. P values less than 0.05 were considered 
statistically significant.   
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RESULTS 
 
Clinical characteristics  
Forty-seven young adults with PWS (24 females) with a median age of 19.2 (17.7; 
21.3) years participated in the current evaluation of LTL (Table 1). We compared LTL 
to 135 age-matched healthy participants (71 females, median age 20 years) and to 
75 young adults born SGA (33 females, median age 20 years) who were treated with 
GH during childhood because of their short stature. The distribution of males and 
females was similar between the 3 groups. Gestational age, BMI and FM% in the 
PWS group were significantly higher and LBM significantly lower compared to the 
healthy participants and the SGA group (p<0.02). Age, birth weight SDS, birth length 
SDS and adult height SDS were lower in young adults with PWS compared to 
healthy participants (p<0.04). Compared to the SGA group, birth weight, birth length, 
adult height SDS and duration of GH treatment were higher in young adults with 
PWS (p<0.02), and age was similar (p=0.47). 
 
 
 
Telomere length in PWS and control groups 
Median LTL was 2.6 (2.4; 2.8) in the PWS group (Figure 1). Forty-four young adults 
with PWS (94%) had a LTL below the 50th percentile of healthy young adults and 20 
(43%) below the 10th percentile. The healthy age-matched young adults and the 
young adults born SGA had a similar median (IQR) LTL, being 3.1 (2.9; 3.5) and 3.1 
(2.8; 3.4), respectively (Figure 1). Median LTL was significantly lower in young adults 
with PWS compared to both control groups (p<0.01), also after correction for age, 
gender, gestational age, birth weight and birth length SDS.  
 
 
Table 1. Clinical characteristics of young adults with PWS, healthy young adults and young adults born SGA
Men / women (n) 23 / 24 64 / 71 42 / 33
Genetic subtype 
    Deletion/mUPD/ICD/# 21 / 22 / 3 / 1 NA NA
Gestational age (weeks) 40.61 (38.9; 41.7) 37.0 (33.0; 40.0) 37.4 (33.0; 40.0)
Birth weight (SDS) -1.21 (-2.1; -0.1) 0.4 (-0.4; 1.0) -2.7 (-3.3; -1.6)
Birth length (SDS) -1.11 (-2.2; -0.2) 0.1 (-0.4; 0.7) -3.1 (-4.5; -2.3) 
Age (yrs) 19.22 (17.7; 21.3) 20.0 (19.0; 22.0) 20.0 (18.0; 21.7) 
Height (SDS) -1.02,3 (-1.8; -0.3) 0 (-0.4; 0.7) -1.5 (-2.0; -0.8)
BMI  (kg/m2) 25.01 (21.8; 27.5) 21.8 (20.5; 23.4) 20.2 (18.8; 22.1) 
BMI for age (SDS) 1.21 (0.0; 1.8) -0.1 (-0.6; 0.6) -0.9 (-1.4; 0.1) 
Duration of GH treatment (years) 13.03 (11.5; 14.0) NA 9.2 (7.1; 11.0)
Fat percentage (%) 39.81 (36.0; 43.6) 22.4 (14.3; 31.4) 18.9 (11.6; 27.8)
Fat percentage (SDS) 2.21 (1.8; 2.5) 0.6 (-0.1; 1.1) 0.5 (-0.1; 1.1) 
Lean mass (SDS) -1.32,3 (-2.1; -0.5) -0.6 (-1.3; 0.1) -0.7 (-1.6; 0.1)
Telomere length (T/S ratio) 2.61 (2.4; 2.8) 3.1 (2.9; 3.5) 3.1 (2.8; 3.4) 
Data expressed as median (IQR). 
mUPD = maternal uniparental disomy. ICD = imprinting center defect. # = genotype unknown. BMI = Body mass index.
1) p<0.01 compared to healthy young adults and SGA group.
2) p<0.04 compared to healthy young adults.
3) p<0.02 compared to SGA group. 
PWS Healthy SGA
                                                 Leukocyte telomere length in young adults with PWS |  117 
 
Figure 1. Leukocyte telomere length for age in 47 GH-treated young adults with PWS and 75 
young adults born SGA who were also treated with GH. The dotted lines represent the 10th 
and 50th percentile of the healthy young adults. Forty-four young adults with PWS (94%) 
have a LTL below the 50th percentile and 20 (43%) below the 10th percentile of the healthy 
young adults. 
 
Correlation analyses in PWS 
Age was not significantly associated with LTL (r=-0.18, p=0.22), which could be 
related to the fact that subjects in our study population had approximately the same 
age. There was no significant difference in LTL between males and females, median 
(IQR) LTL being 2.5 (2.3; 2.8) in males and 2.7 (2.4; 2.8) in females with PWS 
(p=0.35). Median (IQR) LTL was similar in young adults with a deletion and a 
mUPD/ICD, being 2.6 (2.4; 2.8) in both groups (p=0.97). There was no significant 
association between LTL and gestational age, birth weight, birth height, adult height, 
BMI or FM% (p>0.28). A lower LTL tended to be associated with a lower LBM SDS 
and a lower total IQ (r=0.29, p=0.06 and r=0.36, p=0.08, resp.), showing that LBM 
SDS and cognitive functioning in young adults with PWS tend to be lower in those 
with a shorter LTL. Since GH treatment could potentially cause increased replicative 
stress by inducing catch-up growth, we analysed whether LTL was associated with 
the duration of GH treatment or the cumulative GH dose, but we found no significant 
association between either. Table 2 shows metabolic health parameters in young 
adults with PWS. Neither blood pressure SDS and serum cholesterol levels, nor 
HOMA-IR were associated with LTL (p>0.21).   
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RESULTS 
 
Clinical characteristics  
Forty-seven young adults with PWS (24 females) with a median age of 19.2 (17.7; 
21.3) years participated in the current evaluation of LTL (Table 1). We compared LTL 
to 135 age-matched healthy participants (71 females, median age 20 years) and to 
75 young adults born SGA (33 females, median age 20 years) who were treated with 
GH during childhood because of their short stature. The distribution of males and 
females was similar between the 3 groups. Gestational age, BMI and FM% in the 
PWS group were significantly higher and LBM significantly lower compared to the 
healthy participants and the SGA group (p<0.02). Age, birth weight SDS, birth length 
SDS and adult height SDS were lower in young adults with PWS compared to 
healthy participants (p<0.04). Compared to the SGA group, birth weight, birth length, 
adult height SDS and duration of GH treatment were higher in young adults with 
PWS (p<0.02), and age was similar (p=0.47). 
 
 
 
Telomere length in PWS and control groups 
Median LTL was 2.6 (2.4; 2.8) in the PWS group (Figure 1). Forty-four young adults 
with PWS (94%) had a LTL below the 50th percentile of healthy young adults and 20 
(43%) below the 10th percentile. The healthy age-matched young adults and the 
young adults born SGA had a similar median (IQR) LTL, being 3.1 (2.9; 3.5) and 3.1 
(2.8; 3.4), respectively (Figure 1). Median LTL was significantly lower in young adults 
with PWS compared to both control groups (p<0.01), also after correction for age, 
gender, gestational age, birth weight and birth length SDS.  
 
 
Table 1. Clinical characteristics of young adults with PWS, healthy young adults and young adults born SGA
Men / women (n) 23 / 24 64 / 71 42 / 33
Genetic subtype 
    Deletion/mUPD/ICD/# 21 / 22 / 3 / 1 NA NA
Gestational age (weeks) 40.61 (38.9; 41.7) 37.0 (33.0; 40.0) 37.4 (33.0; 40.0)
Birth weight (SDS) -1.21 (-2.1; -0.1) 0.4 (-0.4; 1.0) -2.7 (-3.3; -1.6)
Birth length (SDS) -1.11 (-2.2; -0.2) 0.1 (-0.4; 0.7) -3.1 (-4.5; -2.3) 
Age (yrs) 19.22 (17.7; 21.3) 20.0 (19.0; 22.0) 20.0 (18.0; 21.7) 
Height (SDS) -1.02,3 (-1.8; -0.3) 0 (-0.4; 0.7) -1.5 (-2.0; -0.8)
BMI  (kg/m2) 25.01 (21.8; 27.5) 21.8 (20.5; 23.4) 20.2 (18.8; 22.1) 
BMI for age (SDS) 1.21 (0.0; 1.8) -0.1 (-0.6; 0.6) -0.9 (-1.4; 0.1) 
Duration of GH treatment (years) 13.03 (11.5; 14.0) NA 9.2 (7.1; 11.0)
Fat percentage (%) 39.81 (36.0; 43.6) 22.4 (14.3; 31.4) 18.9 (11.6; 27.8)
Fat percentage (SDS) 2.21 (1.8; 2.5) 0.6 (-0.1; 1.1) 0.5 (-0.1; 1.1) 
Lean mass (SDS) -1.32,3 (-2.1; -0.5) -0.6 (-1.3; 0.1) -0.7 (-1.6; 0.1)
Telomere length (T/S ratio) 2.61 (2.4; 2.8) 3.1 (2.9; 3.5) 3.1 (2.8; 3.4) 
Data expressed as median (IQR). 
mUPD = maternal uniparental disomy. ICD = imprinting center defect. # = genotype unknown. BMI = Body mass index.
1) p<0.01 compared to healthy young adults and SGA group.
2) p<0.04 compared to healthy young adults.
3) p<0.02 compared to SGA group. 
PWS Healthy SGA
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Figure 1. Leukocyte telomere length for age in 47 GH-treated young adults with PWS and 75 
young adults born SGA who were also treated with GH. The dotted lines represent the 10th 
and 50th percentile of the healthy young adults. Forty-four young adults with PWS (94%) 
have a LTL below the 50th percentile and 20 (43%) below the 10th percentile of the healthy 
young adults. 
 
Correlation analyses in PWS 
Age was not significantly associated with LTL (r=-0.18, p=0.22), which could be 
related to the fact that subjects in our study population had approximately the same 
age. There was no significant difference in LTL between males and females, median 
(IQR) LTL being 2.5 (2.3; 2.8) in males and 2.7 (2.4; 2.8) in females with PWS 
(p=0.35). Median (IQR) LTL was similar in young adults with a deletion and a 
mUPD/ICD, being 2.6 (2.4; 2.8) in both groups (p=0.97). There was no significant 
association between LTL and gestational age, birth weight, birth height, adult height, 
BMI or FM% (p>0.28). A lower LTL tended to be associated with a lower LBM SDS 
and a lower total IQ (r=0.29, p=0.06 and r=0.36, p=0.08, resp.), showing that LBM 
SDS and cognitive functioning in young adults with PWS tend to be lower in those 
with a shorter LTL. Since GH treatment could potentially cause increased replicative 
stress by inducing catch-up growth, we analysed whether LTL was associated with 
the duration of GH treatment or the cumulative GH dose, but we found no significant 
association between either. Table 2 shows metabolic health parameters in young 
adults with PWS. Neither blood pressure SDS and serum cholesterol levels, nor 
HOMA-IR were associated with LTL (p>0.21).   
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DISCUSSION 
 
This cross-sectional study in 47 GH-treated young adults with PWS shows that 
median leukocyte telomere length (LTL) is shorter in young adults with PWS 
compared to age-matched healthy young adults and young adults born SGA who 
were also treated with GH. We found no significant association between LTL and the 
duration of GH treatment or the cumulative GH dose. This is the first study to show 
that a shorter LTL might play a role in the reported accelerated ageing process in 
adults with PWS, independent of GH treatment15-17. Sinnema et al described excess 
functional impairment, morbidity and mortality and evidence of premature ageing in 
12 adults with PWS above the age of 50 years17. Ageing is characterized by a 
progressive time-dependent functional decline of tissues and telomere shortening is 
considered to be involved in this process20,21. Individuals with shorter telomere length 
show increased mortality risk, providing support for an association between telomere 
length and lifespan37.  
 
Besides the finding that LTL is shorter in young adults with PWS, we found a 
tendency towards an association between a shorter LTL and a lower total IQ, which 
might imply a role of LTL in cognitive functioning in PWS. A cross-sectional MRI-
study in 20 young adults with PWS showed that predicted brain age was on average 
8.7 years higher than chronological age38. Together with a brain structure resembling 
healthy older brains, indicative of premature neuronal loss and atrophy, this suggests 
premature brain ageing in young adults with PWS38. The same research group found 
a 2.5-year higher predicted brain age than chronological age in 46 adults with Down 
syndrome. A higher brain-predicted age was significantly associated with lower 
cognitive functioning39 and shorter telomeres have been associated with cognitive 
decline and dementia status in patients with Down syndrome40,41. These studies 
support that people with PWS and Down syndrome age prematurely. Our study 
suggests a possible role of shorter LTL in this accelerated ageing process in adults 
with PWS. However, longitudinal studies on LTL, cognitive functioning and brain 
development in a larger cohort of children and (older) adults with PWS are needed to 
Table 2. Metabolic health parameters in 47 young adults with PWS
Systolic blood pressure (SDS) 0.8 (0; 1.6) 
Diastolic blood pressure (SDS) 0.6 (0.3; 1.2)
Total Cholesterol (mmol/L) 4.3 (3.9; 4.8)
HDL (mmol/L) 1.3 (1.1; 1.5)
LDL (mmol/L) 2.8 (2.3; 3.2) 
Triglycerides (mmol/L) 0.8 (0.7; 1.2)
HOMA-IR 1.7 (1.2; 2.9)
Data expressed as median (IQR).
HDL = high-density lipoprotein cholesterol. LDL = low-density lipoprotein cholesterol. 
HOMA-IR = Homeostatic Model Assessment for Insulin Resistance.
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elucidate the natural course of brain development in relation to LTL and cognitive 
functioning. 
 
There is a strong correlation between telomere length in different tissues in humans 
and in other mammals, which shows that telomere length in leukocytes reflects 
systemic telomere length in other tissues42. Besides chronological ageing, a wealth of 
genetic and environmental factors are reported to affect telomere length22. Even 
though none of the genes in the PWS region on chromosome 15 are associated with 
telomere homeostasis, several clinical features of people with PWS are associated 
with an increased risk of shorter telomeres, including obesity, a reduced level of 
physical activity and increased psychosocial stress. Furthermore, adults with PWS 
are prone to develop T2DM and CVD in early life12,13 and several studies have shown 
that shortened telomeres are associated with an increased risk of T2DM and 
CVD20,22,37. As none of the investigated young adults with PWS were diagnosed with 
T2DM and CVD, we investigated the interaction between LTL and putative risk 
factors for T2DM and CVD. We found no significant correlation between LTL and 
age, BMI, FM%, blood pressure, serum cholesterol levels and HOMA-IR. This is in 
accordance with an earlier study demonstrating that the association between LTL 
and CVD is independent of risk factors for CVD35. Probably our study group of young 
adults with PWS was too young to already have T2DM or CVD. Also, with the more 
recent trends of early diagnosis, GH treatment from a young age, and the enhanced 
prevention of potentially impairing health conditions, T2DM and CVD might occur 
later in life. It would be interesting to analyse the association between (risk factors 
for) T2DM and CVD and LTL at a later age, when age-associated diseases become 
more apparent.  
 
All young adults with PWS who participated in the current study were treated with 
long-term GH improving body composition, linear growth, physical strength, cognition 
and adaptive functioning4-9. To evaluate whether GH treatment would cause 
increased replicative stress and shorter LTL, we compared young adults with PWS to 
young adults born SGA who were also treated with GH. The fact that LTL in young 
adults with PWS was shorter compared to both groups and similar in healthy young 
adults and GH-treated young adults born SGA, make adverse effects of long-term 
GH treatment on LTL very unlikely36. Besides, the lack of an association between 
LTL and the duration of GH or the cumulative GH dose in young adults with PWS is 
reassuring with regard to possible negative effects of GH on LTL. 
 
One could even argue that GH treatment might positively influence LTL by improving 
body composition. We know that long-term GH treatment during childhood 
counteracts the clinical course of increasing obesity in children with PWS and has 
substantially changed their phenotype4. Combined with an early diagnosis and 
multidisciplinary support from a very young age, GH treatment has resulted in a new 
generation of children and young adults with PWS without severe obesity. Thus, it 
could be that if our group of young adults had not been treated with GH, they would 
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elucidate the natural course of brain development in relation to LTL and cognitive 
functioning. 
 
There is a strong correlation between telomere length in different tissues in humans 
and in other mammals, which shows that telomere length in leukocytes reflects 
systemic telomere length in other tissues42. Besides chronological ageing, a wealth of 
genetic and environmental factors are reported to affect telomere length22. Even 
though none of the genes in the PWS region on chromosome 15 are associated with 
telomere homeostasis, several clinical features of people with PWS are associated 
with an increased risk of shorter telomeres, including obesity, a reduced level of 
physical activity and increased psychosocial stress. Furthermore, adults with PWS 
are prone to develop T2DM and CVD in early life12,13 and several studies have shown 
that shortened telomeres are associated with an increased risk of T2DM and 
CVD20,22,37. As none of the investigated young adults with PWS were diagnosed with 
T2DM and CVD, we investigated the interaction between LTL and putative risk 
factors for T2DM and CVD. We found no significant correlation between LTL and 
age, BMI, FM%, blood pressure, serum cholesterol levels and HOMA-IR. This is in 
accordance with an earlier study demonstrating that the association between LTL 
and CVD is independent of risk factors for CVD35. Probably our study group of young 
adults with PWS was too young to already have T2DM or CVD. Also, with the more 
recent trends of early diagnosis, GH treatment from a young age, and the enhanced 
prevention of potentially impairing health conditions, T2DM and CVD might occur 
later in life. It would be interesting to analyse the association between (risk factors 
for) T2DM and CVD and LTL at a later age, when age-associated diseases become 
more apparent.  
 
All young adults with PWS who participated in the current study were treated with 
long-term GH improving body composition, linear growth, physical strength, cognition 
and adaptive functioning4-9. To evaluate whether GH treatment would cause 
increased replicative stress and shorter LTL, we compared young adults with PWS to 
young adults born SGA who were also treated with GH. The fact that LTL in young 
adults with PWS was shorter compared to both groups and similar in healthy young 
adults and GH-treated young adults born SGA, make adverse effects of long-term 
GH treatment on LTL very unlikely36. Besides, the lack of an association between 
LTL and the duration of GH or the cumulative GH dose in young adults with PWS is 
reassuring with regard to possible negative effects of GH on LTL. 
 
One could even argue that GH treatment might positively influence LTL by improving 
body composition. We know that long-term GH treatment during childhood 
counteracts the clinical course of increasing obesity in children with PWS and has 
substantially changed their phenotype4. Combined with an early diagnosis and 
multidisciplinary support from a very young age, GH treatment has resulted in a new 
generation of children and young adults with PWS without severe obesity. Thus, it 
could be that if our group of young adults had not been treated with GH, they would 
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have had a higher BMI and FM% and their LTL could have been even shorter. The 
limited age range of our PWS cohort is both a strength and a constraint of our study, 
since it eliminates the confounding effect of age, but restricts generalizations of the 
results to other age groups. Also, we were not able to compare LTL in GH-treated 
young adults with PWS to (young) adults with PWS who were not treated with GH 
and more research is needed on LTL across the life course to be able to determine 
its role in ageing in both GH-treated and untreated people with PWS.  
 
In contrast to previous studies, we found no significant difference in median LTL 
between males and females. Females have been reported to have longer LTL, which 
is thought to be due to higher levels of oestrogen, conferring anti-inflammatory and 
antioxidant properties and promoting telomerase expression22. Since serum 
oestrogen levels are generally low in females with PWS, this could explain the lack of 
a difference between males and females in our study43. We also found similar LTL in 
young adults with a deletion and those with a mUPD or ICD. A recent study by 
Whittington et al reported on 26 adults with PWS over the age of 40 years. In 3 
participants (age 41, 48 and 55) there was a significant deterioration in executive 
functioning with possible dementia. All were women, had UPD or a disomic region 
and all had had psychotic episodes18. Psychiatric disorders are reported more 
commonly in people with a mUPD and a higher level of psychosocial stress is 
associated with shorter telomeres22. Based on these studies, a difference in LTL 
between the deletion and mUPD subtypes was expected. However, since the study 
group of Whittington et al. is considerably older than our group and none of the 
affected individuals were treated with GH, it is difficult to compare results. We 
suggest investigating possible differences in LTL between genetic subtypes in future 
studies.  
 
In conclusion, we found a shorter LTL in 47 GH-treated young adults with PWS 
compared to untreated healthy young adults and young adults born SGA who were 
also treated with GH, which might suggest that a shorter LTL is involved in the 
reported accelerated ageing process in adults with PWS. More research on LTL 
across the life course is needed to be able to determine its exact role in ageing in 
people with PWS. 
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GENERAL DISCUSSION 
 
In the last few decades, considerable progress has been made in the knowledge and 
care of children and (young) adults with Prader-Willi syndrome (PWS). The Dutch 
Growth Research Foundation started investigating children with PWS and the effects 
and safety of growth hormone (GH) treatment in 2002. Thereafter, the care for Dutch 
children and adolescents markedly improved. These efforts eventually led to the 
development of the Dutch PWS Reference Center, which currently provides high-
quality care to children and adults with PWS in close collaboration with 
paediatricians, paediatric-endocrinolgists and internists throughout the Netherlands. 
Nowadays, children with PWS are treated with GH from a very young age and, 
combined with an early diagnosis and multidisciplinary support, this counteracts the 
clinical course of increasing obesity and has resulted in a new generation of children 
and young adults with PWS.  
 
This thesis describes six new studies about children and young adults with PWS. In 
this chapter our results are discussed, also in view of recent literature. Furthermore, 
clinical implications of our results and recommendations for future research are 
presented.  
 
8.1 MENTAL AND MOTOR DEVELOPMENT - INFANTS 
 
Children with PWS are generally delayed in reaching major mental and motor 
developmental milestones. Mental development entails acquirement of mental 
capabilities, such as language, memory and problem solving, while motor 
development refers to the acquirement of fine and gross motor developmental 
milestones. Our group previously showed that delayed brain maturation may underlie 
the delayed psychomotor development in children with PWS, as we found a smaller 
white matter volume, indicating reduced structural connectivity and aberrant 
myelinisation1. 
 
The second chapter of this thesis describes the effects of 3 years of GH treatment on 
psychomotor development in 63 children with PWS with a median age of 1.0 year at 
start of GH. Mental and motor development were measured using the Bayley Scales 
of Infant Development, an individually administered and standardized instrument for 
developmental diagnostics that can be used to evaluate the cognitive and motor 
development of young children with a ‘developmental age’ between 0 and 3.5 
years2,3. Mental and motor development were expressed as percentage of the 
expected mental and motor development for their age and calculated as 
(developmental age / chronological age) * 100%. 
 
Our results demonstrate that both mental and motor development increase 
significantly during 3 years of GH: mental development increases from 58.1% of 
expected at start of GH to 79.6% of expected after 3 years of GH and motor 
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development from 41.9% to 78.2%. One explanation for this improvement could be 
that GH and insulin-like growth factor (IGF)-I are involved in brain growth, 
development and myelinization. GH receptors are expressed throughout the brain 
and serum IGF-I levels are low in children with PWS prior to starting GH treatment. 
Therefore, GH might improve brain development by increasing IGF-I levels4,5. 
Another explanation may be that mental development improved because GH 
treatment improves motor development by increasing lean body mass (LBM). Once 
infants and toddlers reach certain motor milestones, they would be able to better 
explore their environment, enhancing mental development6,7. Although there was no 
association between the change in LBM and the change in motor development, the 
significant correlation between the change in motor and mental development during 3 
years of GH supports this hypothesis.  
 
We cannot exclude that part of the increase in psychomotor development may be 
explained by the increased awareness of PWS and the spontaneous improvement of 
hypotonia with age and early start of physical therapy, as has been suggested in a 
study comparing the effect of 1 year of GH or Co-enzyme Q10 in 26 infants and 
toddlers with PWS7. We acknowledge that an RCT would have been the first-choice 
design to investigate the effects of 3 years of GH on mental and motor development 
in infants with PWS, but it would be unethical to withhold GH for 3 years, knowing the 
positive effects of GH on numerous outcomes in children with PWS. Also, we 
previously performed an RCT during 1 year in 29 infants with PWS, which showed 
that mental and motor development deteriorated in those who were not treated with 
GH6. This shows that GH treatment plays an important role in psychomotor 
development in infants with PWS, aside from the spontaneous improvement of 
hypotonia with age and early start of physical therapy.  
 
Our study also shows that the younger the age at start of GH treatment, the greater 
the improvement in psychomotor development. It suggests that starting GH treatment 
early, in a critical period of neurodevelopment, could enhance psychomotor and 
cognitive development on the longer term5,8. This is in line with 2 of our previous 
studies9,10. The first study also reported a significant positive effect of age at start of 
GH on cognitive development in 50 pre-pubertal children9. The second study in 42 
children with PWS found that if GH was started during infancy, GH had a greater 
effect on adaptive functioning10. In spite of the significant improvement in 
psychomotor development, the average mental and motor development after 3 years 
of GH was still significantly lower compared to healthy references, indicating that 
young children with PWS keep needing extra support with regard to their 
development. 
 
We conclude that mental and motor development increase during 3 years of GH, 
reducing the gap between infants with PWS and healthy peers.	 Secondly, we 
conclude that, the younger at start of GH treatment, the greater the improvement in 
psychomotor development.  
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8.2 COGNITIVE DEVELOPMENT - CHILDREN 
 
In chapter 3 we describe the benefits of long-term GH treatment in children with PWS 
on cognitive functioning. People with PWS typically have mild to moderate cognitive 
impairment with an average IQ between 60 and 709,11. Previous studies have only 
investigated the effects of GH on cognitive functioning in children with PWS who 
received GH treatment for a maximum duration of 4 years. We, therefore, conducted 
a prospective cohort study during 8 years of GH in 43 children with PWS, who started 
GH at a median age of 8.1 years. We longitudinally investigated cognitive functioning 
during 8 years of GH and, secondly, cross-sectionally investigated whether starting 
GH during infancy, i.e. before the age of 2 years, results in higher cognitive 
functioning after 8 years of GH. Cognitive functioning was assessed by a shortened 
version of the Wechsler Intelligence Scale for Children (WISC), which is suitable for 
children between the age of 6 and 16 years14. The subtests Vocabulary, Similarities 
and Block Design were used to assess vocabulary, abstract verbal reasoning and 
visuospatial skills, respectively15.  
 
The results of our study show that visuospatial skills slightly improve during 8 years 
of GH, while abstract verbal reasoning and vocabulary remain similar. After 8 years 
of GH, estimated total IQ ranged from 51 to 94 and 30% of the children had an 
estimated TIQ above 70, the cut-off for mental disability. We previously demonstrated 
in a 2-year randomized controlled trial that cognitive functioning in GH-treated 
children with PWS developed at a similar rate as in healthy references, while there 
was a significant deterioration in abstract verbal reasoning and vocabulary in 
untreated controls9. Furthermore, we have previously shown that visuospatial skills 
and abstract verbal reasoning improved significantly during 4 years of GH treatment 
in 50 children with PWS. In the current study, the change in visuospatial skills and 
abstract verbal reasoning during 8 years of GH was not significant. Nonetheless, our 
results are reassuring as they show that cognitive functioning does not deteriorate 
during long-term GH treatment and progresses at a similar rate compared to healthy 
peers.  
 
Previous studies have shown that cognitive impairment in PWS may be related to 
lower brain volumes and lower cortical complexity, due to alterations in gene 
networks that are important for early brain development1,16. It is, however, still 
unknown how the genetic aberrations underlying PWS lead to cognitive impairment. 
Another question that remains to be elucidated is how GH could affect cognitive 
functioning. A recent review concluded that GH could stimulate GH receptors in brain 
areas involved in learning and memory, thereby improving cognitive functioning5. It is 
known that GH receptors are located throughout the brain and that GH and IGF-I 
affect the genesis of neurons, thereby stimulating brain growth, development and 
myelinisation4,13. In our study we found an association between visuospatial skills 
and serum IGF-I levels, with a tendency towards significantly better visuospatial skills 
with higher serum IGF-I levels. A study in untreated adults with PWS also reported a 
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correlation between lower IGF-I levels and poorer intellectual skills17. This indicates 
that GH treatment might improve cognitive functioning by increasing IGF-I levels in 
patients with PWS. We should, however, also keep in mind that GH has effects on 
the central nervous system that are independent of IGF-I levels18. Therefore, further 
investigation is still warranted. 
 
After 8 years of GH, 22 children who started GH before the age of 2 years had 
significantly higher vocabulary skills and a higher estimated total IQ, compared to the 
children who started GH during childhood, suggesting that early start of GH could be 
beneficial for cognitive functioning on the long term. Even though we could not 
evaluate the longitudinal effects of 8 years of GH in the 22 children who started GH 
during infancy, because WISC is not suitable for children younger than 6 years, these 
results support previous studies showing beneficial effects of early start of GH on 
psychomotor and cognitive development8,19,20. 
 
We conclude that cognitive skills in children with PWS during 8 years of GH 
treatment do not deteriorate and develop at the same pace as healthy references. 
We also conclude that starting GH treatment before the age of 2 years, a critical 
period of neurodevelopment, might benefit cognitive functioning on the long-term. 
 
8.3 GROWTH HORMONE DEFICIENCY - YOUNG ADULTS 
 
Some features of people with PWS resemble those seen in growth hormone 
deficiency (GHD), such as short stature, and an abnormal body composition with a 
low LBM and an increased fat mass (FM). The benefits of GH treatment in children 
with PWS are well established as it improves body composition, bone mineral density 
(BMD), adaptive functioning and linear growth10,12,21. Studies have also shown that 
continuation of GH treatment after attainment of adult height is beneficial for people 
with PWS, with a sustained improvement in FM and LBM, and a deterioration of body 
composition when GH treatment is discontinued22,23. However, GH treatment is 
currently not approved for adults with PWS and can only be reimbursed when they 
fulfil the criteria of adult GHD.  
 
We, therefore, examined the prevalence of adult GHD in 60 previously GH-treated 
young adults with PWS with a median age of 17.9 years. As the insulin tolerance test 
is not feasible in patients with PWS because of the cumbersome procedure and side 
effects, we performed a GHRH-Arginine test. Consensus guidelines for the diagnosis 
of adult GHD using a GHRH-Arginine test require a GH peak level < 9 µg/L in 
combination with a serum IGF-I SDS level < -2 adjusted for age and gender24,25. We 
also applied the BMI-dependent cut-off points for the GHRH-Arginine test: a GH peak 
< 11.5 µg/L if BMI is < 25 kg/m2, a GH peak < 8 µg/L if BMI is 25-30 kg/m2 and a GH 
peak < 4.2 µg/L If BMI > 30 kg/m2,26.  
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Our results demonstrate that serum IGF-I was <-2 SDS in only 2 (3%) patients and 
serum IGFBP-3 was within the normal range in all but one patient. Nine participants 
had a GH peak < 9 µg/L (15%) during the GHRH-Arginine test. None of these 
patients also had an IGF-I < -2.0 SDS. Therefore, not one patient fulfilled the criteria 
for adult GHD, also when BMI-dependent criteria were used. Although GHD cannot 
be demonstrated by conventional testing, it does not mean that it does not exist. It is 
generally accepted that people with PWS have a dysfunction of the hypothalamus, 
which complicates the evaluation of GHD as most GH stimulation tests stimulate 
secretion of GH from the pituitary. Also, there is discussion about the appropriate cut-
off values for GH peak during GHRH-Arginine tests. We chose to use the BMI-
adjusted adult cut-off values since the decision of whether GH treatment is 
reimbursed is made based on these criteria.  
 
The fact that there is hypothalamic dysfunction in PWS and both children and adults 
with PWS respond very well to GH treatment, with a significant improvement in body 
composition, health profile, normalization of stature in children, and a significant 
increase in serum IGF-I and IGFBP-3 levels strongly supports the likelihood of GHD 
in these patients. As the GHRH-Arginine test fails to demonstrate adult GHD it seems 
to be an unreliable test in adults with PWS.  
 
Currently, GH treatment can only be reimbursed when adults fulfil the consensus 
criteria of adult GHD. Our study shows that a GHRH-Arginine test to diagnose adult 
GHD is unreliable in adults with PWS. As GH treatment has been shown to have very 
positive effects in both children and adults with PWS, GH treatment is highly 
recommended for adults with PWS and confirming adult GHD should not be a 
prerequisite for treating adults with PWS.  
 
8.4 BONE MINERAL DENSITY - YOUNG ADULTS 
 
The prevalence of osteopenia and osteoporosis in adults with PWS is increased34-36. 
Bone mineral density (BMD) and peak bone mass are influenced by endocrine 
factors such as GH, IGF-I and sex steroids, and by body composition and body mass 
index27-29. Recent studies have shown that long-term GH treatment optimizes body 
composition and BMD in prepubertal children with PWS21,30, leading to a normal 
BMD compared to peers21,31. During puberty, however, we found a decline in BMD in 
parallel to incomplete pubertal development and low sex hormone levels21,32,33. 
 
When young adults with PWS without adult GHD have attained adult height, they 
have to stop GH treatment. In GH-deficient young adults without PWS, BMD 
deteriorates after cessation of GH37-39. The fifth chapter of this thesis describes the 
effects of one year of GH versus one year of placebo on BMD in 27 young adults with 
PWS who had attained adult height and were treated with GH during childhood. We 
also studied the effects of no sex steroid replacement therapy (SSRT) versus SSRT 
on BMD in hypogonadal young adults with PWS. BMD of the total body and lumbar 
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with PWS, with a sustained improvement in FM and LBM, and a deterioration of body 
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currently not approved for adults with PWS and can only be reimbursed when they 
fulfil the criteria of adult GHD.  
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is not feasible in patients with PWS because of the cumbersome procedure and side 
effects, we performed a GHRH-Arginine test. Consensus guidelines for the diagnosis 
of adult GHD using a GHRH-Arginine test require a GH peak level < 9 µg/L in 
combination with a serum IGF-I SDS level < -2 adjusted for age and gender24,25. We 
also applied the BMI-dependent cut-off points for the GHRH-Arginine test: a GH peak 
< 11.5 µg/L if BMI is < 25 kg/m2, a GH peak < 8 µg/L if BMI is 25-30 kg/m2 and a GH 
peak < 4.2 µg/L If BMI > 30 kg/m2,26.  
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for adult GHD, also when BMI-dependent criteria were used. Although GHD cannot 
be demonstrated by conventional testing, it does not mean that it does not exist. It is 
generally accepted that people with PWS have a dysfunction of the hypothalamus, 
which complicates the evaluation of GHD as most GH stimulation tests stimulate 
secretion of GH from the pituitary. Also, there is discussion about the appropriate cut-
off values for GH peak during GHRH-Arginine tests. We chose to use the BMI-
adjusted adult cut-off values since the decision of whether GH treatment is 
reimbursed is made based on these criteria.  
 
The fact that there is hypothalamic dysfunction in PWS and both children and adults 
with PWS respond very well to GH treatment, with a significant improvement in body 
composition, health profile, normalization of stature in children, and a significant 
increase in serum IGF-I and IGFBP-3 levels strongly supports the likelihood of GHD 
in these patients. As the GHRH-Arginine test fails to demonstrate adult GHD it seems 
to be an unreliable test in adults with PWS.  
 
Currently, GH treatment can only be reimbursed when adults fulfil the consensus 
criteria of adult GHD. Our study shows that a GHRH-Arginine test to diagnose adult 
GHD is unreliable in adults with PWS. As GH treatment has been shown to have very 
positive effects in both children and adults with PWS, GH treatment is highly 
recommended for adults with PWS and confirming adult GHD should not be a 
prerequisite for treating adults with PWS.  
 
8.4 BONE MINERAL DENSITY - YOUNG ADULTS 
 
The prevalence of osteopenia and osteoporosis in adults with PWS is increased34-36. 
Bone mineral density (BMD) and peak bone mass are influenced by endocrine 
factors such as GH, IGF-I and sex steroids, and by body composition and body mass 
index27-29. Recent studies have shown that long-term GH treatment optimizes body 
composition and BMD in prepubertal children with PWS21,30, leading to a normal 
BMD compared to peers21,31. During puberty, however, we found a decline in BMD in 
parallel to incomplete pubertal development and low sex hormone levels21,32,33. 
 
When young adults with PWS without adult GHD have attained adult height, they 
have to stop GH treatment. In GH-deficient young adults without PWS, BMD 
deteriorates after cessation of GH37-39. The fifth chapter of this thesis describes the 
effects of one year of GH versus one year of placebo on BMD in 27 young adults with 
PWS who had attained adult height and were treated with GH during childhood. We 
also studied the effects of no sex steroid replacement therapy (SSRT) versus SSRT 
on BMD in hypogonadal young adults with PWS. BMD of the total body and lumbar 
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spine (BMDTB and BMDLS) were measured by DXA and BMDLS was corrected for 
bone size by calculating bone mineral apparent density of the lower spine (BMADLS) 
and compared to age- and sex-matched references40,41. 
 
Our data show that compared to 1 year of GH, 1 year of placebo did not deteriorate 
BMDTB or BMADLS. This is in line with a study in GH-naïve adults with PWS who 
were randomized to GH or placebo for 1 year, followed by GH for 2 additional 
years42. In that study, BMDTB did not significantly change, while BMADLS significantly 
decreased during 1 year of GH compared to placebo. There were no changes in 
BMDTB or BMADLS during the 2 years of GH treatment42. In patients with adult-onset 
GHD, GH replacement results in an initial increase in bone resorption, and only after 
1 year of GH treatment, a gradual increase in BMD45. Thus, it could be that 1 year of 
GH versus 1 year of placebo is too short to show a positive effect of GH on BMD in 
young adults with PWS who were treated with GH during childhood. 
 
Our study also shows that BMDTB did not significantly change during 2 years, while 
BMADLS decreased, independent of GH or placebo. We previously observed a 
decrease in BMDTB and BMADLS SDS in 64 pubertal children, in parallel to a lack of 
pubertal progression and low sex hormone levels21. Because there is an important 
relation between serum oestradiol and testosterone levels and BMD43,44, we suggest 
that the increased prevalence of hypogonadism in PWS might cause the decrease in 
BMD. Our results demonstrate that both BMDTB and BMADLS decrease in 
hypogonadal young adults without SSRT, while BMDTB improves in hypogonadal 
young adults who receive SSRT. Another study also found a higher BMDTB in women 
with PWS on SSRT or with normal cyclic oestrogen levels compared to hypogonadal 
women with PWS42. It seems that GH is not able to prevent the decline in BMD 
unless it is combined with SSRT, indicating that sex steroids play a major role in the 
development and conservation of BMD in adolescents and (young) adults with PWS. 
Although the administration of SSRT was not randomized, our findings suggest that 
SSRT should be considered in hypogonadal adolescents with PWS to improve their 
bone health in adulthood.  
 
We conclude that, compared to GH treatment, 1 year of placebo after attainment of 
adult height does not deteriorate BMD in young adults with PWS. In addition, our 
data suggest that GH is not able to prevent the decline in BMD in hypogonadal young 
adults with PWS, unless it is combined with SSRT. 
 
8.5 SLEEP-RELATED BREATHING DISORDERS - YOUNG ADULTS 
 
Sleep-related breathing disorders (SRBD) are common in patients with PWS, 
causing poor sleep quality and excessive daytime sleepiness46-48. Several factors are 
thought to influence SRBD in PWS, such as facial dysmorphia, lack of response to 
hypoxia and hypercapnia, and airway collapse caused by pharyngeal wall hypotonia 
and adenoid/tonsil hypertrophy4. Since 2002, children with PWS are being treated 
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with long-term GH12,49,50 and in the early years there were safety concerns regarding 
the effects of GH on SRBD. These concerns were, however, unfounded, as we have 
described a non-significant decline in apnea hypopnea index (AHI) after 6 months of 
GH in 35 prepubertal children with PWS and a recent review has concluded that GH 
can be safely administered, provided that SRBD is monitored and treated 
appropriately54.  
 
Since GH treatment is not registered for adults with PWS, young adults with PWS 
have to stop GH treatment after attainment of adult height, unless they fulfil the 
criteria for adult GHD. We have previously shown that young adults with PWS benefit 
from continuation of GH, without safety concerns regarding their metabolic health 
profile22,51. There were, however, no studies about the safety of GH with regard to 
SRBD. The sixth chapter of this thesis, therefore, investigated the effects of one year 
of GH versus one year of placebo on SRBD in a randomized, double-blind, placebo-
controlled cross-over GH study. A polysomnography (PSG) was performed at start of 
the study, after one year and after two years in 27 young adults with PWS who had 
attained adult height and were treated with GH during childhood. The number of 
obstructive, central and mixed apneas and hypopneas were counted during the total 
sleep time and an AHI, Obstructive Apnea index (OAI) and Central Apnea Index 
(CAI) were calculated per hour of sleep.  
 
Our results show that, compared to placebo, one year of GH did not increase AHI, 
OAI or CAI. Furthermore, after two years in the study, there was no difference in AHI, 
CAI or OAI compared to baseline, regardless of GH or placebo. These findings are 
reassuring and prove that GH can be safely administered to young adults with PWS 
with regard to SRBD. Our study is in line with a previous study that found an 
improvement in AHI in 9 out of 10 GH-treated adults with PWS52. We also evaluated 
the prevalence of obstructive sleep apnea (OSA). Recent guidelines define OSA in 
adults as an AHI  5 events/h combined with typical complaints for OSA (e.g. 
daytime sleepiness, snoring or witnessed apneas) or an AHI  15 events/h 
regardless of complaints53. According to these guidelines 2 patients in our study (7%) 
fulfilled the criteria of OSA, one after 1 year of GH, the other after 1 year of placebo. 
However, only one of them had obstructive apneas during sleep with an OAI of 
merely 1.2 events/hour. Based on these patients we would suggest, besides 
evaluating AHI, to specifically assess the number of obstructive apneas. OAI might 
be a more accurate parameter than AHI for diagnosing OSA in PWS.  
 
The reported prevalence of OSA in people with PWS is variable, but generally higher 
than the 7% we found in our cohort. One reason could be that the median baseline 
BMI of the participants in the current study was 24.1 kg/m2, which is much lower than 
(young) adults with PWS who were never treated with GH. We also did not find a 
correlation between AHI and BMI or FM% SDS, unlike in previous reports. It is likely 
that, due to the reduced prevalence of obesity in our cohort, SRBD occur less 
common. Based on our data in adults with PWS, we would not recommend standard 
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GHD, GH replacement results in an initial increase in bone resorption, and only after 
1 year of GH treatment, a gradual increase in BMD45. Thus, it could be that 1 year of 
GH versus 1 year of placebo is too short to show a positive effect of GH on BMD in 
young adults with PWS who were treated with GH during childhood. 
 
Our study also shows that BMDTB did not significantly change during 2 years, while 
BMADLS decreased, independent of GH or placebo. We previously observed a 
decrease in BMDTB and BMADLS SDS in 64 pubertal children, in parallel to a lack of 
pubertal progression and low sex hormone levels21. Because there is an important 
relation between serum oestradiol and testosterone levels and BMD43,44, we suggest 
that the increased prevalence of hypogonadism in PWS might cause the decrease in 
BMD. Our results demonstrate that both BMDTB and BMADLS decrease in 
hypogonadal young adults without SSRT, while BMDTB improves in hypogonadal 
young adults who receive SSRT. Another study also found a higher BMDTB in women 
with PWS on SSRT or with normal cyclic oestrogen levels compared to hypogonadal 
women with PWS42. It seems that GH is not able to prevent the decline in BMD 
unless it is combined with SSRT, indicating that sex steroids play a major role in the 
development and conservation of BMD in adolescents and (young) adults with PWS. 
Although the administration of SSRT was not randomized, our findings suggest that 
SSRT should be considered in hypogonadal adolescents with PWS to improve their 
bone health in adulthood.  
 
We conclude that, compared to GH treatment, 1 year of placebo after attainment of 
adult height does not deteriorate BMD in young adults with PWS. In addition, our 
data suggest that GH is not able to prevent the decline in BMD in hypogonadal young 
adults with PWS, unless it is combined with SSRT. 
 
8.5 SLEEP-RELATED BREATHING DISORDERS - YOUNG ADULTS 
 
Sleep-related breathing disorders (SRBD) are common in patients with PWS, 
causing poor sleep quality and excessive daytime sleepiness46-48. Several factors are 
thought to influence SRBD in PWS, such as facial dysmorphia, lack of response to 
hypoxia and hypercapnia, and airway collapse caused by pharyngeal wall hypotonia 
and adenoid/tonsil hypertrophy4. Since 2002, children with PWS are being treated 
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with long-term GH12,49,50 and in the early years there were safety concerns regarding 
the effects of GH on SRBD. These concerns were, however, unfounded, as we have 
described a non-significant decline in apnea hypopnea index (AHI) after 6 months of 
GH in 35 prepubertal children with PWS and a recent review has concluded that GH 
can be safely administered, provided that SRBD is monitored and treated 
appropriately54.  
 
Since GH treatment is not registered for adults with PWS, young adults with PWS 
have to stop GH treatment after attainment of adult height, unless they fulfil the 
criteria for adult GHD. We have previously shown that young adults with PWS benefit 
from continuation of GH, without safety concerns regarding their metabolic health 
profile22,51. There were, however, no studies about the safety of GH with regard to 
SRBD. The sixth chapter of this thesis, therefore, investigated the effects of one year 
of GH versus one year of placebo on SRBD in a randomized, double-blind, placebo-
controlled cross-over GH study. A polysomnography (PSG) was performed at start of 
the study, after one year and after two years in 27 young adults with PWS who had 
attained adult height and were treated with GH during childhood. The number of 
obstructive, central and mixed apneas and hypopneas were counted during the total 
sleep time and an AHI, Obstructive Apnea index (OAI) and Central Apnea Index 
(CAI) were calculated per hour of sleep.  
 
Our results show that, compared to placebo, one year of GH did not increase AHI, 
OAI or CAI. Furthermore, after two years in the study, there was no difference in AHI, 
CAI or OAI compared to baseline, regardless of GH or placebo. These findings are 
reassuring and prove that GH can be safely administered to young adults with PWS 
with regard to SRBD. Our study is in line with a previous study that found an 
improvement in AHI in 9 out of 10 GH-treated adults with PWS52. We also evaluated 
the prevalence of obstructive sleep apnea (OSA). Recent guidelines define OSA in 
adults as an AHI  5 events/h combined with typical complaints for OSA (e.g. 
daytime sleepiness, snoring or witnessed apneas) or an AHI  15 events/h 
regardless of complaints53. According to these guidelines 2 patients in our study (7%) 
fulfilled the criteria of OSA, one after 1 year of GH, the other after 1 year of placebo. 
However, only one of them had obstructive apneas during sleep with an OAI of 
merely 1.2 events/hour. Based on these patients we would suggest, besides 
evaluating AHI, to specifically assess the number of obstructive apneas. OAI might 
be a more accurate parameter than AHI for diagnosing OSA in PWS.  
 
The reported prevalence of OSA in people with PWS is variable, but generally higher 
than the 7% we found in our cohort. One reason could be that the median baseline 
BMI of the participants in the current study was 24.1 kg/m2, which is much lower than 
(young) adults with PWS who were never treated with GH. We also did not find a 
correlation between AHI and BMI or FM% SDS, unlike in previous reports. It is likely 
that, due to the reduced prevalence of obesity in our cohort, SRBD occur less 
common. Based on our data in adults with PWS, we would not recommend standard 
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PSG at attainment of adult height in non-obese patients with PWS who were treated 
with GH during childhood and will continue GH in adulthood. However, medical 
professionals should be aware that (mild) upper respiratory tract infections and/or 
adenotonsillar hypertrophy can cause increased obstructive apneas54,55.  
 
We conclude that, compared to placebo, GH treatment does not increase AHI in 
young adults with PWS who were previously treated with GH during childhood. 
These results are reassuring and prove that GH can be safely administered. 
However, clinical signs of SRBD need to be monitored in children and adults with 
PWS, as obstructive apneas can occur in patients with adenotonsillar hypertrophy 
and/or (mild) upper respiratory tract infections.   
 
8.6 LEUKOCYTE TELOMERE LENGTH - YOUNG ADULTS 
 
Studies in GH-untreated adults with PWS describe an increased risk of developing 
age-associated diseases in early adulthood, such as diabetes mellitus type 2 
(T2DM), cardiovascular disease (CVD) and cognitive decline10,35. An approximate 
death rate of 3% per year was calculated across all ages, rising to 7% in those aged 
over 30 years56. As described in premature ageing syndromes, the ageing process 
might be accelerated in PWS57-60 and may partly explain the increased mortality rate 
and the increased risk of developing age-associated diseases early in life. Ageing is 
characterized by a progressive time-dependent decline of normal tissue and organ 
function and recent studies have shown that telomere shortening is involved in this 
process61-64. Telomeres are highly conserved TTAGGG tandem repeat DNA 
sequences at the end of each chromosome arm. Their main function is to protect the 
end of the chromosomes from inappropriate DNA repair mechanisms, preventing the 
loss of crucial DNA. Telomeres shorten during proliferation and telomere length 
declines as a function of chronological age63-65. Individuals with shorter telomere 
length show an increased mortality risk, providing support for an association between 
telomere length and lifespan66. 
 
The seventh chapter of this thesis investigated leukocyte telomere length (LTL) in 47 
GH-treated young adults with PWS with a median age of 19.2 years. LTL was 
compared to 135 age-matched healthy young adults. Because all young adults with 
PWS were treated with GH, we also compared LTL to 75 young adults born short for 
gestational age (SGA) who were also treated with GH. LTL was measured using a 
quantitative PCR-based technique, telomere sequence copy number (T) and single 
copy gene (36B4,S) were measured in separate reactions and calculated relative to a 
calibrator sample (genomic DNA from K562 cell line) included on each run. LTL was 
subsequently expressed as T/S ratio67.   
 
Our results demonstrate that LTL in young adults with PWS is shorter compared to 
age-matched healthy young adults and GH-treated young adults born SGA. There 
are no other studies on LTL in PWS, but previous reports described excess 
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functional impairment, morbidity and mortality and evidence of premature ageing in 
12 adults with PWS above the age of 50 years35. Shorter LTL might play a role. 
Another interesting finding in our group was the tendency of a lower IQ in subjects 
with a shorter LTL, which might imply a role of LTL in cognitive functioning in PWS. A 
cross-sectional MRI-study in 20 young adults with PWS showed that predicted brain 
age was 8.7 years higher than chronological age and their brain pattern resembled 
those of older brains68. Even though LTL was not measured in the latter study, there 
could be a possible role of LTL in accelerated brain ageing in adults with PWS. 
Longitudinal studies on LTL, cognitive functioning and brain development in a larger 
cohort of children and (older) adults with PWS are needed to elucidate the natural 
course of brain development in relation to LTL and cognitive functioning. 
 
In addition to chronological ageing, many genetic and environmental factors, which 
are often present in people with PWS, have been reported to affect telomere length, 
including obesity, a reduced level of physical activity and increased psychosocial 
stress64. Also, several studies have shown that shortened telomeres are associated 
with an increased risk of T2DM and CVD62,64,66 and adults with PWS are prone to 
develop T2DM and CVD in early life. We found no significant association between 
LTL and age, BMI, FM%, blood pressure, serum cholesterol levels or insulin 
sensitivity, which could be explained by the young age of our study group and 
positive effects of GH treatment on (determinants) of T2DM and CVD. It would be 
interesting to analyze the association between (risk factors for) T2DM and CVD and 
LTL in subjects with PWS at a later age, when age-associated diseases become 
more apparent. 
 
To evaluate whether GH treatment would cause increased replicative stress and 
shorter LTL, we compared young adults with PWS to young adults born SGA who 
were also treated with GH. Despite the fact that subjects with PWS were treated with 
GH for a significantly longer time than those born SGA, we found no association 
between LTL and the duration of GH treatment or the cumulative GH dose in young 
adults with PWS. This is reassuring with regard to possible negative effects of GH on 
LTL. Furthermore, LTL was similar in healthy young adults and GH-treated young 
adults born SGA, which makes adverse effects of long-term GH treatment on LTL 
very unlikely69. We could even argue that GH treatment might positively influence 
LTL, because long-term GH treatment during childhood counteracts the clinical 
course of increasing obesity in children with PWS and has resulted in a new 
generation of children and young adults with PWS without severe obesity. It could be 
that LTL would have been even shorter in our group of young adults with PWS if they 
had not been treated with GH and had a higher BMI and FM%. More research is 
needed on LTL across the life course to be able to determine its role in ageing in 
both GH-treated and untreated people with PWS.  
 
 
134 | Chapter 8   
 
PSG at attainment of adult height in non-obese patients with PWS who were treated 
with GH during childhood and will continue GH in adulthood. However, medical 
professionals should be aware that (mild) upper respiratory tract infections and/or 
adenotonsillar hypertrophy can cause increased obstructive apneas54,55.  
 
We conclude that, compared to placebo, GH treatment does not increase AHI in 
young adults with PWS who were previously treated with GH during childhood. 
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length show an increased mortality risk, providing support for an association between 
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PWS were treated with GH, we also compared LTL to 75 young adults born short for 
gestational age (SGA) who were also treated with GH. LTL was measured using a 
quantitative PCR-based technique, telomere sequence copy number (T) and single 
copy gene (36B4,S) were measured in separate reactions and calculated relative to a 
calibrator sample (genomic DNA from K562 cell line) included on each run. LTL was 
subsequently expressed as T/S ratio67.   
 
Our results demonstrate that LTL in young adults with PWS is shorter compared to 
age-matched healthy young adults and GH-treated young adults born SGA. There 
are no other studies on LTL in PWS, but previous reports described excess 
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functional impairment, morbidity and mortality and evidence of premature ageing in 
12 adults with PWS above the age of 50 years35. Shorter LTL might play a role. 
Another interesting finding in our group was the tendency of a lower IQ in subjects 
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including obesity, a reduced level of physical activity and increased psychosocial 
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develop T2DM and CVD in early life. We found no significant association between 
LTL and age, BMI, FM%, blood pressure, serum cholesterol levels or insulin 
sensitivity, which could be explained by the young age of our study group and 
positive effects of GH treatment on (determinants) of T2DM and CVD. It would be 
interesting to analyze the association between (risk factors for) T2DM and CVD and 
LTL in subjects with PWS at a later age, when age-associated diseases become 
more apparent. 
 
To evaluate whether GH treatment would cause increased replicative stress and 
shorter LTL, we compared young adults with PWS to young adults born SGA who 
were also treated with GH. Despite the fact that subjects with PWS were treated with 
GH for a significantly longer time than those born SGA, we found no association 
between LTL and the duration of GH treatment or the cumulative GH dose in young 
adults with PWS. This is reassuring with regard to possible negative effects of GH on 
LTL. Furthermore, LTL was similar in healthy young adults and GH-treated young 
adults born SGA, which makes adverse effects of long-term GH treatment on LTL 
very unlikely69. We could even argue that GH treatment might positively influence 
LTL, because long-term GH treatment during childhood counteracts the clinical 
course of increasing obesity in children with PWS and has resulted in a new 
generation of children and young adults with PWS without severe obesity. It could be 
that LTL would have been even shorter in our group of young adults with PWS if they 
had not been treated with GH and had a higher BMI and FM%. More research is 
needed on LTL across the life course to be able to determine its role in ageing in 
both GH-treated and untreated people with PWS.  
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We conclude that LTL was shorter in GH-treated young adults with PWS compared 
to untreated healthy young adults and young adults born SGA who were also treated 
with GH during childhood. This suggests that a shorter LTL might be involved in the 
reported accelerated ageing process in adults with PWS. More research on LTL 
across the life course is needed to be able to determine its role in ageing in people 
with PWS.  
 
8.7 GENERAL CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
Since 2002, our longitudinal PWS studies investigated the short and long-term 
effects of GH treatment in a large group of children and young adults with PWS. In 
this thesis we describe 6 new studies regarding GH treatment in children and young 
adults with PWS. Chapter 2 shows that mental and motor development improve 
during 3 years of GH, reducing the gap between infants with PWS and healthy peers.	
It also shows that the younger the age at start of GH treatment, the greater the 
improvement in psychomotor development. This suggests that starting GH treatment 
early, in a critical period of neurodevelopment, could enhance psychomotor and 
cognitive development on the longer term. The mean mental and motor development 
after 3 years of GH was, however, still lower than in healthy references, indicating 
that young children with PWS need extra support with regard to their development. 
 
We also demonstrate that visuospatial skills slightly improve during 8 years of GH in 
children with PWS, while abstract verbal reasoning and vocabulary remain similar. 
These results are reassuring as cognitive functioning did not deteriorate and 
developed at a similar rate compared to healthy references. After 8 years of GH, 
children who started GH before the age of 2 years had significantly better vocabulary 
skills and a higher estimated total IQ, compared to children who started GH during 
childhood, suggesting that early start of GH could be beneficial for cognitive 
functioning on the long term. Combined with an early diagnosis and multidisciplinary 
support from a very young age, long-term GH treatment during childhood counteracts 
the clinical course of increasing obesity in PWS and substantially changes the 
phenotype of children with PWS. This study provides further support for the 
importance of GH treatment in children with PWS with regard to cognitive functioning. 
 
In the fourth chapter of this thesis we show that not one patient fulfills the criteria for 
adult growth hormone deficiency (GHD), when tested with a GHRH-Arginine 
stimulation test. However, children and adults with PWS have hypothalamic 
dysfunction and several features that resemble those seen in GHD. Furthermore, the 
fact that they respond very well to GH treatment, with a significant improvement in 
body composition, health profile, normalization of stature in children, and a significant 
increase in serum IGF-I and IGFBP-3 levels strongly supports the likelihood of GHD 
in these patients. In other words, although adult GHD cannot be demonstrated by 
conventional testing using the current consensus criteria, one cannot conclude that it 
does not exist. It seems that conventional testing for adult GHD is not reliable in 
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adults with PWS and adult GHD should not be a prerequisite for treating adults with 
PWS with GH. GH treatment is highly recommended for adults with PWS, regardless 
of whether they fulfil the consensus criteria of adult GHD.  
 
Our randomized, double-blind, placebo-controlled, cross-over study in young adults 
with PWS who were treated with GH during childhood demonstrates that compared 
to one year of GH treatment, one year of placebo after attainment of adult height, 
does not deteriorate BMD. However, we did find that BMD decreased during two 
years, regardless of GH or placebo. This decline was present in hypogonadal young 
adults with PWS without SSRT, but not in hypogonadal young adults with PWS with 
SSRT. It seems that GH is not able to prevent the decline in BMD unless it is 
combined with SSRT, indicating that sex steroids play a major role in the 
development and conservation of BMD in adolescents and (young) adults with PWS. 
This suggests that SSRT should be considered in hypogonadal adolescents with 
PWS to improve their bone health in adulthood. Our two-year study also shows that 
compared to one year of placebo, one year of GH treatment did not increase sleep-
related breathing disorders (SRBD) in young adults with PWS who were treated with 
GH during childhood and had attained adult height. This is reassuring and proves 
that GH can be safely administered with regard to SRBD. However, clinicians should 
keep track of clinical signs of SRBD, e.g. snoring or daytime sleepiness in children 
and adults with PWS, as obstructive apneas can occur or increase in patients with 
adenotonsillar hypertrophy and/or (mild) upper respiratory tract infections.  
 
We found a shorter Leukocyte Telomere Length (LTL) in young adults with PWS 
compared to age-matched healthy young adults and young adults born SGA who 
were also treated with GH during childhood. There was a tendency towards a lower 
IQ in subjects with shorter LTL, which might imply a role of LTL in cognitive 
functioning in PWS. Adults with PWS are at increased risk of developing age-
associated diseases in early adulthood and the ageing process might be accelerated. 
The shorter LTL might be involved in the reported accelerated ageing process in 
adults with PWS. However, more research is needed on LTL across the life course to 
determine its role in ageing in both GH-treated and untreated people with PWS. 
 
8.8 DIRECTIONS FOR FUTURE RESEARCH 
 
GH in adults with PWS 
 
Long-term GH treatment during childhood has well-known beneficial effects on body 
composition, psychomotor development, bone mineral density, linear growth and 
quality of life6,12,21,77. Up to now GH treatment is only approved for children with PWS, 
and adolescents with PWS who reach adult height currently have to stop GH 
treatment if they do not fulfil the criteria of adult growth hormone deficiency. 
However, multiple studies have shown beneficial effects of short-term GH treatment 
in young adults with PWS22,78-80.  
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were also treated with GH during childhood. There was a tendency towards a lower 
IQ in subjects with shorter LTL, which might imply a role of LTL in cognitive 
functioning in PWS. Adults with PWS are at increased risk of developing age-
associated diseases in early adulthood and the ageing process might be accelerated. 
The shorter LTL might be involved in the reported accelerated ageing process in 
adults with PWS. However, more research is needed on LTL across the life course to 
determine its role in ageing in both GH-treated and untreated people with PWS. 
 
8.8 DIRECTIONS FOR FUTURE RESEARCH 
 
GH in adults with PWS 
 
Long-term GH treatment during childhood has well-known beneficial effects on body 
composition, psychomotor development, bone mineral density, linear growth and 
quality of life6,12,21,77. Up to now GH treatment is only approved for children with PWS, 
and adolescents with PWS who reach adult height currently have to stop GH 
treatment if they do not fulfil the criteria of adult growth hormone deficiency. 
However, multiple studies have shown beneficial effects of short-term GH treatment 
in young adults with PWS22,78-80.  
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There are, however, no long-term studies on the efficacy and safety of GH treatment 
in adults with PWS. Future research should focus on the long-term effects of GH 
treatment on body composition, bone mineral density, cognitive functioning, quality of 
life and safety in both GH-treated and GH-naïve adults with PWS. 
 
Genotype-phenotype  
 
PWS is caused by a lack of expression of the paternally inherited genes located on 
15q11-13, i.e. the Prader-Willi region. The loss of the imprinted genes on the PWS 
region causes the PWS phenotype72. Even though some studies have described 
phenotypic differences between people with a deletion and mUPD73-76, the exact 
function of each gene, still needs to be elucidated.  
 
Another subject of interest is the clinical variation between subjects with PWS. Some 
people with PWS eat everything they can find, including inedible products, while the 
appetite of other people with PWS is normal. Severe behavioral problems are more 
of a problem in some persons with PWS than others. It could be that (epi)genetic 
variation in people with PWS cause this variable phenotype. Future studies should 
focus on which (epi)genetic deviations cause different features of PWS, to be able to 
treat and/or prevent particular features accurately. This could improve the life of 
people with PWS and their families. 
 
Appetite regulating hormones  
 
Various clinical features in subjects with PWS change during their life, the most 
obvious being the change in appetite and body composition. Most babies with PWS 
require tube feeding, and infants with PWS show feeding difficulties and a lack of 
appetite. From the age of 2 years an increased interest in food emerges, which shifts 
to an unlimited appetite70. If parents and caregivers do not control the unlimited 
appetite, it will result in morbid obesity with severe complications including diabetes 
mellitus and cardiovascular disease in early adult life.  
 
Appetite regulating hormones play an important role in the regulation of food intake 
and body composition by signaling satiety and energy reserves through hypothalamic 
receptors. Future studies focusing on appetite regulating hormones and 
hypothalamic function are needed to unravel the cause of hyperphagia in patients 
with PWS. Currently, an effective treatment for hyperphagia does not exist. Potential 
treatments for hyperphagia in PWS should be addressed in future studies, as this 
would relieve families of children with PWS from the great responsibility to retain food 
from their children, and would reduce the risk for obesity and comorbidities. 
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Prader-Willi like 
 
In the last few decades, considerable progress has been made in the knowledge 
about children and (young) adults with PWS. Children with PWS are treated with GH 
from a very young age and, combined with an early diagnosis and multidisciplinary 
support, this has resulted in a new generation of children with PWS. Children with 
PWS have a healthier weight and body composition, reach a normal adult height and 
are able to take part in society.  
 
In the past years we have been frequently contacted by parents and caregivers of 
children with similar symptoms as children with PWS, but without the typical genetic 
defect of children with PWS. These Prader-Willi like (PWL) children have the same 
severe medical and behavioural problems as children with PWS, but did not receive 
multidisciplinary care and treatment. Since the beginning of 2019 the Dutch PWS 
Reference Center started providing multidisciplinary care to children and young 
adults with PWL and aims to investigate how multidisciplinary care influences quality 
of life of children with PWL and their families and which (epi)genetic defects underlie 
PWL.   
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SUMMARY 
 
This thesis reports several studies we have performed in the last few years in 
children and young adults with Prader-Willi syndrome (PWS). Their main aim was to 
improve the knowledge about PWS and to optimize the care for patients with PWS. 
This chapter summarizes the studies and their most important outcomes.  
 
Chapter 1  
 
The introduction discusses the clinical manifestations of children and young adults 
with PWS in different stages of life, the genetic cause, hypothalamic dysfunction and 
describes the current knowledge on the effects of GH treatment in children and 
young adults with PWS. Furthermore, the objectives of the studies in this thesis are 
introduced. 
 
Chapter 2  
 
Infants and toddlers with PWS have a mental and motor developmental delay. Short-
term data suggest a positive effect of growth hormone (GH) treatment on 
psychomotor development. Longer-term studies were, however, lacking. We, 
therefore, prospectively investigated the effects of 3 years of GH treatment on 
psychomotor development (by Bayley Scales of Infant Development II) in a large 
group of 63 infants with PWS who started GH treatment at a median age of 1 year. 
We also investigated if a younger age at start of GH treatment would lead to greater 
mental and motor development during 3 years of GH.  
 
We found that both mental and motor development increased during 3 years of GH 
treatment. Our study also demonstrated that the lower psychomotor development 
and the younger the age at start of GH, the greater the improvement in psychomotor 
development.  
 
We conclude that mental and motor development increase during 3 years of GH, 
reducing the gap between infants with PWS and healthy peers. Secondly, we 
conclude that, the younger at start of GH treatment, the greater the improvement in 
psychomotor development.  
 
Chapter 3  
 
Children with PWS generally have mild to moderate cognitive impairment with an IQ 
between 60 and 70. GH is an approved treatment for children with PWS and has 
been associated with cognitive benefits, attributed to the effects of GH and insulin-
like growth factor on brain growth and development. Short-term data suggest positive 
effects of GH treatment on cognitive functioning in children with PWS. There were, 
however, no long-term studies about the effects of GH on cognitive functioning.    
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We, therefore, conducted a prospective cohort study in 43 children with PWS, who 
started GH at a median age of 8 years. We evaluated the effects of 8 years of GH 
treatment on cognitive functioning and whether starting GH before the age of 2 years 
results in higher cognitive functioning after 8 years of GH.  
 
Our study showed that visuospatial skills slightly improve during 8 years of GH 
treatment, while abstract verbal reasoning and vocabulary remained similar. After 8 
years of GH, 22 children who started GH before the age of 2 years had significantly 
higher vocabulary skills and a higher estimated total IQ, compared to the children 
who started GH during childhood.  
 
From these data we conclude that cognitive skills in GH-treated children develop at 
the same pace as in healthy references. We also conclude that starting GH treatment 
before the age of 2 years might lead to higher cognitive functioning on the long-term. 
 
Chapter 4  
 
Some features of subjects with PWS resemble those seen in growth hormone 
deficiency (GHD). Children with PWS are treated with GH, which has substantially 
changed their phenotype. Studies in adults with PWS have also shown beneficial 
effects of GH treatment. GH treatment for adults with PWS is currently not approved 
and can only be reimbursed if they fulfill the consensus criteria of adult GHD. We, 
therefore, investigated the prevalence of GHD in 60 previously GH-treated young 
adults with PWS by GHRH-Arginine stimulation tests. GHD in adults was defined as 
a GH peak level < 9 µg/l in combination with a serum IGF-I SDS level < -2.0. 
 
Our results demonstrate that serum IGF-I was < -2 SDS in 2 (3%) patients and 
IGFBP-3 was within the normal range in all but one patient. Nine participants had a 
GH peak < 9 µg/L (15%) during a GHRH-Arginine test. None of these patients also 
had an IGF-I < -2.0 SDS. Therefore, not one patient fulfilled the criteria for adult 
GHD, also when BMI-dependent criteria were used.  
 
Our study shows that a GHRH-Arginine test to diagnose adult GHD is unreliable in 
adults with PWS. As GH treatment has very positive effects in adults with PWS, adult 
GHD should not be a prerequisite for treating adults with PWS with GH.  
 
Chapter 5  
 
The prevalence of osteoporosis is increased in adults with PWS. In children, GH 
treatment has beneficial effects on bone mineral density (BMD). BMD might 
deteriorate after cessation of GH at adult height, while continuing GH might maintain 
BMD. In our 2-year, randomized, double-blind, placebo-controlled cross-over GH 
study with stratification for gender and BMI, we investigated the effects of 1 year of 
GH versus 1 year of placebo on BMD of the total body (BMDTB) and of the lumbar 
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spine (BMADLS) in 27 GH-treated young adults with PWS who had attained adult 
height. Furthermore, we investigated the effects of sex steroid replacement therapy 
(SSRT) on BMD in hypogonadal young adults with PWS.  
 
At adult height, BMDTB was significantly lower compared to healthy peers, while 
BMADLS was similar. Compared to 1 year of GH, 1 year of placebo did not 
deteriorate BMDTB or BMADLS. We also showed that BMDTB did not significantly 
change during 2 years, while BMADLS decreased, independent of GH or placebo. 
This could be due to the higher prevalence of hypogonadism in PWS. We found that 
BMDTB and BMADLS decreased during the 2-year study in hypogonadal young adults 
without SSRT, while BMDTB increased in those with SSRT.  
 
We conclude that, compared to GH treatment, 1 year of placebo after attainment of 
adult height does not deteriorate BMD in young adults with PWS. Our data suggest 
that GH is not able to prevent the decline in BMD in hypogonadal young adults with 
PWS, unless it is combined with SSRT. 
 
Chapter 6  
 
Sleep-related breathing disorders (SRBD) are common in people with PWS causing 
poor sleep quality and excessive daytime sleepiness. Young adults with PWS benefit 
from GH continuation after adult height by maintaining the improved body 
composition obtained during childhood. There were, however, no studies about the 
effects of GH on SRBD in young adults with PWS who were treated with GH during 
childhood. We, therefore, investigated SRBD in 27 young adults with PWS who were 
treated with GH during childhood and had attained adult height in our 2-year, 
randomized, double-blind, placebo-controlled, cross-over GH-study, stratified for 
gender and BMI. We also investigated the prevalence of obstructive sleep apnea 
(OSA).  
 
Compared to placebo, one year of GH did not increase Apnea hypopnea index (AHI), 
obstructive apnea index (OAI) or central apnea index (CAI). After 2 years, there was 
no difference in AHI, CAI or OAI compared to baseline, regardless of GH or placebo. 
Two patients (7%) fulfilled the criteria of obstructive sleep apnea (OSA). AHI in these 
2 patients consisted mainly of hypopneas, OAI being 0 and 1.2 events/hour.  
 
We conclude that GH compared to placebo does not cause a significant increase in 
AHI, CAI or OAI in adults with PWS who were treated with GH during childhood and 
have attained adult height. Our findings are reassuring and prove that GH can be 
safely administered with regard to SRBD. 
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Chapter 7  
 
Adults with PWS are at increased risk of developing age-associated diseases early in 
life and, like in premature ageing syndromes, ageing might be accelerated. Recently, 
telomere length has been associated with ageing and individuals with shorter 
telomere length show an increased mortality risk. We, therefore, investigated 
leukocyte telomere length (LTL), a marker of biological age, in 47 young adults with 
PWS and cross-sectionally compared LTL to 135 healthy young adults of similar age. 
As all young adults with PWS were treated with growth hormone (GH), we also 
compared LTL in PWS subjects to 75 GH-treated young adults born short for 
gestational age (SGA).  
 
We demonstrate that LTL in young adults with PWS is shorter compared to age-
matched healthy young adults and GH-treated young adults born SGA, suggesting a 
possible role of LTL in the reported accelerated ageing process in PWS. Despite the 
fact that subjects with PWS were treated with GH for a significantly longer time, there 
was no association between LTL and duration of GH treatment or cumulative GH 
dose.  
 
We conclude that young adults with PWS have a significantly shorter median LTL 
compared to age-matched healthy young adults and GH-treated young adults born 
SGA. The shorter telomeres might play a role in premature ageing in PWS, 
independent of GH treatment. 
 
Chapter 8  
 
In the general discussion, we examine our results in view of the current literature and 
suggest clinical implications of our findings. Furthermore, we report our overall 
conclusions and give recommendations for future research.  
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SAMENVATTING 
 
Dit proefschrift geeft een overzicht van de resultaten van 6 studies die we in de 
afgelopen jaren hebben verricht bij kinderen en jongvolwassenen met Prader-Willi 
syndroom (PWS). Het belangrijkste doel was het vergroten van de kennis over PWS 
en het optimaliseren van de zorg voor kinderen en jongvolwassenen met PWS en 
hun gezin. In dit hoofdstuk geven we een samenvatting van de resultaten van de 
verrichte studies.  
 
Hoofdstuk 1  
 
Hoofdstuk 1 geeft achtergrondinformatie over PWS. De kenmerken per levensfase, 
de genetische achtergrond en groeihormoon (GH) behandeling worden besproken. 
Ook wordt een korte inleiding gegeven over de studies die worden beschreven in dit 
proefschrift. 
 
Hoofdstuk 2  
 
Jonge kinderen met PWS hebben een mentale en motorische 
ontwikkelingsachterstand. Korte termijn studies vonden een positief effect van GH op 
de mentale en motorische ontwikkeling bij jonge kinderen met PWS. Tot op heden, 
waren de langere termijn effecten van GH op de mentale en motorische ontwikkeling 
van jonge kinderen met PWS nooit onderzocht. In deze prospectieve studie 
onderzochten we daarom bij 63 peuters met PWS, die op een mediane leeftijd van 1 
jaar waren gestart met GH, de psychomotorische ontwikkeling tijdens 3 jaar GH 
middels de Bayley Scales of Infant Development II. Ook onderzochten we of eerder 
starten met GH leidt tot een betere psychomotorische ontwikkeling.  
 
We vonden dat zowel de mentale als de motorische ontwikkeling verbeterden tijdens 
3 jaar GH behandeling. Ook vonden we dat kinderen die een lagere 
psychomotorische ontwikkeling hadden of jonger waren bij het starten van GH een 
grotere verbetering toonden in hun psychomotorische ontwikkeling.  
 
Uit deze resultaten concluderen we dat zowel de mentale, als de motorische 
ontwikkeling verbeteren tijdens 3 jaar GH behandeling. Dit verkleint de 
psychomotorische verschillen tussen kinderen met PWS en gezonde kinderen. 
Daarnaast concluderen we dat, hoe jonger het kind is bij de start van GH, hoe groter 
de verbetering in psychomotorische ontwikkeling.  
 
Hoofdstuk 3  
 
Kinderen met PWS hebben een milde tot matige verstandelijke beperking met een 
gemiddeld IQ tussen 60 en 70. GH is een geregistreerde behandeling voor kinderen 
met PWS en verschillende studies beschreven positieve effecten van GH op de 
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cognitieve ontwikkeling. Echter, tot op heden waren de lange-termijn effecten van GH 
op de cognitieve ontwikkeling nooit onderzocht. We hebben daarom een 
prospectieve cohort studie verricht bij 43 kinderen met PWS met een mediane leeftijd 
van 8 jaar bij start van GH. We onderzochten de cognitieve ontwikkeling tijdens 8 
jaar GH behandeling. Ook onderzochten we of de cognitieve ontwikkeling na 8 jaar 
GH beter is bij kinderen die voor de leeftijd van 2 jaar waren gestart met GH.  
 
We vonden dat het performaal IQ iets verbeterde tijdens 8 jaar GH, terwijl het verbaal 
IQ gelijk bleef. Na 8 jaar GH vonden we een significant hoger verbaal en totaal IQ bij 
kinderen die voor de leeftijd van 2 jaar waren gestart met GH, ten opzichte van de 
kinderen die na de leeftijd van 2 jaar waren gestart met GH.  
 
We concluderen dat het totaal IQ van kinderen met PWS lager is dan bij gezonde 
kinderen, maar dat de cognitieve ontwikkeling van GH-behandelde kinderen met 
PWS gelijk is aan die van gezonde kinderen. Dit betekent dat de cognitieve 
achterstand niet groter wordt. We concluderen ook dat het starten van GH voor de 
leeftijd van 2 jaar mogelijk tot een betere cognitieve ontwikkeling leidt.  
 
Hoofdstuk 4 
  
Sommige kenmerken van patiënten met PWS komen overeen met het hebben van 
groeihormoondeficiëntie (GHD). Langdurige behandeling met GH bij kinderen met 
PWS verbetert onder andere de lichaamssamenstelling en de groei. Op dit moment 
moeten jongvolwassenen met PWS stoppen met GH bij het bereiken van de 
eindlengte als ze niet voldoen aan de criteria voor volwassen GHD. Echter, 
verschillende studies hebben aangetoond dat GH gunstig is voor volwassenen met 
PWS, met een blijvende verbetering in de lichaamssamenstelling en de metabole 
gezondheid. Er was tot op heden weinig bekend over de prevalentie van GHD bij 
volwassenen met PWS. We hebben daarom middels een GHRH-Arginine 
stimulatietest de prevalentie van GHD onderzocht bij 60 jongvolwassenen met PWS 
die tot het bereiken van de volwassen lengte waren behandeld met GH. De definitie 
van volwassen GHD was een IGF-I <-2 standaarddeviaties (SDS) en een 
groeihormoon piek <9 µg/l. We vonden dat het IGF-I in het bloed lager was dan -2 
SDS bij 2 jongvolwassenen (3%). Negen deelnemers (15%) hadden een GH piek <9 
µg/L. Geen enkele jongvolwassene had een IGF-I < -2 SDS én een GH piek <9 µg/L. 
Geen van de jongvolwassenen met PWS voldeed daarom aan de volwassen GHD 
criteria, ook als er gecorrigeerd werd voor body mass index (BMI).  
 
We concluderen dat de standaard GHRH-Arginine test niet geschikt is om volwassen 
GHD aan te tonen bij jongvolwassenen met PWS. Omdat de positieve effecten van 
GH bij volwassenen met PWS in meerdere studies zijn bewezen, zou het aantonen 
van volwassen GHD geen vereiste moeten zijn voor GH behandeling bij 
volwassenen met PWS.  
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Hoofdstuk 5  
 
Kinderen en adolescenten met PWS hebben een hoger risico op een lagere 
botdichtheid, omdat ze vaak lage groeihormoon (GH) spiegels in het bloed hebben, 
niet goed in de puberteit komen en een inactieve leefstijl hebben. Het is bekend dat 
ouderen met PWS meer risico hebben op osteoporose. Uit eerder onderzoek bij 
kinderen met PWS is gebleken dat GH zorgt voor een verbetering van de 
botdichtheid (BMD). De gevolgen van het stoppen met GH op het moment dat 
jongeren met PWS zijn uitgegroeid was onbekend. In onze gerandomiseerde, 
dubbelblinde, placebo-gecontroleerde cross-over studie onderzochten we de effecten 
van 1 jaar GH versus 1 jaar placebo op de botdichtheid van het gehele lichaam 
(BMDTB) en de botdichtheid van de lumbale wervelkolom (BMADLS) bij 27 
jongvolwassenen met PWS die tot de volwassen lengte waren behandeld met GH. 
Ook onderzochten we bij jongvolwassenen met PWS en hypogonadisme de effecten 
van behandeling met geslachtshormonen (SSRT) op de botdichtheid.  
 
Ten opzichte van 1 jaar GH, zorgde 1 jaar placebo niet voor een afname in BMDTB of 
BMADLS. Wel zagen we dat BMADLS gedurende de 2 jaar durende studie afnam, 
onafhankelijk van groeihormoon of placebo. Omdat we weten dat 
geslachtshormonen een belangrijke rol spelen bij de botdichtheid werden de 
jongvolwassenen met hypogonadisme die behandeld werden met SSRT vergeleken 
met de jongvolwassenen die niet werden behandeld. We vonden dat de 
jongvolwassenen met hypogonadisme die wel SSRT kregen een verbetering hadden 
in BMDTB, terwijl BMDTB en BMADLS daalden bij de jongvolwassenen die geen SSRT 
kregen.  
 
We concluderen dat een jaar placebo geen achteruitgang geeft van de botdichtheid 
bij jongvolwassenen met PWS die tijdens de kindertijd langdurig met groeihormoon 
zijn behandeld. Ook concluderen we dat GH bij jongvolwassenen met PWS en 
hypogonadisme de afname in de botdichtheid niet lijkt te kunnen voorkomen, behalve 
als GH gecombineerd wordt met behandeling met SSRT.  
 
Hoofdstuk 6  
  
Een (sterk) verminderde ademhaling (hypopneu) of een ademstilstand (apneu) in de 
slaap komen regelmatig voor. Bij volwassenen is er sprake van een slaapstoornis als 
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PWS. Het effect van GH of placebo op SRBD bij jongvolwassenen met PWS die de 
eindlengte hadden bereikt was tot op heden nooit onderzocht.  
 
154 | Chapter 9 
cognitieve ontwikkeling. Echter, tot op heden waren de lange-termijn effecten van GH 
op de cognitieve ontwikkeling nooit onderzocht. We hebben daarom een 
prospectieve cohort studie verricht bij 43 kinderen met PWS met een mediane leeftijd 
van 8 jaar bij start van GH. We onderzochten de cognitieve ontwikkeling tijdens 8 
jaar GH behandeling. Ook onderzochten we of de cognitieve ontwikkeling na 8 jaar 
GH beter is bij kinderen die voor de leeftijd van 2 jaar waren gestart met GH.  
 
We vonden dat het performaal IQ iets verbeterde tijdens 8 jaar GH, terwijl het verbaal 
IQ gelijk bleef. Na 8 jaar GH vonden we een significant hoger verbaal en totaal IQ bij 
kinderen die voor de leeftijd van 2 jaar waren gestart met GH, ten opzichte van de 
kinderen die na de leeftijd van 2 jaar waren gestart met GH.  
 
We concluderen dat het totaal IQ van kinderen met PWS lager is dan bij gezonde 
kinderen, maar dat de cognitieve ontwikkeling van GH-behandelde kinderen met 
PWS gelijk is aan die van gezonde kinderen. Dit betekent dat de cognitieve 
achterstand niet groter wordt. We concluderen ook dat het starten van GH voor de 
leeftijd van 2 jaar mogelijk tot een betere cognitieve ontwikkeling leidt.  
 
Hoofdstuk 4 
  
Sommige kenmerken van patiënten met PWS komen overeen met het hebben van 
groeihormoondeficiëntie (GHD). Langdurige behandeling met GH bij kinderen met 
PWS verbetert onder andere de lichaamssamenstelling en de groei. Op dit moment 
moeten jongvolwassenen met PWS stoppen met GH bij het bereiken van de 
eindlengte als ze niet voldoen aan de criteria voor volwassen GHD. Echter, 
verschillende studies hebben aangetoond dat GH gunstig is voor volwassenen met 
PWS, met een blijvende verbetering in de lichaamssamenstelling en de metabole 
gezondheid. Er was tot op heden weinig bekend over de prevalentie van GHD bij 
volwassenen met PWS. We hebben daarom middels een GHRH-Arginine 
stimulatietest de prevalentie van GHD onderzocht bij 60 jongvolwassenen met PWS 
die tot het bereiken van de volwassen lengte waren behandeld met GH. De definitie 
van volwassen GHD was een IGF-I <-2 standaarddeviaties (SDS) en een 
groeihormoon piek <9 µg/l. We vonden dat het IGF-I in het bloed lager was dan -2 
SDS bij 2 jongvolwassenen (3%). Negen deelnemers (15%) hadden een GH piek <9 
µg/L. Geen enkele jongvolwassene had een IGF-I < -2 SDS én een GH piek <9 µg/L. 
Geen van de jongvolwassenen met PWS voldeed daarom aan de volwassen GHD 
criteria, ook als er gecorrigeerd werd voor body mass index (BMI).  
 
We concluderen dat de standaard GHRH-Arginine test niet geschikt is om volwassen 
GHD aan te tonen bij jongvolwassenen met PWS. Omdat de positieve effecten van 
GH bij volwassenen met PWS in meerdere studies zijn bewezen, zou het aantonen 
van volwassen GHD geen vereiste moeten zijn voor GH behandeling bij 
volwassenen met PWS.  
 
                                                                                                               Samenvatting |  155 
Hoofdstuk 5  
 
Kinderen en adolescenten met PWS hebben een hoger risico op een lagere 
botdichtheid, omdat ze vaak lage groeihormoon (GH) spiegels in het bloed hebben, 
niet goed in de puberteit komen en een inactieve leefstijl hebben. Het is bekend dat 
ouderen met PWS meer risico hebben op osteoporose. Uit eerder onderzoek bij 
kinderen met PWS is gebleken dat GH zorgt voor een verbetering van de 
botdichtheid (BMD). De gevolgen van het stoppen met GH op het moment dat 
jongeren met PWS zijn uitgegroeid was onbekend. In onze gerandomiseerde, 
dubbelblinde, placebo-gecontroleerde cross-over studie onderzochten we de effecten 
van 1 jaar GH versus 1 jaar placebo op de botdichtheid van het gehele lichaam 
(BMDTB) en de botdichtheid van de lumbale wervelkolom (BMADLS) bij 27 
jongvolwassenen met PWS die tot de volwassen lengte waren behandeld met GH. 
Ook onderzochten we bij jongvolwassenen met PWS en hypogonadisme de effecten 
van behandeling met geslachtshormonen (SSRT) op de botdichtheid.  
 
Ten opzichte van 1 jaar GH, zorgde 1 jaar placebo niet voor een afname in BMDTB of 
BMADLS. Wel zagen we dat BMADLS gedurende de 2 jaar durende studie afnam, 
onafhankelijk van groeihormoon of placebo. Omdat we weten dat 
geslachtshormonen een belangrijke rol spelen bij de botdichtheid werden de 
jongvolwassenen met hypogonadisme die behandeld werden met SSRT vergeleken 
met de jongvolwassenen die niet werden behandeld. We vonden dat de 
jongvolwassenen met hypogonadisme die wel SSRT kregen een verbetering hadden 
in BMDTB, terwijl BMDTB en BMADLS daalden bij de jongvolwassenen die geen SSRT 
kregen.  
 
We concluderen dat een jaar placebo geen achteruitgang geeft van de botdichtheid 
bij jongvolwassenen met PWS die tijdens de kindertijd langdurig met groeihormoon 
zijn behandeld. Ook concluderen we dat GH bij jongvolwassenen met PWS en 
hypogonadisme de afname in de botdichtheid niet lijkt te kunnen voorkomen, behalve 
als GH gecombineerd wordt met behandeling met SSRT.  
 
Hoofdstuk 6  
  
Een (sterk) verminderde ademhaling (hypopneu) of een ademstilstand (apneu) in de 
slaap komen regelmatig voor. Bij volwassenen is er sprake van een slaapstoornis als 
een apneu 's nachts meer dan vijf keer per uur plaatsvindt en dit minimaal tien 
seconden duurt. Er is sprake van een obstructieve slaapstoornis (OSA) als iemand 
wel een prikkel heeft om adem te halen, maar de ingeademde lucht niet verder komt 
dan de keel door een gedeeltelijke of volledige blokkade van de luchtweg. Slaap-
gerelateerde ademhalingsproblemen (SRBD) komen vaak voor bij mensen met 
PWS. Het effect van GH of placebo op SRBD bij jongvolwassenen met PWS die de 
eindlengte hadden bereikt was tot op heden nooit onderzocht.  
 
156 | Chapter 9 
In onze gerandomiseerde, dubbelblinde, placebo-gecontroleerde cross-over studie 
onderzochten we de effecten van 1 jaar GH versus 1 jaar placebo op SRBD bij 27 
jongvolwassenen met PWS die tot de volwassen lengte waren behandeld met GH. 
We onderzochten ook hoe vaak OSA voorkomt in ons cohort van jongvolwassenen 
met PWS. We vonden dat, in vergelijking met placebo, 1 jaar GH niet zorgde voor 
een toename in het aantal apneus en hypopneus. Na 2 jaar was er geen significant 
verschil in het aantal apneus en hypopneus ten opzichte van start van de studie, 
onafhankelijk van GH of placebo. Twee jongvolwassenen (7%) voldeden aan de 
OSA criteria. Beiden waren obees en hadden vergrote amandelen.  
 
We concluderen dat er geen toename is in het aantal apneus en hypopneus tijdens 1 
jaar GH. Onze bevindingen zijn geruststellend en laten zien dat GH behandeling 
veilig is met betrekking tot SRBD bij volwassenen met PWS.    
 
Hoofdstuk 7  
 
Veel volwassenen met PWS ontwikkelen op jonge leeftijd ouderdomsziekten. In de 
literatuur wordt een versnelde veroudering beschreven bij mensen met PWS. 
Mogelijk spelen telomeren hierin een rol. De telomeerlengte was nooit eerder 
onderzocht bij mensen met PWS. We hebben daarom bij 47 jongvolwassenen met 
PWS de telomeerlengte in leukocyten (LTL) gemeten en vergeleken met 135 
gezonde jongvolwassenen. Omdat alle jongvolwassenen met PWS behandeld 
werden met GH, hebben we LTL ook vergeleken met 75 jongvolwassenen die te 
klein waren bij de geboorte en tot het bereiken van de eindlengte ook behandeld 
waren met GH.  
 
We vonden dat de LTL korter was bij jongvolwassenen met PWS in vergelijking met 
gezonde jongvolwassenen en GH-behandelde jongvolwassenen die te klein waren 
bij de geboorte. Dit suggereert een mogelijke rol van LTL in het versnelde 
verouderingsproces bij PWS. We vonden geen verband tussen LTL en de duur van 
de GH-behandeling of de cumulatieve GH-dosis.  
 
We concluderen dat jongvolwassenen met PWS een significant kortere mediane LTL 
hebben in vergelijking met gezonde jongvolwassenen en GH-behandelde 
jongvolwassenen die te klein waren bij de geboorte. Mogelijk speelt de kortere 
telomeerlengte een rol in de versnelde veroudering bij mensen met PWS, 
onafhankelijk van GH. 
 
Hoofdstuk 8  
 
In de algemene discussie bespreken we onze resultaten in het kader van de huidige 
literatuur, presenteren we de praktische implicaties van onze bevindingen en geven 
we suggesties voor toekomstig onderzoek. 
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LIST OF ABBREVIATIONS 
 
ACTH  corticotropin 
AH  adult height  
AHI  apnea hypopnea index  
BMADLS  bone mineral apparent density of the lumbar spine  
BMD  bone mineral density 
BMDLS bone mineral density of the lumbar spine  
BMDTB  bone mineral density of the total body  
BMI  body mass index 
BP  break point 
BSID  Bayley Scales of Infant Development 
CAI  central apnea index 
CI  confidence interval  
CoQ10 co-enzyme Q10 
CRH  corticotropin-releasing hormone 
CV  coefficient of variation 
CVD  cardiovascular disease 
DNA  deoxyribonucleic acid  
DXA  dual-energy x-ray absorptiometry  
%ed  percentage of expected development 
FFM  fat free mass 
FM  fat mass  
FM%  fat mass percentage 
FSH  follicle stimulating hormone 
GH  growth hormone  
GHD  growth hormone deficiency 
GHRH growth hormone-releasing hormone 
GnRH  gonadotropin-releasing hormone  
HDLc  high-density lipoprotein cholesterol 
HOMA-IR homeostatic model assessment of insulin resistance 
ICD  imprinting center defect  
IGFBP-3 IGF binding protein 3  
IGF-I  insulin-like growth factor type I  
IQ  intelligence quotient  
IQR  interquartile range  
LBM  lean body mass  
LBM% lean body mass percentage 
LDLc  low-density lipoprotein cholesterol 
LH   luteinizing hormone 
LTL  leukocyte telomere length  
MD  medical doctor 
mUPD maternal uniparental disomy  
OAI  obstructive apnea index 
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OSA  obstructive sleep apnea 
PRL  prolactin 
PSG  polysomnography 
PWS  Prader-Willi syndrome  
RCT  randomized controlled trial  
SaO2  oxygen saturation 
SE  standard error 
SEM  standard error of the mean 
SGA  short for gestational age 
SDS  standard deviation score  
SPSS  Statistical Package for Social Sciences  
SRBD  sleep related breathing disorders 
T2DM  diabetes mellitus type 2 
TC  total cholesterol 
TG  triglyceride 
TIQ  total IQ 
TRH  thyrotropin-releasing hormone 
TSH  thyrotropin 
WAIS  Wechsler Adult Intelligence Scale 
WISC  Wechsler Intelligence Scale for Children  
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